Monday Research Poster Presentations

POSTER SESSION I:

Poster Display Hours – 8:45 - 14:15 Poster Author Discussion Hour – 13:15 - 14:15

POSTER SESSION II:

Poster Display Hours – 15:45 - 19:45 Poster Author Discussion Hour – 18:45 - 19:45

POSTER SESSION I: PRM: RESEARCH ON METHODS PIH: INDIVIDUAL'S HEALTH PIN: INFECTION PND: NEUROLOGICAL DISORDERS

ROWS A-G ROWS G-H ROWS H-J ROWS J-L

POSTER SESSION II: PHP: RESEARCH ON METHODS PGI: RESPIRATORY-RELATED DISORDERS PUK: URINARY/KIDNEY DISORDERS

ROWS A-K ROWS K-L ROWS L-L

RESEARCH POSTER PRESENTATIONS - SESSION I RESEARCH ON METHODS STUDIES RESEARCH ON METHODS - Clinical Outcomes Methods PRM1

A1

PRM2

A2

PRM3

A3

PRM4

A4

PRM5

A5

PRM6

A6

PRM7

A7

PRM8

A8

PRM9

A9

PRM10 A10

PRM11 A11

PRM12 A12

COMPARISON OF THE EUROPEAN SOCIETY FOR MEDICAL ONCOLOGY MAGNITUDE OF CLINICAL BENEFIT SCALE (ESMO-MCSB) AND THE AMERICAN SOCIETY OF CLINICAL ONCOLOGY (ASCO) FRAMEWORK FOR ASSESSING VALUE IN CANCER CARE 1 2 3 4 1 5 1 2 Rémuzat C , Chouaid C , Auquier P , Borget I , Kornfeld A , Toumi M , Creativ-Ceutical, Paris, France, INSERM U955 and 3 Université Paris Est (UPEC), UMR U955, Faculté de médecine, Créteil, France, Aix-Marseille Université, Université de la 4 5 Méditerranée, Marseille, France, Institut Gustave Roussy, Villejuif, France, Faculté de Médecine, Laboratoire de Santé Publique, Aix-Marseille Université, Marseille, France CONSIDERATIONS IN META-ANALYTIC NETWORK DESIGN: THE CASE OF PLATINUM DOUBLET CHEMOTHERAPIES IN ADVANCED NON-SMALL CELL LUNG CANCER (ADVNSCLC) 1 2 3 4 1 1 2 4 5 4 Goring SM , Scott DA , Briggs A , Penrod JR , Wilson JB , Waser N , Thompson JC , Korytowsky B , Chirita O , Wong B , Yuan 4 1 2 3 Y , ICON Epidemiology, Vancouver, BC, Canada, ICON Health Economics & Epidemiology, Abingdon, UK, University of 4 5 Glasgow, Glasgow, UK, Bristol-Myers Squibb, Princeton, NJ, USA, Bristol-Myers Squibb, Uxbridge, UK CAUSES OF DEATH STATISTICS UNDERESTIMATE THE BURDEN OF HEAD AND NECK (H&N) CANCERS: A NATIONWIDE STUDY FROM FRANCE IN 2008-2012 (EPICORL STUDY) 1 2 3 4 5 5 6 2 1 Schwarzinger M , Even C , Pointreau Y , Geoffrois L , Bec M , Godard C , Huguet F , Témam S , Sagaon Teyssier L , 5 1 2 Levy-Bachelot L , THEN (Translational Health Economics Network), Paris, France, Institut Gustave Roussy, Villejuif, 3 4 France, Centre Jean Bernard-Clinique Victor Hugo, LE MANS, France, Institut de Cancérologie de Lorraine, 5 6 Vandœuvre-lès-Nancy, France, MSD France, Courbevoie, France, Tenon hospital, Paris, France A REVIEW EVALUATING THE VALIDITY OF MOTION-BASED GAMING PLATFORMS TO MEASURE CLINICAL OUTCOMES IN CLINICAL RESEARCH 1 2 31 2 Byrom B , Breedon P , Muehlhausen W , ICON Clinical Research, Marlow, UK, Nottingham Trent University, Nottingham, 3 UK, ICON plc, Dublin 18, Ireland MAN VERSUS MACHINE - IS ACCURATE AUTOMATION OF DATA ABSTRACTION ACHIEVABLE? 1 1 1 2 1 1 2 Kiff C , Scott DA , Thompson JC , Quigley JM , Eaton J , ICON Health Economics and Epidemiology, Abingdon, UK, ICON Health Economics & Epidemiology, Abingdon, UK EVALUATING THE QUALITY OF EVIDENCE FROM THE ASPIRE AND ENDEAVOR CLINICAL TRIALS USING THE GRADING OF RECOMMENDATIONS, ASSESSMENT, DEVELOPMENT AND EVALUATION (GRADE) APPROACH 1 2 3 2 2 1 1 1 Biedermann P , Esposito B , Glen C , Pippo L , Avallone G , Gonzalez-McQuire S , Gatta F , Amgen (Europe) GmbH, Zug, 2 3 Switzerland, Amgen GmbH, Milan, Italy, Oxford PharmaGenesis Ltd, Tubney, UK PSYCHOMETRIC ANALYSES OF CLINICAL OUTCOME ASSESSMENT (COA) QUESTIONNAIRES DESIGNED TO EVALUATE SATISFACTION WITH PHARMACOLOGICAL STRESS AGENTS (PSAS) USED IN ECHOCARDIOGRAPHY 1 2 3 3 1 3 1 1 3 3 Spalding J , Hudgens S , Litcher-Kelly L , Shields A , Kitt T , Ojo O , Kristy R , Lee E , Mathias A , Morrissey L , Houle 1 1 2 3 C , Astellas Pharma Global Development, Northbrook, IL, USA, Clinical Outcomes Solutions, Tucson, AZ, USA, Adelphi Values, Boston, MA, USA SINGLE-ARM TRIALS IN SYSTEMATIC REVIEWS: ARE THEY ADEQUATELY CAPTURED BY EXISTING SEARCH FILTERS? 1 2 2 1 2 O'Rourke JM , Ward KE , Thompson JC , ICON Health Economics & Epidemiology, Abingdon, UK, ICON Health Economics and Epidemiology, Abingdon, UK GUIDELINES FOR TRANSLATION AND CROSS-CULTURAL ADAPTATION OF NON-TECHNICAL SKILLS RATING INSTRUMENTS 1 2 1 2 Repo JP , Rosqvist E , University of Helsinki and Helsinki University Hospital, Helsinki, Finland, Central Finland Health Care District, Jyväskylä, Finland, Jyvaskyla, Finland EXPECTED IMPACT OF THE EUROPEAN SOCIETY FOR MEDICAL ONCOLOGY MAGNITUDE OF CLINICAL BENEFIT SCALE (ESMO-MCSB) ON HEALTH TECHNOLOGY ASSESSMENT 1 2 3 4 1 5 1 2 Rémuzat C , Chouaid C , Auquier P , Borget I , Kornfeld A , Toumi M , Creativ-Ceutical, Paris, France, Centre Hospitalier 3 Intercommunal, DHU-ATVB, Département de Pneumologie et Pathologie Professionnelle, Créteil, France, Aix-Marseille 4 5 Université, Université de la Méditerranée, Marseille, France, Institut Gustave Roussy, Villejuif, France, Faculté de Médecine, Laboratoire de Santé Publique, Aix-Marseille Université, Marseille, France WEAKNESS OF REGISTRATION BIOEQUIVALENT DRUGS Krakowian P, Iwanczuk T, Zaremba A, Misiak J, Tatara T, Wysoczanski W,Agency for Health Technology Assessment and Tariff System in Poland (AOTMiT), Warsaw, Poland APPLYING THE ACCEPTED TECHNIQUES OF INDIRECT TREATMENT COMPARISON TO MEET PAYER NEEDS FOR BRIVARACETAM VERSUS ADJUNCTIVE ANTIEPILEPTIC MEDICATIONS FOR THE TREATMENT OF FOCAL SEIZURES IN ADULT PATIENTS. DO THEY REFLECT THE NEED FOR INDIVIDUALISED PATIENT CARE IN HETEROGENEOUS

PRM13 A13

PRM14 A14

PRM15 A15

PRM16 A16

PRM18 A18

PRM19 A19

PRM20 A20

PRM21 A21 PRM22 A22

PRM23 A23

PRM24 A24

PRM25 A25

PRM26 A26

PRM27 A27

PRM28 A28

POPULATIONS IN EPILEPSY? 1 2 3 4 5 1 2 Charokopou M , Harvey R , Srivastava K , Townsend R , Borghs S , UCB Pharma, Brussels, Belgium, BresMed Health 3 4 5 Solutions, Sheffield, UK, BresMed Health Solutions, Goa, India, UCB Pharma, Smyrna, GA, USA, UCB Pharma, Slough, UK ANALYSIS OF THE ASCO VALUE FRAMEWORK NET HEALTH BENEFIT SCORE AS A TOOL FOR ASSESSING NOVEL THERAPIES IN RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM) Cork D, Nelson L, Curry A,SIRIUS Market Access, London, UK PATIENCE IS A VIRTUE WHEN CONNECTING EVIDENCE NETWORKS 1 2 3 3 2 1 2 Halfpenny NJ , Quigley JM , Gurung B , Scott DA , Thompson JC , ICON Health Economics, Abingdon, UK, ICON Health 3 Economics & Epidemiology, Abingdon, UK, ICON Health Economics and Epidemiology, Abingdon, UK THE AMERICAN SOCIETY OF CLINICAL ONCOLOGY (ASCO) NET HEALTH BENEFIT (NHB) ASSESSMENT TOOL: WHICH IMPLICATIONS FOR VALUE ASSESSMENT OF CANCER THERAPIES? 1 2 3 4 1 5 1 2 Rémuzat C , Chouaid C , Auquier P , Borget I , Kornfeld M , Toumi M , Creativ-Ceutical, Paris, France, Centre Hospitalier 3 Intercommunal, DHU-ATVB, Département de Pneumologie et Pathologie Professionnelle, Créteil, France, Aix-Marseille 4 5 Université, Université de la Méditerranée, Marseille, France, Institut Gustave Roussy, Villejuif, France, Faculté de Médecine, Laboratoire de Santé Publique, Aix-Marseille Université, Marseille, France A NEW MODEL TO IDENTIFY MULTIVARIATE CAUSES OF HIGH COST IN PATIENT WITH ADVANCED LIVER DISEASE 1 2 1 2 Turri JA , Ferreira LA , Sao Paulo Medical School - Sao Paulo University, Sao Paulo, Brazil, University of Sao Paulo, Sao Paulo, Brazil PAYER REQUIREMENTS IN THE TREATMENT OF CHRONIC HEART FAILURE 1 2 3 4 1 2 Bergenheim K , Hellsten Kronander A , Lauks S , van Engen A , AstraZeneca, Mölndal, Sweden, AstraZeneca, Gothenburg, 3 4 Sweden, Quintiles, Reading, UK, Quintiles Advisory Services, Hoofddorp, The Netherlands DEVELOPING A CLASSIFICATION SYSTEM OF PATIENTS BASED ON RISK RELATED TO EPIDEMIOLOGICAL AND DEMOGRAPHIC VARIABLES 1 2 3 2 4 1 Romero Prada ME , Marrugo R , Celis S , Alfonso Quiñones PA , Vivas-Consuelo D , Fundación Salutia, Bogotá, 2 3 4 Colombia, Salutia Foundation, Bogotá, Colombia, Salutia Foundation, Bogota, Colombia, Universitat Politècnica de València (UPV), Valencia, Spain OPTIMAL DESIGN OF PRE-AUTHORIZATION TRIALS FOR EFFECTIVENESS EVALUATION IN SEVERE ASTHMA 1 2 2 3 4 5 1 2 Karcher H , Meng J , Fu S , Loefroth E , Cao H , Peress E , LASER Analytica, London, UK, LASER Analytica, Loerrach, 3 4 5 Germany, Novartis Sverige AB, Stockholm, Sweden, Novartis, East Hanover, NJ, USA, Novartis, Basel, Switzerland DETECTION AND ANALYSIS OF THERAPY LINES AND OTHER EVENT SEQUENCES IN CLAIMS DATA Ertl J, Hapfelmeier J, Ansorge S,arvato health analytics, Munich, Germany EVALUATING THE EFFECTIVENESS OF TREATMENTS OF OPIOID USE DISORDER BASED ON RECOVERY OUTCOMES: HOW TO BRIDGE THE DISCONNECT BETWEEN CLINICAL TRIAL OUTCOMES AND RECOVERY OUTCOMES? 1 2 3 2 3 1 2 Elroy PW , Ronquest NA , Barnes A , Nadipelli VR , Akehurst R , BresMed Health Solutions, Utrecht, The Netherlands, Indivior 3 Inc., Richmond, VA, USA, BresMed Health Solutions, Sheffield, UK PARAMETRIC SIMULATION OF HEADACHE DAY FREQUENCY USING A NEGATIVE BINOMIAL DISTRIBUTION: A CASE STUDY OF ERENUMAB IN EPISODIC MIGRAINE 1 2 3 4 1 1 2 Porter JK , Brennan A , Palmer S , Sapra S , Cristino J , Amgen (Europe) GmbH, Zug, Switzerland, University of Sheffield, 3 4 Sheffield, UK, University of York, Heslington, York, UK, Amgen Inc, Thousand Oaks, CA, USA DIFFERENCES IN PERCEPTION OF HEALTH-RELATED QUALITY OF LIFE ASSOCIATES TO SOCIOECONOMIC, CULTURAL AND HOUSING FACTORS: MULTILEVEL ANALYSIS 1 2 3 4 5 5 5 1 Romero Prada ME , Alvis Guzman N , Sanabria M , Celis S , Lancheros J , Gallo D , Huerfano LM , Universidad Nacional de 2 Colombia, Bogota, Colombia, Universidad de Cartagena. Centro de Investigación y Docencia. Hospital Infantil Napoleón Franco 3 Pareja, Cartagena de Indias, Colombia, Salutia´s Foundation- Research center in economy, management and health 4 5 technologies., Bogota, Colombia, Salutia Foundation, Bogota, Colombia, Salutia Foundation - Research center in economy, management and health technologies., Bogota, Colombia INCREASING THE INTERPRETABILITY OF PATIENT-REPORTED OUTCOMES QUESTIONNAIRE FINDINGS USING A MIXED METHODS DESIGN: AN EXAMPLE IN A RARE CARDIAC CLINICAL TRIAL Marrel A, Fofana F, Guillemin I,Mapi Group - Patient-Centered Outcomes, Lyon, France SYNTHESIS OF BINARY OUTCOME DATA ON THE LOG-ODDS AND ABSOLUTE RISK SCALES – A CASE STUDY IN CHRONIC HEPATITIS C 1 1 1 1 1 1 1 2 1 Nagy L , Kay G , Parker C , Padhiar A , O'Rourke JM , Quigley JM , Mealing S , Hawkins N , ICON Health Economics & 2 Epidemiology, Abingdon, UK, University of Glasgow, Glasgow, UK FOUR DECADES OF RASCH ANALYSIS ON PATIENT-REPORTED OUTCOMES INSTRUMENTS VALIDATION: A SYSTEMATIC LITERATURE REVIEW de Bock E, Williams P, Tugaut B, Guillemin I,Mapi Group, Patient-Centered Outcomes, Lyon, France REVIEW OF METHODS FOR COMBINING INDIVIDUAL AND AGGREGATE DATA IN A META-ANALYSIS

1

PRM29 A29

PRM30 A30

2

2

2 1

Kapso Kapnang R , Thokagevistk K , Vataire A , Aballéa S , National School For Statistics and Information Analysis (ENSAI), 2 Bruz, France, Creativ-Ceutical, Paris, France EPIDEMIOLOGICAL PROFILE OF KNEE ARTHROPLASTY SURGERY IN HEALTH CARE SYSTEM OF PUBLIC EMPLOYEES LOCATED IN NORTHEAST BRAZIL BETWEEN JULY 2014 AND DECEMBER 2015 1 2 1 1 1 2 Silva Jd , de Souza NN , Silva Sd , Novis CS , Escola Bahiana de Medicina e Saúde Pública, Salvador, Brazil, UFBA, SALVADOR, Brazil EVALUATION OF THE EFFECT OF PHARMACEUTICAL CARE INTERVENTIONS ON THE MEAN DAILY DOSE OF ORAL ANTIDIABETES DRUGS IN A NIGERIAN TERTIARY HOSPITAL Ogbonna B,NNAMDI AZIKIWE UNIVERSITY, ANAMBRA STATE, Nigeria

RESEARCH ON METHODS - Cost Methods PRM31 A31

PRM32 A32

PRM33 A33 PRM34 A34

PRM35 A35

PRM36 A36

PRM37 A37 PRM38 A38

PRM39 B1

PRM40 B2

PRM41 B3

PRM42 B4 PRM43 B5

PRM44 B6

PRM45 B7

ECONOMIC AND HUMANISTIC IMPACT ASSUMPTIONS FOR HYPOGLYCEMIC EVENTS: IMPLICATIONS FOR COST-EFFECTIVENESS ANALYSES IN INSULIN-TREATED DIABETES 1 2 3 3 1 2 Tunis SL , Klinkenbijl B , Graham C , Weaver D , Independent, Indianapolis, IN, USA, Dexcom, Inc., Essertines sur Rolle, 3 Switzerland, Dexcom, Inc., San Diego, CA, USA VALIDATING THE PROJECTED MORTALITY RATES USED IN ONCOLOGY COST-EFFECTIVENESS ANALYSIS: A PITFALL OF SIMPLE BENCHMARKING WITH LIFE TABLE AGE-SPECIFIC MORTALITY RATES FOR A TRIAL POPULATION 1 2 2 1 2 Zhang Y , Dyer M , Vereecken W , Astrazeneca, Gaithersburg, MD, USA, AstraZeneca UK Ltd., Luton, UK HEALTH ECONOMIC COSTING METHODS AND REPORTING IN AUSTRIA Mayer S, Kiss N, Laszewska A, Simon J,Medical University of Vienna, Vienna, Austria WHICH COSTS MATTER? COSTS INCLUDED IN ECONOMIC EVALUATION AND THEIR IMPACT ON DECISION UNCERTAINTY: THE EXAMPLE OF ACUTE MYOCARDIAL INFARCTION 1 2 1 3 2 1 2 Lomas JR , Asaria M , Bojke L , Richardson G , Walker S , University of York, York, UK, University of York, Heslington, York, 3 UK, University of York, Heslington, UK COMPARING DIFFERENT DATA ON DISEASE BURDEN IN MULTIPLE SCLEROSIS 1 1 1 2 3 1 2 Berg J , Gannedahl M , Capsa D , Eriksson J , Kobelt G , Mapi, Stockholm, Sweden, Mapi Group, Stockholm, 3 Sweden, European Health Economics, Mulhouse, France VALUING CANCER-RELATED PREMATURE MORTALITY: A COMPARISON OF CONSUMER-LED VERSUS PRODUCER-LED APPROACHES Hanly P,National College of Ireland, Dublin, Ireland SPILL OVER ECONOMIC IMPACTS ON FAMILIES OF CHILDREN RECEIVING HOSPITAL-BASED CARE Samnaliev M,Harvard University, Boston, MA, USA A SYSTEMATIC LITERATURE REVIEW (SLR) OF HEALTH-ECONOMIC EVALUATIONS OF TREATMENTS FOR RARE DISEASES Garcia Sanchez JJ, Norman DL,MAP BioPharma Limited, Cambridge, UK EVALUATING THERAPEUTIC TREATMENTS FOR PSORIATIC ARTHRITIS: CAN WE MAKE BETTER USE OF PATIENT DATA REGISTRIES? 1 1 2 1 1 2 Walton MJ , Bojke L , Manca A , Patton T , University of York, York, UK, University of York, Heslington, York, UK CHALLENGES IN ECONOMIC EVALUATIONS CONDUCTED ALONGSIDE CLINICAL TRIALS OF SCHIZOPHRENIA: THE CASE OF THE ACTIONS STUDY Kiss N, Simon J,Medical University of Vienna, Vienna, Austria VALUING INFORMAL CARE: MAKING NORMATIVE JUDGMENTS IN A POSITIVE MILIEU 1 1 2 3 1 2 Hanly P , Maguire R , Balfe M , Sharp L , National College of Ireland, Dublin, Ireland, University College Cork, Cork, 3 Ireland, Newcastle University, Newcastle, UK SYSTEMATIC REVIEW OF BUDGET IMPACT ANALYSIS ON VACCINES 1 2 1 2 Itria A , Loze P , GOIAS UNIVERSITY, goiânia, Brazil, Goiania University, GOIANIA , GOIÁS, Brazil THREE METHODS FOR MEASURING PRODUCTIVITY LOSSES DUE TO HEALTH RELATED PRESENTEEISM IN ECONOMIC EVALUATIONS Shephard C, Hirst A, Buckland A, Vlachaki I,WG Access Ltd, London, UK A GENERAL MODEL FOR THE ESTIMATION OF SOCIETAL COSTS OF LOST PRODUCTION AND INFORMAL CARE IN ITALY Pradelli L, Ghetti G,AdRes Srl, Torino, Italy HOW TIME AND SEVERITY INCREASES THE OVERALL COST AND RESOURCE UTILIZATION OF PATIENT WITH SEVERE LIVER DISEASE. MAIN BURDENS AND CONSEQUENCES TO HEALTH SYSTEM Turri JA, Ferreira LA,Sao Paulo Medical School - Sao Paulo University, Sao Paulo, Brazil

PRM46 B8

PRM47 B9

PRM48 B10

PRM49 B11

PRM50 B12 PRM51 B13

PRM52 B14

PRM53 B15

THE ECONOMIC BURDEN OF PULMONARY EMBOLISM IN EUROPE 1 2 3 4 5 6 7 8 1 Gumbs PD , Ling-Hsiang Chuang L , Cohen AT , Agnelli G , Willich SN , Monreal M , Jimenez D , van Hout B , Daiichi-Sankyo 2 3 Europe GmbH, Munich, Germany, Pharmerit, Rotterdam, The Netherlands, Guy's and St Thomas' NHS Foundation Trust, 4 5 6 London, UK, University of Perugia, Italy, Perugia, Italy, Charité - Universitätsmedizin Berlin, Berlin, Germany, Hospital 7 Universitari Germans Trias I Pujol, Barcelona, Spain, Ramon y Cajal Hospital, IRYCIS and Alcala University, Madrid, 8 Spain, Pharmerit International, York, UK COST-EFFECTIVENESS OF BRIVARACETAM VERSUS OTHER ANTIEPILEPTIC DRUGS USED AS ADJUNCTIVE TREATMENT FOR FOCAL SEIZURES IN THE UK: A DISCRETE EVENT SIMULATION MODEL 1 2 3 4 4 5 1 1 2 Charokopou M , Sander J , Saha R , Beard S , Kidd R , Coward E , Plumb J , UCB Pharma, Brussels, Belgium, UCL Institute of 3 4 5 Neurology, London, UK, 3. Nuffield Health Hospital, Brighton, UK, BresMed Health Solutions, Sheffield, UK, UCB Pharma, Slough, UK THE VALUE OF TIMELY IMPLEMENTATION IN HIV/STI TESTING: COST-EFFECTIVENESS VS. SPEED OF INTERVENTION ROLLOUT 1 2 3 3 1 2 Beck E , Armbruster B , Birkett M , Mustanski B , Creativ-Ceutical, London, UK, Northwestern University, Evanston, IL, 3 USA, Northwestern University, Chicago, IL, USA THE COST-EFFECTIVENESS OF BLUE-LIGHT THERAPY VS FIXED COMBINATION OF CALCIPOTRIOL AND BETAMETHASONE DIPROPIONATE GEL IN THE TREATMENT OF MILD-TO-MODERATE PSORIASIS 1 2 3 1 1 2 Ansaripour A , Thio HB , Maessen R , Redekop WK , Erasmus University Rotterdam, Rotterdam, The Netherlands, Erasmus 3 University Medical Center Rotterdam, Rotterdam, The Netherlands, Philips Lighting, Eindhoven, The Netherlands CHALLENGING MODEL COMPLEXITY; A SIMPLER APPROACH FOR DEVELOPING MARKETS Marijam A, Standaert B,GSK Vaccines, Wavre, Belgium THE BENEFITS OF A HOLISTIC VIEW: CONSIDERING MULTIPLE HEALTH OUTCOMES FOR HIV AND STI TESTING 1 2 3 3 1 2 Beck E , Armbruster B , Birkett M , Mustanski B , Creativ-Ceutical, London, UK, Northwestern University, Evanston, IL, 3 USA, Northwestern University, Chicago, IL, USA CONCEPTUAL MODELLING FOR COST-EFFECTIVENESS ANALYSIS OF INTRAVITREAL THERAPY WITH RANIBIZUMAB, AFLIBERCEPT OR BEVACIZUMAB FOR MACULAR OEDEMA DUE TO CENTRAL RETINAL VEIN OCCLUSION Goodall M, Tosh J, Alshreef A, Tappenden P,University of Sheffield, Sheffield, UK CHALLENGES IN THE HEALTH ECONOMICS OF ACUTE PAIN: A RAPID REVIEW OF THE LITERATURE 1 1 1 1 2 1 2 Braileanu G , Johnson BC , Ashraf S , Borrill J , Hirst M , Adelphi Values, Bollington, Cheshire, UK, Mundipharma International Ltd, Cambridge, UK

RESEARCH ON METHODS - Databases & Management Methods PRM55 B17

PRM56 B18

PRM57 B19

PRM58 B20

PRM59 B21

PRM60 B22

PRM61 B23

PRM62 B24

IDENTIFYING POTENTIAL EARLY BIOMARKERS OF ACUTE MYOCARDIAL INFARCTION IN THE BIOMEDICAL LITERATURE: A COMPARISON OF TEXT MINING AND MANUAL SIFTING TECHNIQUES Paisley S, Seva J, Stevenson M, Archer R, Preston L, Chilcott J, Thornhill M,University of Sheffield, Sheffield, UK VIABILITY OF USING ELECTRONIC MEDICAL RECORDS FROM EUROPEAN COUNTRIES AS DATA IN NOVELTY (A NOVEL OBSERVATIONAL LONGITUDINAL STUDY OF PATIENTS WITH ASTHMA AND/OR COPD) 1 2 3 4 4 4 4 4 Wang X , Sveréus A , Rennard S , Hiller J , Wong D , Nasuti P , Jenner H , McKenney A , Gerhardsson de Verdier 2 1 2 3 4 M , AstraZeneca, Gaithersburg, MD, USA, AstraZeneca, Gothenburg, Sweden, AstraZeneca, Melbourn, UK, IMS Health, London, UK LINKAGE OF THE PHARMO DATABASE NETWORK AND THE NETHERLANDS PERINATAL REGISTRY TO CONSTRUCT A COHORT THAT CAPTURES PREGNANCY AND POSTNATAL OUTCOMES Houben E, Bezemer ID, Herings RM,PHARMO Institute for Drug Outcomes Research, Utrecht, The Netherlands ACCURACY OF TEXT PROCESSING TOKENISERS FOR AUTOMATED IDENTIFICATION OF DISEASES AND INTERVENTIONS IN ABSTRACTS OF STUDIES ON HUMANISTIC AND ECONOMIC BURDEN OF DISEASE 1 2 2 1 2 Challen R , Martin A , Martin C , Terminological Ltd, Hove, UK, Crystallise Ltd., London, UK ELICITING PAYERS PREFERENCES IN CENTRAL AND EASTERN EUROPE: RESULTS OF MCDA CASE STUDY 1 1 2 1 2 Piniazhko O , Zalis'ka O , Zah V , Danylo Halytsky Lviv National Medical University, Lviv, Ukraine, Health Economist, Belgrade, Serbia COMPARISON OF ESTIMATED EFFECTIVENESS OF BIOLOGICS FOR RHEUMATOID ARTHRITIS (RA) IN LARGE INSURANCE DATABASES USING A CLAIMS-BASED ALGORITHM Rascati KL, Popp R, Davis M,The University of Texas at Austin, College of Pharmacy, Austin, TX, USA ETHICAL STANDARDS IN REPORTING RESEARCH FROM RETROSPECTIVE OBSERVATIONAL STUDIES BASED ON DATABASES USING ANONYMOUS AND PERSONALLY UNIDENTIFIABLE 1 1 2 3 3 1 2 Hiroi S , Uda A , Tokaji A , Takeshima T , Iwasaki K , Takeda Pharmaceutical Company Ltd., Tokyo, Japan, MDS-CMG Inc., 3 Tokyo, Japan, Milliman, Tokyo, Japan USE OF SURVEILLANCE DATABASES TO DESCRIBE INFLUENZA EPIDEMIOLOGY IN EUROPE

PRM63 B25

PRM64 B26 PRM65 B27

PRM66 B28

PRM67 B29 PRM68 B30 PRM69 B31

PRM70 B32

PRM71 B33

PRM72 B34

PRM73 B35 PRM74 B36 PRM75 B37 PRM76 B38

PRM77 C1

PRM78 C2

Riera M, Ferreira G, Cattaert T, Verstraeten T,P95 Pharmacovigilance and Epidemiology Services, Leuven, Belgium PEDIATRIC REGISTRY OF PATIENTS WITH SEVERE PERSISTENT UNCONTROLLED ASTHMA RECEIVING OMALIZUMAB Namazova-Baranova L, Vishneva E, Dobrynina E, Alekseeva A, Levina J, Efendieva K, Smirnov V, Antonova E, Voznesenskaya N, Selimzianova L,Scientific Centre of Children Health, Moscow, Russia ARTIFICIAL INTEGLIGENCE TO SUPPORT THE DEVELOPMENT OF HEALTH TECHNOLOGY ASSESSMENT REPORTS Sekiewicz B, Rodak W, Rutkowski J, Plisko R, Miazga P,HTA Consulting, Krakow, Poland THE USE OF ADMINISTRATIVE DATA TO DETERMINE PREVALENCE AND INCIDENCE OF COPD: A SYSTEMATIC REVIEW 1 2 3 4 5 1 Gothe H , Rajsic S , Gottfried E , Vukicevic D , Siebert U , Medical Faculty, TU Dresden / UMIT, Dresden / Hall in Tirol, 2 Germany, UMIT - University for Health Sciences, Medical Informatics and Technology, Institute of Public Health, Medical Decision 3 Making and Health Technology Assessment, Hall in Tirol, Austria, Main Association of the Austrian Social Insurance Institutions, 4 Vienna, Austria, UMIT - University for Health Sciences, Medical Informatics and Technology, Institute of Public Health, Medical Decision Making and Health Technology Assessment, Department of Public Health, Health Services Research and Health 5 Technology Assessment, Hall i.T., Austria, and Director, Division for HTA, ONCOTYROL – Center for Personalized Cancer Medicine, Hall i.T., Austria PROQOLID DATABASE: EVOLUTION OF CONTENT, STRUCTURE, AND FUNCTIONALITIES (2012-2016) - INTEGRATION IN EPROVIDE, A NEW ONLINE PLATFORM DEDICATED TO CLINICAL OUTCOME ASSESSMENT (COA) RESEARCH Perret C, Perrier L, Castex M, Acquadro C,Mapi Research Trust, Lyon, France MEASURES TAKEN BY THE ROMANIAN MINISTRY OF HEALTH FOR BETTER ACCESS TO ANTI-EGFR DRUGS Turcu-Stiolica A, Subtirelu M, Mic OC,University of Medicine and Pharmacy, Craiova, Romania MARKOV MODELS FOR HEALTH ECONOMIC EVALUATION MODELLING IN R WITH THE HEEMOD PACKAGE Filipovic-Pierucci A, Zarca K, Durand-Zaleski I,APHP, Paris, France DEVELOPMENT OF A SEARCH ENGINE FOR THE MEDLINE DATABASE WITH SEARCH RESULTS RANKING FROM THE PERSPECTIVE OF EVIDENCE-BASED MEDICINE 1 2 2 2 1 1 Kolbin A , Kamalov M , Dobrynin V , Balykina Y , Verbitskaya E , First Pavlov State Medical University of St. Petersburg, Saint 2 Petersburg, Russia, Saint Petersburg State University, Saint Petersburg, Russia AN INVESTIGATION INTO OPEN-SOURCE MODELLING IN HEALTH ECONOMICS: OPPORTUNITIES AND CHALLENGES 1 2 3 1 2 1 2 Mason N , Kenworthy JJ , Akehurst R , Sullivan W , Dunlop W , BresMed, Sheffield, UK, Mundipharma International Ltd, 3 Cambridge, UK, BresMed Health Solutions, Sheffield, UK PREDICTION OF COSTS ASSOCIATED WITH THE HOSPITAL MANAGEMENT OF HIV PATIENTS IN FRANCE USING AN ADVANCED DATA MINING APPROACH ON THE FRENCH MEDICAL INFORMATION SYSTEM DATABASE 1 2 2 3 3 1 2 3 Prodel M , Amaz C , Vainchtock A , Finkielsztejn L , Aubin C , HEVA, LYON, France, HEVA, Lyon, France, ViiV Healthcare France, Marly-le-Roi, France EVALUATING SOCIO-DEMOGRAPHIC CHARACTERISTICS OF PATIENTS IN THE UNITED STATES DEPARTMENT OF DEFENSE POPULATION 1 1 1 2 1 2 Wang L , Li L , Pandya S , Baser O , STATinMED Research, Plano, TX, USA, Columbia University and STATinMED Research, New York, NY, USA MAPPING THE INVOLVEMENT OF EUNETHTA PARTICIPANTS IN EU RESEARCH PROJECTS Kozák A, Hankó B, Lám J, Merész G,Semmelweis University, Budapest, Hungary EXPERT ELICITATION: CAN VARIATION IN ELICITED DISTRIBUTIONS BE EXPLAINED BY EXPERT HETEROGENEITY? Jankovic D,University of York, York, UK NETWORK ANALYSIS APPROACH TO EXPLORE SPONSOR INVOLVEMENT IN CLINICAL TRIALS Merész G, Kozák A, Hankó B, Szócska M,Semmelweis University, Budapest, Hungary CHARACTERISTICS OF A PATIENT POPULATION RECRUITED USING SOCIAL MEDIA (FACEBOOK) COMPARED WITH NEWSPAPER ADVERTISING (DAILY MAIL) Wade AG, Crawford GM, McLennan K,Patients Direct, Glasgow, UK NOT ALL COCHRANE REVIEWS ARE GOOD QUALITY SYSTEMATIC REVIEWS 1 1 1 1 1 1 1 2 1 Deshpande S , Misso K , Westwood M , Stirk L , de Kock S , Kleijnen J , Clayton D , Kleijnen J , Kleijnen Systematic Reviews 2 Ltd., York, UK, Maastricht University, Maastricht, The Netherlands QUINOLONES UTILIZATION IN TWO TERTIARY HOSPITALS IN NIGERIA; EXPLORING DRUG USE TOWARDS IMPROVED TREATMENT OUTCOMES Ogbonna B,NNAMDI AZIKIWE UNIVERSITY, ANAMBRA STATE, Nigeria

RESEARCH ON METHODS - Modeling Methods PRM79 C3

MISSING THE VALUE OF HERD IMMUNITY IN COST-EFFECTIVENESS ANALYSIS. A SYSTEMATIC REVIEW Nymark L,aarhus university, aarhus v, Denmark

PRM80 C4

PRM81 C5

PRM82 C6 PRM83 C7

PRM84 C8

PRM85 C9

PRM86 C10

PRM87 C11 PRM89 C13

PRM90 C14

PRM91 C15

PRM92 C16

PRM93 C17

PRM94 C18

PRM95 C19

PRM96 C20

ANALYSIS OF THE RELATIONSHIP BETWEEN BLOOD PRESSURE IN HEALTH CHECKUP AND EFFECTIVENESS OF ANTIHYPERTENSIVES 1 1 2 2 2 1 1 2 Iwasaki K , Nakamura Y , Hiroi S , Uda A , Shimasaki Y , Koizumi H , Milliman, Tokyo, Japan, Takeda Pharmaceutical Company Ltd., Tokyo, Japan IMPLICATIONS OF INTRODUCING PATIENT HETEROGENEITY IN COST EFFECTIVENESS MODELING 1 2 3 1 2 Foos V , McEwan P , Lamotte M , IMS Health, Zaventem, Belgium, Health Economics and Outcomes Research Ltd, Cardiff, 3 UK, IMS Health, Vilvoorde, Belgium A SYSTEMATIC REVIEW ON THE EVIDENCE OF ADEQUATE DISCOUNT RATES FOR VACCINES IN GERMANY Koerber F, Redeker M, Wieninger E, Welte R,GSK, München, Germany EMPIRICAL ASSESSMENT OF THE IMPACT OF MODEL CHOICE (MARKOV STATE TRANSITION VERSUS PARTITIONED SURVIVAL) IN MODELLING SMALL-CELL LUNG CANCER 1 1 1 2 2 1 McEwan P , Gordon J , Ward T , Penrod JR , Yuan Y , Health Economics and Outcomes Research Ltd, Cardiff, 2 UK, Bristol-Myers Squibb, Princeton, NJ, USA COMPARISON OF MARKOV MODELS USED FOR THE ECONOMIC EVALUATION OF COLORECTAL CANCER SCREENING: A SYSTEMATIC REVIEW Silva NS,University of Chile, Santiago, Chile REPLACING INPUT PROBABILITY DISTRIBUTIONS WITH MEAN VALUES CAN BIAS SIMULATION OUTPUT: AN ILLUSTRATION USING THE CORE DIABETES MODEL 1 2 3 1 2 McEwan P , Foos V , Lamotte M , Health Economics and Outcomes Research Ltd, Cardiff, UK, IMS Health, Zaventem, 3 Belgium, IMS Health, Vilvoorde, Belgium STRUCTURED REVIEW OF HEALTH ECONOMIC MODELS IN ASTHMA 1 1 2 2 1 2 Enstone A , Price G , Viejo I , Dunlop W , Adelphi Values Ltd, Bollington, UK, Mundipharma International Limited, Cambridge, UK THE IMPLICATIONS OF PARAMETER INDEPENDENCE IN PROBABILISTIC SENSITIVITY ANALYSIS Taylor M,York Health Economics Consortium, Heslington, York, UK RECOMMENDATIONS FOR THE CALCULATION OF TRANSITION PROBABILITIES IN MARKOV COHORT MODELS: A TARGETED LITERATURE REVIEW 1 1 1 1 1 1 2 3 1 Olariu E , Cadwell K , Fox D , Hancock E , Trueman D , Ratcliffe M , Grieve R , Chevrou-Severac H , PHMR Ltd, London, 2 3 UK, London School of Hygiene and Tropical Medicine, London, UK, Takeda Pharmaceuticals International AG, Glattpark-Opfikon, Switzerland TO WHAT EXTENT DOES THE PUBLISHED ECONOMIC ANALYSES OF TREATMENTS FOR OPIOID USE DISORDER CAPTURE ITS CHRONIC, RELAPSING NATURE AND ITS IMPACT ON SOCIETY? 1 2 1 2 1 1 2 Cranmer H , Ronquest NA , Barnes A , Nadipelli VR , Akehurst R , BresMed Health Solutions, Sheffield, UK, Indivior Inc., Richmond, VA, USA REVIEW OF HEALTH ECONOMIC MODELS FOR ANTIBIOTICS 1 1 1 2 1 3 1 2 Virhage M , Polyzoi M , Geale K , Geale K , Corcoran K , Anell B , PAREXEL International, Stockholm, Sweden, Umeå 3 University, Umeå, Sweden, Parexel International, Stockholm, Sweden AUTOMATIC EXTRACTION AND CLASSIFICATION OF PATIENTS’ SMOKING STATUS FROM FREE TEXT USING NATURAL LANGUAGE PROCESSING 1 2 3 2 1 2 Caccamisi A , Jörgensen L , Dalianis H , Rosenlund M , Karolinska Institute, Stockholm, Sweden, IMS Health, Stockholm, 3 Sweden, Stockholm University, Stockholm, Sweden POTENTIAL EFFICACY OF LOMITAPIDE, A MTP (MICROSOMAL TRIGLYCERIDE TRANSFER PROTEIN) INHIBITOR, ON SURVIVAL IN HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLAEMIA (HOFH): RESULTS OF AN EVENT MODELLING ANALYSIS 1 2 1 3 4 5 1 2 Leipold R , Raal F , Ishak J , Phillips H , Jakouloff D , Deanfield J , Evidera, Bethesda, MD, USA, University of the 3 4 Witwatersrand, Johannesburg, South Africa, Aegerion Pharmaceuticals Ltd, Berkshire, UK, Aegerion Inc, Cambridge, MA, 5 USA, University College London, London, UK THE IMPACT OF THE DIFFERENCE IN NATURAL HISTORY MODELS ON THE COST-EFFECTIVENESS OF ANTIVIRAL AGENTS FOR PATIENTS WITH GENOTYPE 1 CHRONIC HEPATITIS C 1 2 1 3 4 1 2 Ishida H , Ikai H , Suenaga R , Suka M , Hirao T , Yamaguchi University, Ube, Japan, Yamaguchi University Hospital, Ube, 3 4 Japan, The Jikei University School of Medicine, Tokyo, Japan, Kagawa University, MIki-Cho, Japan DETERMINISTIC VS MICROSIMULATION; A CASE STUDY IN SYSTEMIC LUPUS ERYTHEMATOSUS (SLE) 1 2 3 4 1 van Oostrum I , Guenther O , Postma MJ , Heeg BM , University Medical Center Groningen (UMCG), Groningen, The 2 3 4 Netherlands, Merck KGaA, Darmstadt, Germany, University of Groningen, Groningen, The Netherlands, Ingress-health Netherlands, Rotterdam, The Netherlands USE OF THE PERT AND UNIFORM DISTRIBUTIONS WITH THE CENTRAL LIMIT THEOREM (CLT) TO DECREASE VARIANCE IN COMPLICATION COST ESTIMATION IN PROBABILISTIC MODELS

PRM97 C21

PRM98 C22

PRM99 C23 PRM100 C24

PRM101 C25

PRM102 C26

PRM103 C27

PRM104 C28

PRM105 C29

PRM106 C30

PRM107 C31

PRM108 C32

PRM109 C33 PRM110 C34

PRM111 C35

Reynecke DP, Robson JP,FPH Care, Auckland, New Zealand ACCOUNTING FOR THE IMPERFECT EXTERNAL VALIDITY OF DISCRETE CHOICE EXPERIMENTS WHEN PREDICTING DEMAND 1 1 2 3 1 Quaife M , Terris-Prestholt F , Di Tanna GL , Vickerman P , London School of Hygiene and Tropical Medicine, London, 2 3 UK, Queen Mary University of London, London, UK, University of Bristol, Bristol, UK EXTRAPOLATION WITH PATIENT LEVEL TIME-TO-EVENT DATA IN VARIOUS DISEASE AREAS: A REVIEW OF CURRENT RECOMMENDATIONS AND GAPS Kamra S, Kaur J, Kartheek J, Sehgal M, Siddiqui MK,PAREXEL International, Chandigarh, India SAMPLING OF COMMONLY USED POPULATION CHARACTERISTICS: IS A NORMAL APPROXIMATION VALID? Davis JA, Mittard V, Saunders R,Coreva Scientific, Freiburg im Breisgau, Germany SYSTEMATIC REVIEW OF COST-EFFECTIVENESS MODELS IN DIABETES FOR INSULIN ANALOGUES 1 2 3 1 1 2 Ng CH , Shafie AA , Chaiyakunapruk N , Tan YP , Universiti sains malaysia, Penang, Malaysia, Universiti Sains Malaysia, 3 Penang, Malaysia, Monash University Malaysia, Selangor, Malaysia COST-EFFECTIVENESS DEPENDS ON THE SUBSEQUENT TREATMENT SEQUENCE: AN EXAMPLE FROM MULTIPLE SCLEROSIS Asseburg C, Svensson J, Andersson E, Persson U, Willis M,The Swedish Institute for Health Economics (IHE), Lund, Sweden EVALUATION OF METHODOLOGICAL VARIATIONS IN THE EVENT SIMULATION APPROACHES OF PUBLISHED HEALTH ECONOMIC MODELS IN OBESITY PREVENTION AND THERAPY 1 2 3 3 1 2 Schwander B , Nuijten M , Hiligsmann M , Evers SM , AHEAD GmbH, Loerrach, Germany, Ars Accessus Medica, Jisp, The 3 Netherlands, Maastricht University, Maastricht, The Netherlands IDENTIFYING THE KEY PARAMETERS OF THE EUROPEAN-STUDY ON QUANTIFYING UTILITY OF INVESTMENT IN PROTECTION FROM TOBACCO (EQUIPT) MODEL 1 2 3 4 2 5 2 6 1 Nemeth B , Kulchaitanaroaj P , Lester-George A , Huic M , Pokhrel S , Coyle D , Coyle K , Kaló Z , Józwiak-Hagymásy J , Nagy 1 1 2 3 B , Syreon Research Institute, Budapest, Hungary, Brunel University, Uxbridge, Middlesex, UK, LeLan Solutions, Bristol, 4 5 UK, Agency for Quality and Accreditation in Health Care and Social Welfare, Zagreb, Croatia, University of Ottawa Faculty of 6 Medicine, Ottawa, ON, Canada, Eötvös Loránd University (ELTE), Budapest, Hungary HOW TO HANDLE DATA QUALITY ISSUES IN EQ-5D-5L VALUATION STUDIES. THE SPANISH CASE 1 2 3 4 5 6 7 1 Ramos-Goñi JM , Craig BM , Oppe M , Ramallo-Fariña Y , Pinto-Prades JL , Luo N , Rivero-Arias O , EuroQol Research 2 3 Foundation, Tacoronte, Spain, University of South Florida, Tampa, FL, USA, EuroQol Research Foundation, Rotterdam, The 4 5 Netherlands, HTA Unit of Canary Island Health Service, Canary Islands, Spain, University of Navarra, Plamplona, 6 7 Spain, National University of Singpaore, Singapore, Singapore, University of Oxford, Oxford, UK DIVERSITY IN ECONOMIC EVALUATIONS HAMPERS VALID DECISION-MAKING IN METASTATIC COLORECTAL CANCER 1 1 2 1 1 2 Merkens GL , Tamminga HJ , Hovels A , Frederix GW , Utrecht University, Utrecht, The Netherlands, Utrecht Institute for Pharmaceutical Sciences, Utrecht, The Netherlands HOW ARE ADVERSE EFFECTS INCORPORATED IN COST-EFFECTIVENESS MODELS? A STUDY OF CURRENT PRACTICE IN ONCOLOGY STUDIES SUBMITTED TO HAS 1 1 1 1 2 1 Pibouleau L , Drezet A , Cognet M , Scemama O , Le galès C , Haute Autorité de Santé (HAS), Saint-Denis La Plaine, 2 France, INSERM, Villejuif Cedex, France A NOVEL METHOD FOR EVALUATING VALUE ASSESSMENT FRAMEWORKS 1 2 3 4 5 6 7 8 8 9 Bentley TG , Cohen JT , Elkin EB , Huynh J , Mukherjea A , Neville TH , Mei MG , Copher R , Knoth RL , Popescu I , Zambrano 1 1 1 1 1 2 JM , Chang E , Broder MS , Lee J , Partnership for Health Analytic Research, LLC, Beverly Hills, CA, USA, Center for the 3 Evaluation of Value and Risk in Health,Tufts Medical Center, Boston, CA, USA, Memorial Sloan-Kettering Cancer Center, New 4 5 York, CA, USA, Hematology Oncology Medical Group of San Fernando Valley, Encino, CA, USA, California State University, 6 7 East Bay, Hayward, CA, USA, UCLA Department of Medicine, Los Angeles, CA, USA, City of Hope National Medical Center, 8 9 Duarte, CA, USA, Eisai, Inc., Woodcliff Lake, NJ, USA, David Geffen School of Medicine at UCLA, Department of Medicine, Los Angeles, CA, USA MULTITHREADING: TURBOCHARGED COST-EFFECTIVENESS ANALYSES IN MICROSOFT EXCEL 1 2 1 1 2 Kiff C , Mealing S , Fenwick E , ICON Health Economics and Epidemiology, Abingdon, UK, ICON Health Economics & Epidemiology, Abingdon, UK TREATMENT EFFICACY IN SEQUENCE MODELLING – A REVIEW OF PUBLISHED APPROACHES Polyzoi M, Medin E,PAREXEL International, Stockholm, Sweden A REVIEW ON THE CURRENT STATUS OF HEALTH ECONOMIC MODELING IN PERSONALIZED MEDICINE 1 2 2 1 2 Degeling K , Koffijberg H , IJzerman MJ , University of Twente, Enschede, The Netherlands, MIRA institute for Biomedical Technology and Technical Medicine, University of Twente, Enschede, The Netherlands CURRENT ISSUES AND FUTURE RESEARCH PRIORITIES FOR HEALTH ECONOMIC MODELLING OF AT RISK POPULATION FOR ALZHEIMER’S DISEASE/DEMENTIA

1

PRM112 C36 PRM113 C37

PRM114 C38 PRM115 D1

PRM116 D2

PRM117 D3

PRM118 D4

PRM119 D5

PRM120 D6

PRM121 D7

PRM122 D8

PRM123 D9

PRM124 D10

2

3

4

5

6

7

8

9

Gustavsson A , Green C , Jones RW , Simsek D , de Reydet de Vulpillieres F , Adlard N , Bhattacharyya S , Wimo A , Förstl H , 1 1 2 3 Luthman S , Quantify Research, Stockholm, Sweden, Exeter University, Exeter, UK, The Research Institute for the Care of Older 4 5 6 People, Bath, UK, Novartis Pharma AG, Basel, Switzerland, NOVARTIS PHARMA AG, Basel, Switzerland, Novartis 7 8 Pharmaceuticals UK Ltd, Camberley, UK, Novartis Healthcare Pvt. Ltd., Hyderabad, India, Karolinska Institutet, Stockholm, 9 Sweden, Technische Universität München, München, Germany HYPERBOLIC DISCOUNTING OF EFFECTS IN ECONOMIC EVALUATIONS Fókás L,Numerus, Tübingen, Germany THE APPLICATION OF POPULATION MODELS TO IMPROVE ACCESS TO MEDICAL INNOVATIONS AND POPULATION HEALTH – A SYSTEMATIC REVIEW 1 2 2 3 4 2 5 6 4 Jahn B , Conrads-Frank A , Sroczynski G , Rochau U , Zauner G , Bundo M , Gyimesi M , Endel G , Popper N , Siebert 7 1 U , Department of Public Health, Health Services Research and Health Technology Assessment, Medical Informatics and 2 Technology (UMIT), Hall i.T., Austria, UMIT - University for Health Sciences, Medical Informatics and Technology, Institute of Public Health, Medical Decision Making and Health Technology Assessment, Department of Public Health, Health Services 3 Research and Health Technology Assessment, Hall i.T., Austria, UMIT - University for Health Sciences, Medical Informatics and Technology, Institute of Public Health, Medical Decision Making and HTA, Department of Public Health, Health Services Research 4 5 and HTA/ ONCOTYROL - Center for Personalized Medicine, Hall i.T./ Innsbruck, Austria, dwh GmbH, Vienna, Austria, Austrian 6 7 Public Health Institute, Vienna, Austria, Main Association of Austrian Social Insurance Institutions, Vienna, Austria, and Director, Division for HTA, ONCOTYROL – Center for Personalized Cancer Medicine, Hall i.T., Austria REQUIREMENTS FOR ECONOMIC EVIDENCE ACROSS DIFFERENT HTA BODIES Vlachaki I, Shephard C, Hirst A,WG Access Ltd, London, UK THREE-MONTHLY LONG-ACTING FORMULATION OF PALIPERIDONE PALMITATE IS A DOMINANT TREATMENT OPTION, COST SAVING WHILE ADDING QALYS, COMPARED TO THE ONE-MONTHLY FORMULATION IN THE TREATMENT OF SCHIZOPHRENIA IN FRANCE 1 2 1 3 11 2 Arteaga Duarte C , Colin X , De Moor R , Guillon P , van Gils CW , IMS Health, Zaventem, Belgium, IMS Health, La Défense, 3 France, Janssen-Cilag France, Issy-les-Moulineaux, Cedex, France ESTIMATING THE APPROPRIATE PRICE DISCOUNTS FOR BIOSIMILARS IN THE TREATMENT OF RHEUMATOID ARTHRITIS IN THE NORDIC SETTING USING AN EXCEL-BASED INTERACTIVE TOOL 1 2 1 1 3 4 2 5 1 Mahon R , Cassel T , Balkin PE , Burke C , Bhattacharyya S , Gokhale SB , Handin J , Mendoza C , Product Lifecycle Services 2 3 Novartis Business Services, Dublin, Ireland, Sandoz A/S, Copenhagen, Denmark, Novartis Healthcare Pvt. Ltd., Hyderabad, 4 5 India, Product Lifecycle Services - Novartis Business Services, Hyderabad, India, Sandoz International GmbH, Holzkirchen, Germany ADAPTIVE PREDICTION OF SYMPTOMS RETURN UPON DISCONTINUATION OF OMALIZUMAB TREATMENT IN CHRONIC SPONTANEOUS URTICARIA PATIENTS 1 2 1 3 1 1 1 1 Saldana Miranda D , Ferrer M , Janssens N , Gimenez-Arnau A , Balp M , Khalil S , Risson V , Novartis Pharma AG, Basel, 2 3 Switzerland, Clínica Universitaria de Navarra, Pamplona, Spain, Hospital del Mar. Parc de Salut Mar, Barcelona, Spain MATHEMATICAL MODEL TO SYNTHESIZE NATURAL HISTORY OF TICK BORNE ENCEPHALITIS AND LYME BORRELIOSIS FOR THE PURPOSE OF COST-EFFECTIVENESS ANALYSIS 1 2 3 4 4 1 1 Mihajlovic J , Hovius JW , Sprong H , Strle F , Bogovic P , Postma MJ , University of Groningen, Groningen, The 2 3 Netherlands, The Academic Medical Center Amsterdam, Amsterdam, The Netherlands, National Institute for Public Health and 4 the Environment (RIVM), Bithoven, The Netherlands, University Medical Center Ljubljana, Ljubljana, Slovenia AN EXPLORATION OF TECHNIQUES FOR ADDRESSING UNCERTAINTY IN SURVIVAL ESTIMATES USED WITHIN PARTITIONED-SURVIVAL MODELS Bullement A, Critchlow S,BresMed Health Solutions, Sheffield, UK DO HEALTH TECHNOLOGY AGENCIES ACCEPT METHODS FOR DEALING WITH TREATMENT SWITCHING AND IMMATURE OS DATA? 1 2 3 4 5 1 2 Zhang Y , Wright J , Luke S , Ryan J , van Engen A , Astrazeneca, Gaithersburg, MD, USA, Quintiles, Reading, 3 4 5 UK, AstraZeneca, Macclesfield, UK, AstraZeneca, Cambridge, UK, Quintiles Advisory Services, Hoofddorp, The Netherlands THE IMPORTANCE OF MODEL CONCEPTUALISATION: A CASE STUDY IN ANKYLOSING SPONDYLITIS (AS) AND NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS (NR-AXSPA) Sideris E, Soares M, Palmer S,University of York, Heslington, York, UK UNDERSTANDING THE POLICY-RELEVANT PORTION OF THE EFFICIENT FRONTIER IN SCREENING INTERVENTIONS: THE IMPORTANCE OF COMPARATOR STRATEGIES O'Mahony JF,Trinity College Dublin, Dublin, Ireland INVESTIGATING THE IMPLEMENTATION OF ADVERSE EVENTS IN ECONOMIC MODELS: A SYSTEMATIC LITERATURE REVIEW IN MULTIPLE SCLEROSIS AND HUMAN IMMUNODEFICIENCY VIRUS 1 2 2 1 2 Gillies H , Polyzoi M , Medin E , PAREXEL International, London, UK, PAREXEL International, Stockholm, Sweden MAPPING THE IRRITABLE BOWEL SYNDROME QUALITY OF LIFE MEASURE (IBS-QOL) TO EQ-5D IN PATIENTS WITH IRRITABLE BOWEL SYNDROME WITH DIARRHOEA (IBS-D)

1

PRM125 D11

PRM126 D12

PRM127 D13 PRM128 D14

PRM129 D15

PRM130 D16

PRM131 D17

PRM132 D18

PRM133 D19

PRM134 D20

PRM135 D21

PRM136 D22

PRM137 D23

PRM138 D24

PRM139 D25

PRM140 D26

2

3

4

5

6

7 1

Bjorner JB , Rendas-Baum R , Carson RT , Boer R , Tucker C , Andrae DA , Brazier JE , Optum Outcomes, Lincoln, RI, 2 3 4 5 USA, Optum, Lincoln, RI, USA, Allergan plc, Jersey City, NJ, USA, Allergan plc, Irvine, CA, USA, Allergan plc, Marlow, 6 7 Buckinghamshire, UK, Allergan plc, Austin, TX, USA, University of Sheffield, Sheffield, UK INFLUENCE OF AIR POLLUTION ON SOME PREGNANCY OUTCOMES AND BURDEN OF PNEUMONIA ON CHILDREN UNDER FIVE YEARS OLD IN MONGOLIA Dorj G, Dorj G, Gendenragchaa B, Ochir C,Mongolian National University of Medical Sciences, Ulaanbaatar, Mongolia DEFINING REAL-WORLD PRODUCT PERFORMANCE USING SURVIVAL ANALYSIS AND SUPERIVSED MACHINE LEARNING 1 2 1 1 2 Geldof T , van Dyck W , Moreau Y , KU Leuven, Leuven, Belgium, Vlerick Business School, Brussels, Belgium COMPARISON STUDY BASED ON SIMULATION OF PATIENT PATHWAYS USING MULTI-STATE MODELS IN ONCOLOGY Rakonczai P, Lang Z, Balazs T, Bacskai M,Healthware Consulting Ltd., Budapest, Hungary PHARMACOLOGICAL INTERVENTIONS FOR FAMILIAL HYPERCHOLESTEROLAEMIA IN CHILDREN AND ADOLESCENTS: AN EXPLORATORY EVALUATION USING ADVANCED HIERARCHICAL NETWORK META-ANALYSIS TECHNIQUES Langford BE, Wickstead RM, Murphy D, Marsh W, Beale RC, Evans JS, Kusel J, Griffiths M,Costello Medical Consulting Ltd, Cambridge, UK INVESTIGATING THE EFFECTS OF TESTING AND ADJUSTING FOR NONLINEARITY USING CATEGORIZATION IN PREDICTION MODELS WITH COSTS AS OUTCOME Brouwers DB, Nieboer D, Bosmans JE, van Tulder MW, Heymans MW, van Dongen JM,Vrije Universiteit Amsterdam, Amsterdam, The Netherlands COMPARATIVE EFFICACY OF TIME TO VIROLOGIC SUPPRESSION IN TREATMENT-NAIVE HIV-1 PATIENTS: A NETWORK META-ANALYSIS OF LONGITUDINAL DATA Snedecor SJ,Pharmerit International, Bethesda, MD, USA METHODOLOGICAL REVIEW OF SURVIVAL MODELS: APPLICATION TO A PERSISTENCE ANALYSIS BASED ON LONG ACTING PARENTERAL ANTIPSYCHOTIC IN RETAIL PHARMACIES IN FRANCE Harmand S, El Mouaddin N,IMS Health, Puteaux, France PREDICTING PATIENT-REPORTED OUTCOMES FROM DISEASE-SPECIFIC QUESTIONNAIRES: A COMPARISON OF SEVEN METHODOLOGIES Gheorghe M,Erasmus University, Rotterdam, The Netherlands GENERALISING RESULTS FROM COST-EFFECTIVENESS ANALYSIS: A COMPARISON OF METHODS TO ACCOUNT FOR COVARIATES 1 1 2 1 2 Mantopoulos T , Dias S , Welton NJ , University of Bristol, BRISTOL, UK, University of Bristol, Bristol, UK STATISTICAL MODELS TO PREDICT INDICATION OF RESPIRATORY PATIENTS BETWEEN ASTHMA AND COPD 1 1 2 1 1 3 2 1 2 Ilgin Y , Staus A , Chauvin F , Leheyda N , Wolk A , Witte M , Subramani S , IMS Health, Frankfurt, Germany, IMS Health, La 3 Defense Cedex, France, IMS Health, London, UK BRAIN METASTASIS PREDICTION IN BREAST CANCER WOMEN: USEFULNESS OF MATHEMATICAL MODELING OF MONTECARLO 1 2 2 3 4 5 1 Sat-Muñoz D , Balderas-Peña L , Cruz-Corona E , Ortiz-González F , Chagollán-Ramírez J , Chávez-Hurtado J , Universidad de 2 Guadalajara. Centro Universitario de Ciencias de la Salud, Guadalajara, Jalisco, Mexico, UMAE Hospital de Especialidades 3 Centro Médico Nacional de Occidente IMSS, Guadalajara, Jalisco, Mexico, Unidad Médica de Alta Especialidad Hospital de 4 Especialidades. Centro Médico Nacional de Occidente, Guadalajara, Jalisco, Mexico, Universidad de Guadalajara. Centro 5 Universitario de Ciencias Económico Administrativas, Zapopan, Jalisco, Mexico, Universidad de Guadalajara, Zapopan, Mexico REFLECTING UNCERTAINTY IN EARLY HTA WHEN EVIDENCE ON PARAMETER DISTRIBUTIONS IS LACKING: A COMPARISON OF METHODS 1 1 2 1 1 2 Koffijberg H , Degeling K , Janssen MP , IJzerman MJ , University of Twente, Enschede, The Netherlands, University Medical Center Utrecht, Utrecht, The Netherlands LENALIDOMIDE FOR TREATING MULTIPLE MYELOMA AFTER 1 PRIOR TREATMENT; AN APPLICATION OF MULTI-STATE MARKOV MODELLING FOR THE EXTRAPOLATION OF PATIENT LEVEL SURVIVAL DATA 1 1 1 2 1 2 Saunders O , Gregory J , Lee D , Farrell J , BresMed, Sheffield, UK, Celgene, Uxbridge, UK BOOSTING A MODELLER'S ARMOURY: PURSUING REALISTIC AND EFFICIENT COMPETING RISK HEALTH ECONOMIC MODELS (HEMS) Kay SW,Model Outcomes Ltd, Cheshire, UK METHODS FOR TIME-VARYING EXPOSURE – A LITERATURE REVIEW 1 2 1 3 4 5 1 1 Linder M , Vago E , Bahmanyar S , Heeg B , Myers D , Zhang M , Andersen M , Karolinska Institutet, Stockholm, 2 3 4 5 Sweden, Jansen, Budapest, Hungary, Ingress Health, Rotterdam, The Netherlands, Jansen, Stockholm, Sweden, Jansen Scientific Affairs, Titusville, NJ, USA CORRECTLY CAPTURING UNCERTAINTY IN TREATMENT EFFECTS IN SIMULATION MODELING

Willis M, Asseburg C,The Swedish Institute for Health Economics (IHE), Lund, Sweden PRM141 D27 DEVELOPING A CONCEPTUAL FRAMEWORK AND A TOOL FOR MEASURING ABSORPTIVE CAPACITY IN PHARMACEUTICAL COMPANIES 1 2 3 2 4 1 Sanati E , Kebriaeezadeh A , Davari M , Abdollahi asl A , Keshavarz K , Tehran University of Medical Sciences, Faculty of 2 Pharmacy, Tehran, Iran (Islamic Republic of), Department of Pharmacoeconomics and Pharmaceutical Management, Faculty of 3 Pharmacy, Tehran University of Medical Sciences, Tehran, Iran (Islamic Republic of), Tehran University of Medical Sciences, 4 Tehran, Iran (Islamic Republic of), Shiraz University of Medical Sciences, School of Management and Information Sciences, Shiraz, Iran (Islamic Republic of) PRM142 D28 KEY ASPECTS IN THE MODELLING OF DENGUE TRANSMISSION: RESULTS FROM A FOCUSED LITERATURE REVIEW 1 1 2 1 2 Kharitonova E , Aballea S , Knerer G , Creativ-Ceutical, Paris, France, Takeda Pharmaceuticals International GmbH, Zurich, Switzerland RESEARCH ON METHODS - Patient-Reported Outcomes Studies PRM143 D29 QUALITY OF LIFE OF PATIENTS TREATED FOR MULTIPLE MYELOMA (MM) IN FRANCE IN A REAL-WORLD SETTING 1 2 2 2 3 3 1 1 1 Despiegel N , Touboul C , Flinois A , Saba G , Gonzalez-McQuire S , Suzan F , Blachier-Poisson C , Guilhaume C , Amgen 2 3 France, Paris, France, Kantar Health, Paris, France, Amgen (Europe) GmbH, Zug, Switzerland PRM144 D30 DEVELOPMENT OF A RESPONDER DEFINITION FOR THE MIGRAINE PHYSICAL FUNCTION IMPACT DIARY (MPFID) 1 1 2 2 2 1 3 4 5 Kawata AK , Hsieh R , Sapra S , Desai PR , Ortmeier BG , Poon JL , Tepper S , Stewart W , Dodick DW , Hareendran 6 1 2 3 4 A , Evidera, Bethesda, MD, USA, Amgen Inc, Thousand Oaks, CA, USA, Dartmouth, Lebanon, NH, USA, Sutter Health, Walnut 5 6 Creek, CA, USA, Mayo Clinic, Phoenix, AZ, USA, Evidera, London, UK PRM145 D31 USING ACOUSTIC SIMULATIONS OF HEARING LOSS TO DESCRIBE HEALTH STATES: ARE THEY FEASIBLE AND RELIABLE TO USE? 1 1 2 1 1 Williams NJ , Pierzycki R , Akeroyd MA , Kitterick PT , NIHR Nottingham Hearing Biomedical Research Unit, Nottingham, 2 UK, MRC Institute of Hearing Research, Nottingham, UK PRM146 D32 FURTHER VALIDATION OF THE HAEMOPREF IN A REAL-WORLD SETTING 1 1 1 2 3 4 1 2 Tolley C , Staunton H , Brohan E , Spurden D , Cicchetti M , Cappelleri JC , Adelphi Values Ltd, Bollington, UK, Pfizer Limited, 3 4 Surrey, UK, ExecuPharm Inc (On assignment as Protocol Operations Lead), Collegeville, PA, USA, Pfizer, Inc, Groton, CT, USA PRM147 D33 AN INTERNATIONAL PATIENT SURVEY ON HEALTH RELATED QUALITY OF LIFE ASPECTS NOT CPATURED BY EQ-5D-5L 1 2 2 1 2 Mossman J , Efthymiadou O , Kanavos P , European Brain Council, Brusells, Belgium, London School of Economics and Political Science, London, UK PRM148 D34 EXTERNAL VALIDITY AT STAKE IN MAPPING NON-PREFERENCE BASED DISEASE SPECIFIC MEASURES TO GENERIC PREFERENCE-BASED UTILITY VALUES IN ADVANCED CUTANEOUS MELANOMA 1 1 2 2 3 4 5 Franken M , Leeneman B , Jochems A , Schouwenburg M , Aarts M , van Akkooi A , van den Berkmortel F , van den Eertwegh 6 7 8 4 9 10 11 12 13 14 A , Groenewegen G , de Groot J , Haanen J , Hospers G , Kapiteijn H , Koornstra R , Kruit W , Louwman M , Piersma D , van 15 16 17 4 2 1 18 1 Rijn R , ten Tije A , Vreugdenhil G , Wouters M , van Zeijl M , van der Hoeven J , Uyl-de Groot C , Erasmus University 2 3 Rotterdam, Rotterdam, The Netherlands, Dutch Institute for Clinical Auditing, Leiden, The Netherlands, Maastricht University 4 5 Medical Center, Maastricht, The Netherlands, Netherlands Cancer Institute, Amsterdam, The Netherlands, Zuyderland Hospital, 6 7 Heerlen, The Netherlands, VU University Medical Center, Amsterdam, The Netherlands, University Medical Center Utrecht, 8 9 Utrecht, The Netherlands, Isala Hospital, Zwolle, The Netherlands, University Medical Center Groningen, Groningen, The 10 11 Netherlands, Leiden University Medical Center, Leiden, The Netherlands, Radboud University Medical Center, Nijmegen, The 12 13 Netherlands, Erasmus Medical Center, Rotterdam, The Netherlands, Netherlands Comprehensive Cancer Organisation, 14 15 Eindhoven, The Netherlands, Medical Spectrum Twente, Enschede, The Netherlands, Medical Center Leeuwarden, 16 17 Leeuwarden, The Netherlands, Amphia Hospital, Breda, The Netherlands, Maxima Medical Center, Eindhoven, The 18 Netherlands, Erasmus University, Rotterdam, The Netherlands PRM149 D35 MEASURING CAREGIVER QUALITY OF LIFE; WHICH ASPECTS REALLY MATTER? Efthymiadou O,London School of Economics and Political Science, London, UK PRM150 D36 VALUATION OF EQ-5D-5L HEALTH STATES: A COMPARISON OF THREE ASIAN COUNTRIES 1 1 2 3 1 2 Luo N , Wang P , Liu G , Juntana P , National University of Singpaore, Singapore, Singapore, Peking University, Beijing, 3 China, Social and Administrative Pharmacy Excellence Research Unit (SAPER Unit), Department of Pharmacy, Faculty of Pharmacy, Mahidol University, Bangkok, Thailand PRM151 D37 A NEW APPROACH TO PRESENTING HEALTH STATES IN STATED PREFERENCE VALUATION STUDIES 1 1 2 1 1 1 2 Cole AM , Shah K , Mulhern B , Feng Y , Devlin N , Office of Health Economics, London, UK, University of Technology Sydney, Sydney, Australia PRM152 D38 THE QUALITY-ADJUSTED TIME WITHOUT SYMPTOMS AND TOXICITY (Q-TWIST) IN (IMMUNO)-ONCOLOGY: A SYSTEMATIC REVIEW OF THE LITERATURE Wan Y, Tai M, Botteman M,Pharmerit International, Bethesda, MD, USA PRM153 E1 DEVELOPMENT OF A MAPPING ALGORITHM BETWEEN THE SGRQ AND EQ-5D-5L UTILITY VALUES IN A SEVERE ASTHMA POPULATION

1

PRM154 E2

PRM155 E3

PRM156 E4

PRM157 E5

PRM158 E6

PRM159 E7 PRM160 E8

PRM161 E9

PRM162 E10

PRM163 E11

PRM164 E12 PRM165 E13

PRM166 E14

2

2

3

4

5

2 1

Willson J , Mukuria CW , Labeit A , Gunsoy N , Starkie Camejo H , Alfonso-Cristancho R , Brazier J , GSK, Middlesex, 2 3 4 5 UK, University of Sheffield, Sheffield, UK, GSK, Stockley Park, Uxbridge, Middlesex, UK, GSK, Uxbridge, UK, GSK, Collegeville, PA, USA PSYCHOMETRIC VALIDATION OF THE PULMONARY ARTERIAL HYPERTENSION SYMPTOMS AND IMPACT ® (PAH-SYMPACT ) QUESTIONNAIRE 1 2 3 4 5 6 7 8 9 10 Gomberg-Maitland M , Channick R , Chin K , Fischer A , Frantz R , Roberts L , Miller C , Hunsche E , Zamanian R , Zastrow M , 4 1 2 3 Badesch D , University of Chicago, Chicago, IL, USA, Massachusetts General Hospital, Boston, MA, USA, University of Texas 4 5 Southwestern, Dallas, TX, USA, University of Colorado Denver, Aurora, CO, USA, Mayo Clinic Rochester, Rochester, MN, 6 7 8 USA, Evidera, Bethesda, MD, USA, Piedmont Healthcare, Atlanta, GA, USA, Actelion Pharmaceuticals Ltd, Allschwil, 9 10 Switzerland, Stanford University, Stanford, CA, USA, Actelion Pharmaceuticals US Inc, South San Francisco, CA, USA AN ANCHOR-BASED APPROACH TO DEFINE AN IMPAIRED DAY IN MIGRAINE PATIENTS UTILIZING THE MIGRAINE PHYSICAL FUNCTION IMPACT DIARY 1 1 2 2 2 1 1 3 4 Kawata AK , Hsieh R , Sapra S , Desai PR , Ortmeier BG , Gleeson S , Revicki DA , Lipton RB , Bayliss M , Hareendran 5 1 2 3 A , Evidera, Bethesda, MD, USA, Amgen Inc, Thousand Oaks, CA, USA, Albert Einstein College of Medicine, Bronx, NY, 4 5 USA, Optum, Lincoln, RI, USA, Evidera, London, UK TO TREAT OR WATCH? IDENTIFYING DRIVERS OF DECISIONS FOR PATIENTS WITH GEP-NET USING REFLECTIVE MULTI-CRITERIA DECISION ANALYSIS 1 2 2 2 2 2 2 2 3 4 Goetghebeur MM , Samaha D , Khoury H , O'Neil B , Lavoie L , Bennetts L , Wagner M , Badgley D , Gabriel S , Berthon A , 5 6 1 2 Dolan J , Kulke M , LASER Analytica and School of Public Health, University of Montreal, Montreal, QC, Canada, LASER 3 4 Analytica, Montreal, QC, Canada, IPSEN Pharma, Boulogne-Billancourt, France, IPSEN, Boulogne-Billancourt, 5 6 France, University of Rochester, Rochester, NY, USA, Dana-Farber Cancer Institute, Boston, MA, USA DEVELOPMENT AND CONTENT VALIDITY OF THE ADVANCED SYSTEMIC MASTOCYTOSIS SYMPTOM ASSESSMENT FORM (ADVSM-SAF) 1 2 1 2 1 1 3 4 5 1 1 Mazar I , Evans E , Taylor F , Patki A , Ojo O , Lamoureux RE , Horny H , Reiter A , Gotlib J , Shields A , Adelphi Values, 2 3 Boston, MA, USA, Blueprint Medicines, Cambridge, MA, USA, Ludwig-Maximilians University, München, 4 5 Germany, Universitätsmedizin Mannheim, Mannheim, Germany, Stanford University, Standord, CA, USA CONCEPTUAL MODEL AND CLINICAL OUTCOMES ASSESSMENTS FOR ANGELMAN’S SYNDROME: UTILIZING PRAGMATIC METHODS IN RARE DISEASES 1 2 2 2 2 1 2 Abetz-Webb L , Cabo R , Grieco J , Rakhit A , During M , Patient-Centred Outcomes Assessments, Bollington, UK, Ovid Therapeutics, New York, NY, USA ANALYZING A GERMAN INDEX FOR THE EQ-5D-5L BASED ON EXPERIENCED HEALTH Leidl R, Reitmeir P,Helmholtz Zentrum Munchen, Neuherberg, Germany THE IMPACT OF COUNTRY-SPECIFIC UTILITY TARIFFS ON THE OUTCOME OF COST-UTILITY ANALYSES; A CASE STUDY Bosmans JE, Rossenaar MM, van Dongen JM, van Tulder MW,Vrije Universiteit Amsterdam, Amsterdam, The Netherlands USING ORTHOGONAL DESIGN IN SELECTING HEALTH STATES FOR THE CONSTRUCTION OF EQ-5D-3L VALUE SET 1 2 3 4 1 2 Yang Z , Luo N , van Busschbach J , Stolk E , Erasmus University Rotterdam, Rotterdam, The Netherlands, National University 3 4 Singapore, Singapore, Singapore, Erasmus MC, Rotterdam, The Netherlands, EuroQol Research Foundation, Rotterdam, The Netherlands ELICITING STATED PREFERENCES REGARDING LIFE EXTENSIONS NEAR THE END OF LIFE: A PILOT STUDY FOR A REFINEMENT OF THE QALY 1 2 3 1 2 Taylor M , Filby A , Elvidge JS , York Health Economics Consortium, York, UK, York Health Economics Consortium, Heslington, 3 York, UK, University of Manchester, Manchester, UK HEALTH-RELATED QUALITY OF LIFE IN OPIOID USE DISORDER MEASURED BY UTILITIES: A SYSTEMATIC LITERATURE REVIEW 1 2 1 2 1 1 2 Cranmer H , Ronquest NA , Barnes A , Nadipelli VR , Akehurst R , BresMed Health Solutions, Sheffield, UK, Indivior Inc., Richmond, VA, USA RECONSIDERING EQ-5D; QUALITY OF LIFE DOMAINS THAT ARE IMPORTANT FOR MULTIPLE SCLEROSIS PATIENTS Mossman J, Efthymiadou O, Tinelli M, Kanavos P,London School of Economics and Political Science, London, UK "WHY CAN'T I JUST USE GOOGLE TRANSLATE?" A STUDY ON THE EFFECTIVENESS OF ONLINE TRANSLATION TOOLS IN TRANSLATION OF COAS 1 2 2 2 1 2 Lear A , Oke L , Forsythe C , Richards A , ICON PLC, Abingdon, UK, ICON Plc, Abingdon, UK WHAT MATTERS MOST? AN EXPLORATION OF DECISION CRITERIA CONSIDERED BY PATIENTS WITH GEP-NET AND PHYSICIANS USING HOLISTIC MULTI-CRITERIA DECISION ANALYSIS 1 2 2 2 2 2 2 2 3 4 Goetghebeur MM , Samaha D , O'Neil B , Khoury H , Bennetts L , Lavoie L , Wagner M , Badgley D , Gabriel S , Berthon A , 5 6 1 2 Dolan J , Kulke M , LASER Analytica and School of Public Health, University of Montreal, Montreal, QC, Canada, LASER 3 4 Analytica, Montreal, QC, Canada, IPSEN Pharma, Boulogne-Billancourt, France, IPSEN, Boulogne-Billancourt, 5 6 France, University of Rochester, Rochester, NY, USA, Dana-Farber Cancer Institute, Boston, MA, USA

PRM167 E15

PRM168 E16

PRM169 E17

PRM170 E18

PRM171 E19

PRM172 E20

PRM173 E21

PRM174 E22

PRM175 E23

PRM176 E24

PRM177 E25

PRM178 E26

PRM179 E27

PRM180 E28

A SYSTEMATIC REVIEW OF UTILITY DERIVATION METHODS: TIME TRADE OFF IN COMPARISON TO EQ-5D 1 2 2 1 2 Vollmer L , Shannon RJ , Walzer S , Geographic Solutions in Health, Tuebingen, Germany, MArS-imulation UG (h.b.), Weil am Rhein, Germany QUALITATIVE RESEARCH APPROACHES IN RARE DISEASES: ACID SPHINGOMYELINASE DEFICIENCY (ASMD) SYMPTOMS AND IMPACT AS REPORTED BY PATIENTS AND CAREGIVERS 1 2 3 1 1 1 1 2 Avetisyan R , Hareendran A , Stringer S , Tan S , Sanson B , Hass S , Sanofi Genzyme, Cambridge, MA, USA, Evidera, 3 London, UK, Evidera, Bethesda, MD, USA FORE! SWEEPING GENERALISATIONS DO NOT BOWL OVER ALL CULTURES… CULTURAL ADAPTATION IN THE KIDNEY DISEASE QUALITY OF LIFE QUESTIONNAIRE Richards A, Mead H, Towns L,ICON Plc, Abingdon, UK SYSTEMATIC REVIEW OF PSYCHOMETRIC PROPERTIES OF THE EQ-5D QUESTIONNAIRES IN PATIENTS WITH HEMATOLOGIC MALIGNANT NEOPLASMS 1 1 2 1 2 Mlynczak K , Wojcik A , Golicki D , HealthQuest, Warsaw, Poland, Department of Experimental & Clinical Pharmacology, Medical University of Warsaw, Warsaw, Poland ® CONTENT VALIDATION OF THE PULMONARY ARTERIAL HYPERTENSION SYMPTOMS AND IMPACT (PAH-SYMPACT ) QUESTIONNAIRE 1 2 3 4 5 6 7 8 9 Gomberg-Maitland M , Channick R , Chin K , Fischer A , Frantz R , Roberts L , Miller C , Hunsche E , Zamanian R , Badesch 4 1 2 3 D , University of Chicago, Chicago, IL, USA, Massachusetts General Hospital, Boston, MA, USA, University of Texas 4 5 Southwestern, Dallas, TX, USA, University of Colorado Denver, Aurora, CO, USA, Mayo Clinic Rochester, Rochester, MN, 6 7 8 USA, Evidera, Bethesda, MD, USA, Piedmont Healthcare, Atlanta, GA, USA, Actelion Pharmaceuticals Ltd, Allschwil, 9 Switzerland, Stanford University, Stanford, CA, USA A STUDY OF THE SUCCESSFUL ADAPTATION OF THE QUALITY OF LIFE QUESTIONNAIRE - BRONCHIECTASIS FROM PAPER TO ELECTRONIC FORMAT 1 2 3 4 5 1 2 Simpson H , Ong SH , Quittner A , McEvoy K , Dhariwal M , Corporate Translations, Inc., East Hartford, CT, USA, Novartis 3 4 5 Pharma AG, Basel, Switzerland, University of Miami, Miami, FL, USA, CRF Health, London, UK, Novartis Ireland Ltd, Dublin, Ireland COMPARING THE EQ-5D-5L VALUE SETS ACROSS DIFERENT COUNTRIES – IMPACT ON INPERTRETATION OF CLINICAL STUDY RESULTS 1 2 3 4 1 5 1 1 Gerlinger C , Bamber L , Leverkus F , Schwenke C , Haberland C , Schmidt G , Endrikat J , Bayer Pharma AG, Berlin, 2 3 4 Germany, Bayer Pharma AG, Wuppertal, Germany, Pfizer Deutschland GmbH, Berlin, Germany, SCO:SSiS, Berlin, 5 Germany, Saarland University, Homburg/Saar, Germany TRANSLATABILITY EVALUATION OF THE ROME IV DIAGNOSTIC QUESTIONNAIRE FOR ADULTS 1 1 2 3 4 5 5 1 Crane AL , Campbell T , Popielnicki A , Sperber AD , Drossman D , Palsson OS , Whitehead WE , Sweeney E , O'Brien 1 1 2 3 K , TransPerfect, New York, NY, USA, TransPerfect, Boston, MA, USA, Ben-Gurion University of the Negev, Beer-Sheva, 4 5 Israel, 2University of North Carolina, Chapel-Hill, NC, USA, University of North Carolina, Chapel Hill, NC, USA UNDERSTANDING THE UTILITY VALUE OF PATIENTS WITH HEAVILY PRE-TREATED MULTIPLE MYELOMA 1 1 1 2 1 2 Hadi M , Swinburn P , de Freitas HM , Ito T , Mapi Group, London, UK, Janssen Health Economics & Market Access EMEA, High Wycombe, UK WELL-BEING: WHAT IS IT, HOW DOES IT COMPARE TO HEALTH AND WHAT ARE THE IMPLICATIONS OF USING IT TO INFORM HEALTH POLICY? 1 1 1 2 1 2 Brazier J , Mukuria CW , Peasgood T , Bjorner JB , University of Sheffield, Sheffield, UK, Optum, Lincoln, RI, USA CROSS-CULTURAL ADAPTATION OF THE ZARIT CAREGIVER INTERVIEW FOR ALZHEIMER'S DISEASE (ZCI-AD) AND THE CAREGIVER GLOBAL IMPRESSION SCALES IN 13 LANGUAGES 1 1 1 2 3 4 1 1 Le Scouiller S , Edgar C , Rylands A , Giroudet C , Regnault A , Zarit S , Rofail D , Roche Products Limited, Welwyn Garden 2 3 4 City, UK, Mapi, Lyon, France, Modus Outcomes, Lyon, France, Pennsylvania State University, University Park, PA, USA USING ANALYTIC HIERARCHY PROCESS TO WEIGHT PATIENT-RELEVANT OUTCOMES IN THE TREATMENT OF PSORIASIS FOR CALCULATING THE PATIENT BENEFIT INDEX 1 2 1 1 2 Gutknecht M , Danner M , Augustin M , University Medical Center Hamburg-Eppendorf, Hamburg, Germany, University Hospital Cologne, Cologne, Germany TRANSLATION OF THE DN4 (DOULEUR NEUROPATHIQUE EN 4 QUESTIONS) INTO 85 LANGUAGES: CHALLENGES AND IMPORTANCE OF THE CONCEPTUAL DEFINTION OF THE ORIGINAL VERSION 1 2 2 3 2 1 2 Bouhassira D , Dulac M , Bindi P , Nguyen A , Acquadro C , Ambroise Paré Hospital, Boulogne-Billancourt, France, Mapi 3 Research Trust, Lyon, France, Mapi, Lyon, France MULTIPLE MYELOMA AND HEALTH-RELATED QUALITY OF LIFE FROM EQ-5D AND EORTC: A SYSTEMATIC LITERATURE REVIEW 1 2 3 3 4 4 5 6 1 Qerimi V , Jahn B , Vukicevic D , Jevdjevic M , Holzner B , Kemmler G , Siebert U , Rochau U , UMIT - University for Health Sciences, Medical Informatics and Technology, Department of Public Health, Health Services Research and Health Technology 2 Assessment/Ss. Cyril and Methodius University in Skopje, Faculty of Pharmacy, Skopje, Macedonia, Hall i.T., Austria, Department

PRM181 E29

PRM182 E30

PRM183 E31 PRM184 E32

PRM185 E33

PRM186 E34

PRM187 E35

PRM188 E36

PRM189 E37

PRM190 E38

PRM191 F1

PRM192 F2

PRM193 F3

of Public Health, Health Services Research and Health Technology Assessment, Medical Informatics and Technology (UMIT), Hall 3 i.T., Austria, UMIT - University for Health Sciences, Medical Informatics and Technology, Institute of Public Health, Medical Decision Making and Health Technology Assessment, Department of Public Health, Health Services Research and Health 4 Technology Assessment, Hall i.T., Austria, Medical University of Innsbruck, Department of Psychiatry and Psychotherapy, 5 Innsbruck, Austria, and Director, Division for HTA, ONCOTYROL – Center for Personalized Cancer Medicine, Hall i.T., 6 Austria, UMIT - University for Health Sciences, Medical Informatics and Technology, Department of Public Health, Health Services Research and Health Technology Assessment/ONCOTYROL - Center for Personalized Cancer Medicine, Area Health Technology Assessment, Hall i.T./Innsbruck, Austria TRANSLATION OF CHINESE VERSION OF MEASURE YOURSELF MEDICAL OUTCOME PROFILE (MYMOP) AND APPLICATION IN THE CORONARY HEART DISEASE 1 2 1 1 2 1 Zhang F , Zhang S , Wang Y , Zhang Z , Yang G , The Affiliated Hospital of Liaoning University of Traditional Chinese Medicine, 2 Liaoning, China, Shenyang, China, Liaoning University of Traditional Chinese Medicine, Liaoning, China, Shenyang, China EUROQOL TO ASSESS THE QUALITY OF LIFE WITH SMARTPHONE 1 1 1 2 1 Vorobiev A , Vorobiev P , Krasnova L , Vorobiev M , Russian Society for Pharmacoeconomics and Outcomes Research, 2 Moscow, Russian Federation, Newdiamed, Moscow, Russian Federation PERFORMANCE OF SEARCH FILTERS TO IDENTIFY HEALTH STATE UTILITY STUDIES Arber M, Garcia S, Veale T, Edwards M, Shaw A, Glanville J,York Health Economics Consortium, York, UK WHEN SHOULD TRANSLATIONS OF CLINICAL OUTCOME ASSESSMENTS (COAS) BE CONSIDERED OBSOLETE? RECOMMENDATIONS FROM MAPI’S TRANSLATIONS LIFE EXPECTANCY WORKING GROUP 1 1 1 2 1 1 1 2 Giroudet C , Salmassi L , Prill M , Berne C , Berrou M , Boudrot A , Mapi, Lyon, France, Mapi Research Trust, Lyon, France RECOMMENDATIONS ON COGNITIVE DEBRIEF AND USABILITY STUDIES FOR INSTRUMENT MIGRATION FROM PAPER TO ELECTRONIC MODALITIES BASED ON A QUALITATIVE SYNTHESIS OF VALIDATION STUDIES 1 2 3 1 2 3 Muehlhausen W , Byrom B , Skerritt B , ICON plc, Dublin 18, Ireland, ICON Clinical Research, Marlow, UK, ICON, Dublin, Ireland LINGUISTIC VALIDATION AND ELECTRONIC MIGRATION OF THE KANSAS CITY CARDIOMYOPATHY QUESTIONNAIRE (KCCQ) 1 2 1 2 Sydor B , Spertus J , TransPerfect, Washington, DC, USA, Health Outcomes Sciences, Overland Park, KS, USA LINGUISTIC VALIDATION OF THE INJECTION-TREATMENT ACCEPTANCE QUESTIONNAIRE (I-TAQ) 1 2 3 1 2 3 Crane AL , Popielnicki A , Sanchez RJ , TransPerfect, New York, NY, USA, TransPerfect, Boston, MA, USA, PHARMO Institute for Drug Outcomes Research, Utrecht, The Netherlands DEVELOPMENT OF A GUIDANCE ON THE IMPLEMENTATION AND USE OF EORTC INSTRUMENTS IN ELECTRONIC APPLICATIONS 1 1 2 3 4 5 1 2 Kulis D , Bottomley A , Holzner B , Koller M , Swinburn P , Itani A , EORTC, Brussels, Belgium, Medical University of Innsbruck, 3 4 5 Innsbruck, Austria, University Hospital Regensburg, Regensburg, Germany, Mapi Group, London, UK, Mapi, Lyon, France VIEWPOINTS OF THALASSAEMIA PATIENTS ON THE COMBINATION OF TRADITIONAL & COMPLEMENTARY MEDICINE (T&CM) WITH THE CONVENTIONAL THALASSAEMIA TREATMENT:A QUALITATIVE UNDERSTANDING APPROACH 1 2 3 4 1 Ismail wI , Hassali MA , Farooqui M , Saleem F , Faculty of Health Sciences University Technology MARA, Penang, 2 3 4 Malaysia, Universiti Sains Malaysia, Penang, Malaysia, Qassim University, Qassim, Saudi Arabia, University of Bolochistan, Quetta, Pakistan INCORPORATING BIOMETRIC DATA FROM WEARABLE ACTIVITY TRACKERS WITH STUDY DATA IN FRANCE AND THE UK 1 1 1 2 3 3 1 1 2 Fink L , Chanot G , Bernard F , Mondry B , Normand A , Vegreville M , Bondarenko K , Kantar Health, Paris, France, Kantar 3 Health, New York, NY, USA, Withings, Issy-les-Moulineaux, France WATCH OUT FOR BERKSON'S BIAS (BB)! SETTING HEALTH-RELATED QUALITY OF LIFE (HRQOL) TREATMENT TARGETS WITH MATCHING-ADJUSTED INDIRECT COMPARISON (MAIC) IN ORDER TO PREDICT MATCHED GENERAL POPULATION CONTROL (MGPC) TARGETS, ASSESS POTENTIAL TO BENEFIT (PTB) AND REVEAL UNMET MEDICAL NEED (UMN) 1 2 2 3 4 1 2 Soini EJ , Heinonen J , Miettola E , Ryynänen O , Koskela T , ESIOR Oy, Kuopio, Finland, School of Medicine, University of 3 Tampere, Finland, Faculty of Health Sciences, University of Eastern Finland, and Unit of Primary Health Care, Kuopio University 4 Hospital, Kuopio, Finland, Department of General Practice, University of Tampere, and Omapihlaja, Pihlajalinna Terveys Oy, Tampere, Finland AN A PRIORI DECISION CRITERIA ELICITATION METHOD FOR TREATMENT DECISION-MAKING IN ELDERLY COLORECTAL CANCER PATIENTS 1 1 1 2 1 2 Keizer J , IJzerman MJ , van Til JA , Wymenga AM , University of Twente, Enschede, The Netherlands, Medical Spectrum Twente Hospital, Enschede, The Netherlands THE ECONOMIC IMPACT OF INFLUENZA-LIKE ILLNESS ON FAMILIES LIVING IN THE UK DEMONSTRATED BY THE COLLECTION OF ONLINE DATA Wade AG, Crawford GM, McLennan K,Patients Direct, Glasgow, UK

RESEARCH ON METHODS - Statistical Methods PRM194 F4

PRM195 F5

PRM196 F6 PRM197 F7

PRM198 F8

PRM199 F9

PRM200 F10

PRM201 F11 PRM202 F12 PRM203 F13

PRM204 F14

COMPARISON OF METHODS FOR INDIRECT TREATMENT COMPARISON COMBINING INDIVIDUAL AND AGGREGATE PATIENT DATA: A SIMULATION Rasouliyan L,RTI Health Solutions, Barcelona, Spain THE ADDED VALUE OF REAL-WORLD EVIDENCE TO CONNECT DISCONNECTED NETWORKS FOR NETWORK META-ANALYSIS: A CASE STUDY IN RHEUMATOID ARTHRITIS Jenkins DA, Martina R, Dequen P, Bujkiewicz S, Abrams K,University of Leicester, Leicester, UK COMPARISON OF BAYESIAN NETWORK META-ANALYSES IN A WINBUGS AND SAS FRAMEWORK Le Moine J, Abeysinghe SS,RTI Health Solutions, Didsbury, UK ADJUSTING VARIANCE PARAMETERS TO INCORPORATE UNCERTAINTY INTO HEALTH ECONOMICS MODELS FOLLOWING TREATMENT SWITCHING 1 2 2 1 2 Ray J , Bennett I , Paracha N , F. Hoffmann-La Roche, Basel, Switzerland, F. Hoffman-La Roche, Basel, Switzerland EXTRACTING DOSAGE PER DAY FROM FREE-TEXT MEDICATION PRESCRIPTIONS 1 2 3 1 2 1 2 Törnblom M , Bergman G , Jørgensen L , Fackle-Fornius E , Rosenlund M , Stockholm University, Stockholm, Sweden, IMS 3 Health, Solna, Sweden, Pygargus/IMS Health, Solna, Sweden IDENTIFYING HIGHER-VALUE SUBPOPULATIONS FOR TREATMENT IN HETEROGENOUS RARE DISEASES: AN EXAMPLE STUDY OF EARLY RESPONDERS TO TEDUGLUTIDE FOR SHORT BOWEL SYNDROME 1 2 2 3 4 5 3 1 2 Chen K , Xie J , Tang C , Zhao J , Olivier C , Jeppesen PB , Signorovitch J , Shire plc, Lexington, MA, USA, Analysis Group, 3 4 5 New York, NY, USA, Analysis Group, Boston, MA, USA, Shire GmbH, Zug, Switzerland, Rigshospitalet, Copenhagen, Denmark IS EARLY INITIATION OF BIOLOGIC TREATMENT MORE EFFECTIVE THAN A STEP UP TREATMENT APPROACH FOR NEW ONSET JUVENILE IDIOPATHIC ARTHRITIS?-- USING A CAUSAL INFERENCE APPROACH TO ACHIEVE A DOUBLE ROBUST ESTIMATE 1 1 1 1 1 2 1 1 Huang B , Morgan E , Chen C , Adams M , Brunner H , Guo J , Seid M , Cincinnati Children's Hospital Medical Center, 2 Cincinnati, OH, USA, Univeristy of Cincinnati, Cincinnati, OH, USA ADJUSTMENT OF OS IN CRYSTAL FOR POST-STUDY ANTI-CANCER THERAPIES 1 1 2 1 2 Stapelkamp C , Byrne B , van Hout B , Merck Serono Ltd., Feltham, UK, University of Sheffield, Sheffield, UK NETWORK META-ANALYSIS ACROSS LONGITUDINAL TIME POINTS: A COMPARISON OF AVAILABLE METHODS 1 1 1 2 1 2 Tallarita M , de Iorio M , Baio G , Karabis A , University College London, London, UK, Mapi Group, Houten, The Netherlands THE USE OF ‘OFF THE SHELF’ INFORMATIVE PRIOR DISTRIBUTIONS IN RANDOM EFFECT NETWORK META-ANALYSIS MODELS 1 2 2 1 2 Batson S , Abrams K , Sutton A , DRG, Bicester, UK, University of Leicester, Leicester, UK RECREATIONAL USE OF PHOSPHODIESTERASE 5 INHIBITORS AND ITS ASSOCIATED FACTORS AMONG UNDERGRADUATE MALE STUDENTS IN AN ETHIOPIAN UNIVERSITY: A CROSS-SECTIONAL STUDY 1 1 2 1 2 2 1 Gebreyohannes EA , Bhagavathula AS , Gebresillassie bM , Tefera YG , Belachew SA , Erku dA , University of Gondar, 2 Gondar, Ethiopia, university of gondar, gondar, Ethiopia

RESEARCH ON METHODS - Study Design PRM205 F15

PRM206 F16

PRM207 F17

PRM208 F18

PRM209 F19

A SYSTEMATIC LITERATURE REVIEW ON THE EFFICACY-EFFECTIVENESS GAP: COMPARISON OF RANDOMIZED CONTROLLED TRIALS AND OBSERVATIONAL STUDIES OF GLUCOSE-LOWERING DRUGS 1 1 2 3 4 1 2 Ankarfeldt MZ , Adalsteinsson E , Groenwold RH , Ali S , Klungel O , Novo Nordisk A/S, Soeborg, Denmark, University Medical 3 4 Center Utrecht, Utrecht, The Netherlands, University of Oxford, Oxford, UK, Utrecht University, Utrecht, The Netherlands MAKING SENSE OF CLINICAL DATA REPORTED IN SECONDARY CONDITIONS: THE EPIDEMIOLOGY AND CLINICAL BURDEN OF HYPERGLYCAEMIA Cadwell K, Pooley N, Olariu E, Jones G, Papageorgakopoulou C, Fox D,PHMR Ltd, London, UK HOW TO MAXIMISE THE VALUE AND PAYERS’ ACCEPTANCE OF SINGLE ARM TRIAL DATA IN ONCOLOGY? 1 2 3 4 1 1 2 3 Hoyle C , Wright J , Ede J , van Engen A , Ryan J , AstraZeneca, Cambridge, UK, Quintiles, Reading, UK, AstraZeneca, 4 Cambridgeshire, UK, Quintiles Advisory Services, Hoofddorp, The Netherlands IMPORTANT METHODOLOGICAL CONSIDERATIONS AND STRATEGIES FOR RESOLUTION FOR MULTINATIONAL RETROSPECTIVE CHART REVIEW STUDIES Bassel M,UBC: An Express Scripts Company, Dorval, QC, Canada VALIDITY AND RELIABILITY OF THREE NEW INSTRUMENTS FOR PARENTS AND CHILDREN ASSESSING NUTRITION AND PHYSICAL ACTIVITY BEHAVIORS, ENVIRONMENT AND KNOWLEDGE AND HEALTH IN CHILDHOOD AND ADOLESCENCE IN GREECE DURING THE ECONOMIC RECESSION: DATA FROM THE NATIONAL ACTION PLAN FOR PUBLIC HEALTH (MIS301205) 1 2 3 3 3 2 4 5 Carayanni V , Vlachopapadopoulou E , Psaltopoulou T , Koutsouki D , Bogdanis G , Karachaliou F , Manios Y , Kapsali A , 2 3 2 1 2 Papadopoulou A , Hatzakis A , Michalakos S , Technological Educational Institute of Athens, Athens, Greece, Children's Hosp. 3 4 5 P. & A. Kyriakou, Athens, Greece, Univ. of Athens, Athens, Greece, Harokopio Univ. of Athens, Athens, Greece, Ministry of

PRM210 F20 PRM211 F21

Health, Αthens, Greece ADAPTING TO THE CHALLENGE: HOW ARE INNOVATIVE STUDY DESIGNS BEING USED IN RARE DISEASES? Berry LJ, Eddowes LA,Costello Medical Consulting Ltd, Cambridge, UK MAKING PRAGMATIC TRIALS WORK 1 1 1 2 1 1 1 Zuidgeest MG , Stolk P , Oude Rengerink K , Goetz IA , Welsing PM , Grobbee DE , University Medical Center Utrecht, Utrecht, 2 The Netherlands, Eli Lilly and Company, Windlesham, Surrey, UK

RESEARCH ON METHODS - Conceptual Papers PRM212 F22

PRM214 F24 PRM215 F25

PRM216 F26

PRM217 F27 PRM218 F28 PRM219 F29

PRM220 F30

PRM221 F31

PRM222 F32

PRM223 F33 PRM224 F34

PRM225 F35

PRM226 F36

PRM227 F37

PRM228 F38

GENERATING REAL WORLD EVIDENCE: GUIDANCE ON THE DESIGN AND CONDUCT OF RETROSPECTIVE CHART REVIEW STUDIES Korol E, Osenenko KM, Kayaniyil S, McMullen S,ICON Commercialisation & Outcomes, Vancouver, BC, Canada QUASI-EXPERIMENTAL METHODS FOR REAL WORLD DATA Menke JM,A. T. Still Research Institute, Mesa, AZ, USA WHEN IS THE USE OF A SYSTEMATIC LITERATURE REVIEW APPROPRIATE? A COMPARISON OF SYSTEMATIC, RAPID, AND SCOPING REVIEWS AND THEIR APPLICATION TO THE HTA PROCESS Pooley N, Olariu E, Floyd D,PHMR Ltd, London, UK RATIONALE AND DESIGN OF A MULTI-CENTER SURVEY TO EVALUATE PRODUCTIVITY LOSSES AND INDIRECT COSTS AFTER CARDIOVASCULAR EVENTS IN EUROPE 1 2 2 1 3 1 2 Gerlier L , Sidelnikov E , Kutikova L , Lamotte M , Annemans L , IMS Health, Zaventem, Belgium, Amgen (Europe) GmbH, Zug, 3 Switzerland, Ghent University - Brussels University, Ghent, Belgium INNOVATIVE APPROACH TO KEEPING EVIDENCE CURRENT AND GUIDELINES LIVING Lewis SZ, Newton M,Doctor Evidence, Santa Monica, CA, USA COMPARISON BETWEEN CANCER DRUGS ASSESSMENT IN PORTUGAL AND UNITED KINGDOM 1 2 1 1 2 Carmo S , Ramos R , Crespo N , ISCTE-IUL, Lisbon, Portugal, INFARMED, I.P., Lisbon, Portugal APPLICATION OF QUALITY INDICATORS TO ENABLE ECONOMIC EVALUATION OF QUALITY IMPROVEMENTS – A BAYESIAN DECISION THEORETICAL AND VALUE OF INFORMATION ANALYTICAL FRAMEWORK Vestergaard AS, Holger Ehlers L,Aalborg University, Aalborg, Denmark METHODS FOR THE DESIGN AND CONDUCT OF MEDICAL RECORD REVIEWS IN ONCOLOGY 1 2 3 4 5 4 4 1 Wilke T , Baeten S , Solem CT , Penrod JR , Verleger K , Lees M , Manley Daumont M , INGRESS-Health HWM GmbH, Wismar, 2 3 Germany, SiRM - Strategies in Regulated Markets B.V., Den Haag, The Netherlands, Pharmerit International, Bethesda, MD, 4 5 USA, Bristol-Myers Squibb, Paris, France, Pharmerit International, Berlin, Germany HEALTH ECONOMICS ANALYSIS PLANS: WHERE ARE WE NOW? 1 2 2 3 3 1 1 1 Thorn JC , Ridyard CH , Hughes D , Wordsworth S , Mihaylova B , Noble S , Hollingworth W , University of Bristol, Bristol, 2 3 UK, Bangor University, Bangor, UK, University of Oxford, Oxford, UK MULTI-CRITERIA DECISION ANALYSIS FROM THE COST-EFFECTIVENESS PERSPECTIVE: IS MCDA A COHERENT WAY TO ALLOCATE HEALTHCARE RESOURCES? O'Mahony JF,Trinity College Dublin, Dublin, Ireland SYSTEMATIC REVIEW TOOLBOX 1 2 1 2 Marshall C , Sutton A , York Health Economics Consortium Ltd, York, UK, University of Sheffield, Sheffield, UK A PATIENT LEVEL SIMULATION MODEL 1 1 2 3 4 1 1 Gharibnaseri Z , Davari M , Cheraghali A , Eshghi P , Ravanbod R , Spendar R , Tehran University of Medical Sciences, Tehran, 2 3 Iran (Islamic Republic of), Baghyatollah Medical Sciences University, Tehran, Iran (Islamic Republic of), Shahid Beheshti 4 University of Medical Sciences, Tehran, Iran (Islamic Republic of), Tarbiat Modares University, Tehran, Iran (Islamic Republic of) INTERACTIVE HEALTH ECONOMIC MODELS CONFIGURED WITH GOOGLE ANALYTICS. DATA AND METRICS APPLICABLE FOR A HEALTHCARE RESEARCH 1 2 2 1 2 Topachevskyi O , Siabro V , Volovyk A , Digital Health Outcomes, Brussels, Belgium, Digital Health Outcomes, Kiev, Ukraine A CONCEPTUAL APPROACH FOR INCLUDING PRODUCTIVITY LOSSES IN HEALTH ECONOMIC EVALUATIONS FROM A SOCIETAL VIEWPOINT Müller M, Hofmann S,WifOR GmbH, Darmstadt, Germany GUIDANCE ON SELECTING APPROPRIATE METHODS WHEN CONSIDERING ADJUSTING OVERALL SURVIVAL FOR TREATMENT SWITCH IN ONCOLOGY STUDIES 1 2 3 4 1 2 Watkins CL , Latimer N , Wang J , Wright EJ , Clarostat Consulting Limited, Alderley Edge, UK, University of Sheffield, Sheffield, 3 4 UK, Celgene International, Boudry, Switzerland, Roche, Basel, Switzerland USING EVIDENCE REVIEWS TO DEVELOP FOCUSED SYSTEMATIC REVIEW QUESTIONS Upton CM, Chadda S, Chapman R, Curry A,SIRIUS Market Access, London, UK

PRM229 G1

PRM230 G2

PRM231 G3 PRM232 G4

PRM233 G5

PRM234 G6

UTILISATION OF SURVIVAL OUTCOMES DATA TO FORECAST ECONOMIC IMPACT OF PRICING AND MARKET ACCESS SCENARIOS IN A MULTI-INDICATION PATIENT FLOW MODELS 1 1 2 3 1 1 2 Sogokon P , Hunt M , Kjeldgaard-Pedersen J , Furneri G , Chalmers M , CBPartners, London, UK, data2Impact, Copenhagen, 3 Denmark, EBMA Consulting SRL, Melegnano, Italy VALUE AND COST CONUNDRUM IN ADVANCED ONCOLOGY: INTEGRATION OF VALUE FRAMEWORKS INTO COST-EFFECTIVENESS ANALYES 1 2 1 1 1 2 Ambavane A , Benedict A , Lanitis T , Kongnakorn T , Evidera, London, UK, Evidera, Budapest, Hungary DESIGN AND OPERATIONAL CONSIDERATIONS FOR HYBRID RETROSPECTIVE-PROSPECTIVE STUDIES Page MJ, Walke HL,Medpace, Cincinnati, OH, USA HOW ASSESSMENT METHODS MAY AFFECT THE EFFICIENCY OF APPRAISAL PROCESS: A CRITICAL REVIEW Giorgia Tedesco G, Francesco Faggiano F, Andellini M, Leo E, Losito G, Pietro Derrico P, Matteo Ritrovato M,Bambino Gesù Children's Hospital, Rome, Italy METHODS FOR ANALYZING PATIENT-REPORTED OUTCOMES IN ONCOLOGY TRIALS 1 1 1 2 1 2 Williams P , Fofana F , de la Loge C , Arnould B , Mapi Group, Patient-Centered Outcomes, Lyon, France, Mapi Group, Lyon, France A SECURE SMARTPHONE APPLICATION FOR CLINICAL RESEARCH ON WOUND HEALING: NURSTRIAL Allaert F,Medical evaluation Chair ESC Dijon, Dijon, France

DISEASE- SPECIFIC STUDIES INDIVIDUAL'S HEALTH - Clinical Outcomes Studies PIH1 G7

PIH3 G8

PIH4 G9

PIH5 G10

PIH6 G11

PIH7 G12

PIH8 G13

ASSOCIATION BETWEEN EXPOSURE TO ANTICHOLINERGIC AND SEDATIVE DRUGS AND HEALTHCARE COSTS IN ELDERLY PATIENTS WITH COGNITIVE COMPLAINT 1 2 2 3 1 Gervais F , Dauphinot V , Krolak-Salmon P , Mouchoux C , Hôpital Edouard Herriot, Hospices Civils de Lyon, Lyon, 2 3 France, Clinical and Research Memory Centre of Lyon, Villeurbanne, France, Clinical Research Centre (CRC) - VCF (Aging – Brain - Frailty), Villeurbanne, France DETERMINATION OF CLINICAL AND COST-EFFECTIVENESS OF VARIOUS METHODS OF PREDICTING PRETERM BIRTH IN WOMEN WITH HIGH RISK Tuletova A, Dochshanova A,Astana Medical University, Astana, Kazakhstan EFFECT OF A MULTIFACTORIAL, INTERDISCIPLINARY INTERVENTION ON FALLS AND FALL RATE OF THE OLDER PEOPLE IN THE COMMUNITY 1 2 1 2 Lee SH , Kim HS , Gachon University, Incheon, South Korea, Chonbuk National University, Jeonju, Jeolabuk-do, South Korea THE PUBLIC HEALTH PERSPECTIVE OF AN INVESTIGATIONAL HERPES ZOSTER VACCINE IN THE UNITED KINGDOM (UK) 1 2 3 2 1 1 2 van Oorschot DA , Hunjan M , Varghese L , Canavan C , Curran D , GSK Vaccines, Wavre, Belgium, GSK UK, Uxbridge, 3 UK, GlaxoSmithKline Vaccines, Singapore, Singapore THE PUBLIC HEALTH IMPACT OF A NEW HERPES ZOSTER VACCINE TO THE GERMAN POPULATION 1 2 2 3 2 1 1 van Oorschot DA , Anastassopoulou A , Schlegel K , Varghese L , von Krempelhuber A , Curran D , GSK Vaccines, Wavre, 2 3 Belgium, GSK Germany, München, Germany, GlaxoSmithKline Vaccines, Singapore, Singapore THE PREVALENCE OF SEXUAL DYSFUNCTIONS AMONG HUNGARIAN MEN 1 1 1 2 1 1 1 1 1 Palancsa M , Damásdi M , Gitta S , Tardi P , Járomi M , Ács P , Boncz I , Hock M , University of Pécs, Pécs, 2 Hungary, Train-Health Nonprofit Ltd., Harkány, Hungary IRON DEFICIENCY ANEMIA IN PREGNANT WOMEN IN FRANCE: A PROSPECTIVE COHORT STUDY 1 2 3 4 3 5 1 2 Clavel T , Zkik A , Berdeaux G , Auges M , Sanchez C , Harvey T , Thierry Clavel Consulting, REVEL, France, Pierre Fabre, 3 4 Boulogne Billancourt, France, Pierre Fabre Medicament, Boulogne-Billancourt, France, Pierre Fabre, boulogne billancourt, 5 France, Maternité GH Diaconesses Croix St Simon, Paris, France

INDIVIDUAL'S HEALTH - Cost Studies PIH9 G14 BUDGET IMPACT OF ULIPRISTAL ACETATE 5MG IN PRE-OPERATIVE TREATMENT OF UTERINE FIBROIDS: AN ANALYSIS BASED ON PUBLIC DATA ON HOSPITAL STAYS IN FRANCE 1 2 1 1 2 Trancart M , Lehmann M , Lafuma A , Cemka-Eval, Bourg La Reine, France, Gedeon Richter - PregLem S.A., Geneva, Switzerland PIH10 G15 BUDGET-IMPACT ANALYSIS (BIA) OF THE INTRODUCTION OF 52MG LEVONORGESTREL-RELEASING INTRAUTERINE SYSTEM (LNG-IUS) AS A CONTRACEPTIVE METHOD OPTION IN THE BRAZILIAN PUBLIC HEALTHCARE SYSTEM (SUS) TO AVOID UNINTENDED PREGNANCY (UP) IN 15 TO 19 YEAR-OLD ADOLESCENTS Ramos NB, Honda A, Sakagute M, Nakada C, Tobaruella F,Bayer Healthcare, São Paulo, Brazil PIH11 G16 AVAILABILITY AND COSTS OF PEDIATRIC FORMULATIONS IN INDIA : A CASE STUDY 1 2 1 2 Tayal H , Roy V , Maulana Azad Medical college, Delhi, India, Maulana Azad Medical College, University of Delhi, New Delhi, India PIH12 G17 ECONOMIC EVALUATION OF RFSH AND HP-HMG FOR INFERTILITY TREATMENT IN BRAZIL

1

PIH13 G18

PIH14 G19

PIH15 G20

PIH16 G21 PIH17 G22

PIH18 G23 PIH19 G24

PIH20 G25 PIH21 G26

PIH22 G27

PIH23 G28

PIH24 G29

2

1

1 1

2

Souza PV , Simões AC , Zanini FE , Sato CC , Merck, São Paulo, Brazil, Merck, Rio de Janeiro, Brazil INFERTILITY TREATMENT OF WOMEN OVER AGE 35 IN BRAZIL: AN ECONOMIC EVALUATION OF RECOMBINANT VS. URINARY GONADOTROPINS 1 2 1 1 1 2 Souza PV , Simões AC , Zanini FE , Sato CC , Merck, São Paulo, Brazil, Merck, Rio de Janeiro, Brazil EVALUATING THE ECONOMIC IMPACT OF POTENTIALLY INAPPROPRIATE PRESCRIBING IN OLDER PEOPLE IN IRELAND USING A MARKOV MODELLING APPROACH Moriarty F, Bennett K, Cahir C, Fahey T,Royal College of Surgeons in Ireland, Dublin, Ireland COST IMPLICATIONS OF INAPPROPRIATE PRESCRIBING OF ANTI-MALARIAL THERAPY FOR TREATMENT OF UNDIFFERENTIATED FEBRILE ILLNESS AMONG ELDERLY Menon VB, Ramesh M, Pereira P, CR V, Undela K, Hathur BG,JSS Hospital, Mysore, India ANALYSIS OF REAL DATA FOR TREATMENT OF NAUSEA AND VOMITING OF PREGNANCY (NVP) IN UKRAINE Maksymovych N, Zalis'ka O, Brezden O,Danylo Halytsky Lviv National Medical University, Lviv, Ukraine COST-EFFECTIVENESS ANALYSIS OF 52 MG LEVONORGESTREL-RELEASING INTRAUTERINE SYSTEM (LNG-IUS) VERSUS SHORT-ACTING HORMONAL CONTRACEPTIVES IN AVOIDING UNINTENDED PREGNANCY (UP) IN 15 TO 19 YEAR-OLD ADOLESCENTS UNDER THE BRAZILIAN PUBLIC HEALTHCARE SYSTEM (SUS) Honda A, Ramos NB, Sakagute M, Nakada C, Tobaruella F,Bayer Healthcare, São Paulo, Brazil COST-EFFECTIVENESS OF RECOMBINANT HUMAN FOLLICLE STIMULATING HORMONE BIOSIMILARS IN PORTUGAL Silverio N, Botica F, Batista AR,Merck SA, Lisboa, Portugal CLINICAL AND ECONOMIC ANALYSIS OF TWO SURFACTANTS FOR THE PREVENTION AND TREATMENT OF RESPIRATORY DISTRESS SYNDROME Krasnova L, Vorobiev P, Tyurina I,Russian Society for Pharmacoeconomics and Outcomes Research, Moscow, Russian Federation COST-EFFECTIVENESS ANALYSIS OF LAPAROSCOPIC SURGERY FOR PRESUMED LEIOMYOMAS Lin Y, Lang H,National Yang-Ming University, Taipei, Taiwan COST MINIMISATION ANALYSIS OF FOLLITROPIN DELTA VERSUS FOLLITROPIN ALFA IN ASSISTED REPRODUCTIVE TECHNOLOGIES (IVF/ICSI) IN THE UNITED KINGDOM 1 2 1 1 2 Sivignon M , Palencia R , Roze S , HEVA HEOR Sarl, Lyon, France, Ferring Pharmaceuticals A/S, Copenhagen, Denmark VAGINAL BIRTH AFTER CAESAREAN VERSUS ELECTIVE REPEAT CAESAREAN DELIVERY IN FOUR EUROPEAN COUNTRIES: A COST-UTILITY ANALYSIS 1 2 2 3 1 2 3 Fobelets M , Beeckman K , Faron G , Putman K , Vrije Universiteit Brussel, Jette, Belgium, UZ Brussel, Jette, Belgium, Vrije Universiteit Brussel, Brussels, Belgium COST‐UTILITY ANALYSIS OF ULIPRISTAL ACETATE (5 MG) FOR LONG-TERM TREATMENT OF MODERATE TO SEVERE SYMPTOMS OF UTERINE FIBROIDS IN PORTUGAL 1 2 3 4 1 2 Paquete A , Lehmann M , Silva DP , Pinto CG , CISEP, Lisboa, Portugal, Gedeon Richter - PregLem S.A., Geneva, 3 4 Switzerland, Coimbra Medical Institute, Coimbra, Portugal, University of Lisbon, Lisbon, Portugal THE IMPACT ON SOCIETAL BURDEN OF CHANGED UPTAKE OF HORMONAL TREATMENTS 1 1 2 3 1 1 2 Widen J , Hallberg S , Bobula J , Moffatt M , Borgstrom F , Quantify Research, Stockholm, Sweden, Pfizer Inc, Collegeville, PA, 3 USA, Pfizer Inc, New York, NY, USA

INDIVIDUAL'S HEALTH - Patient-Reported Outcomes & Patient Preference Studies PIH25 G30 COMPARISON BETWEEN EQ-5D AND HUI IN JAPANESE POPULATION NORMS 1 1 2 3 4 3 5 6 7 8 Noto S , Izumi R , Moriwaki K , Shiroiwa T , Igarashi A , Fukuda T , Ikeda S , Saito S , Shimozuma K , Ishida H , Kobayashi 9 1 2 3 M , Niigata University of Health and Welfare, Niigata, Japan, Kobe Pharmaceutical University, Kobe, Japan, National Institute of 4 5 Public Health, Wako, Japan, University of Tokyo, Graduate School of Pharmaceutical Sciences, Tokyo, Japan, International 6 7 University of Health and Welfare, Ohtawara, Japan, Okayama University, Okayama, Japan, Ritsumeikan University, Kusatsu, 8 9 Japan, Yamaguchi University, Ube, Japan, Takeda Pharmaceutical Company Ltd., Tokyo, Japan PIH26 G31 TRANSLATION AND VALIDATION OF CONDITION-SPECIFIC QUALITY OF LIFE PFDI-20 AND PFIQ-7 QUESTIONNAIRES FOR WOMEN WITH PELVIC FLOOR DYSFUNCTION IN THE NORWEGIAN CONTEXT 1 1 2 3 4 5 6 4 7 8 1 Teig CJ , Bond MJ , Cvancarova MS , Grotle M , Engh ME , Prinsen CA , Kjøllesdal M , Øresland T , Saga S , Martini A , Flinders 2 3 University, Adelaide, Australia, Oslo and Akershus University College of Applied Sciences, Oslo, Norway, Oslo and Akershus 4 5 University College of Applied Sciences; Faculty of Health Science, Oslo, Norway, Akershus University Hospital, Oslo, Norway, VU 6 7 University Medical Center, Amsterdam, The Netherlands, Drammen Gynaecology Private Clinic, Drammen, Norway, Norwegian 8 University of Science and Technology, Trondheim, Norway, University of Western Australia, School of Population Health, Perth, Australia PIH27 G32 A REVIEW OF PATIENT-REPORTED OUTCOME MEASURES TO ASSESS INFERTILITY-RELATED QUALITY OF LIFE 1 1 1 2 3 1 2 Kitchen H , Aldhouse NV , Trigg A , Palencia R , Mitchell S , DRG Abacus, Manchester, UK, Ferring Pharmaceuticals A/S, 3 Copenhagen, Denmark, DRG Abacus, Bicester, UK PIH28 G33 RESCALING THE OVERALL SCORE IN THE CERVANTES SHORT-FORM SCALE FOR MEASURING HEALTH-RELATED

QUALITY OF LIFE IN MENOPAUSAL WOMEN SEXUALLY INACTIVE 1 2 3 3 3 1 Coronado PJ , Sánchez-Borrego R , Ruiz MA , Rejas J , Collaborative Group CH , Hospital Clínico San Carlos, Madrid, 2 3 Spain, Clínica DIATROS, Barcelona, Spain, Pfizer, Alcobendas, Spain PIH29 G34 SELF-EFFICACY AND HEALTH BEHAVIORS IMPACT QUALITY OF LIFE OF ELDERLY ALONG EASTERN SEA COAST OF THAILAND 2015 Auamnoy T, Onnim P, Suriyong P, Dechrat P, Meepradist Y, Phanudulkitti C, Watcharapisittinon S,Burapha University, Chonburi, Thailand PIH30 G35 WILLINGNESS TO PAY FOR PRIMARY DYSMENORRHEA HEALTH STATES 1 2 2 2 3 2 1 Ruzsa G , Gulacsi L , Brodszky V , Péntek M , Gradvohl E , Rencz F , Corvinus University of Budapest, Department of Statistics; 2 Eötvös Loránd University of Sciences, Institute of Psychology, Doctoral School of Psychology, Budapest, Hungary, Corvinus 3 University of Budapest, Budapest, Hungary, Semmelweis University, Budapest, Hungary INDIVIDUAL'S HEALTH - Health Care Use & Policy Studies PIH31 G36 KANGAROO MOTHER CARE- A COST EFFECTIVE AND AN ALTERNATE METHOD TO MANAGE HYPOTHERMIA IN LOW BIRTH WEIGHT BABIES FOR BETTER CLINICAL OUTCOME Kanodia P,NGMC, nepalgunj, Nepal PIH32 G37 IRRATIONAL USE OF ANTIBIOTICS IN TURKEY 1 2 1 1 2 Malhan S , Numanoglu Tekin R , Oksuz E , Baskent University, Ankara, Turkey, Baskent University, Health Care Management, Ankara, Turkey PIH33 G38 ANALYSIS OF ANTIBIOTICS’ USE IN THE TREATMENT OF TONSILLOPHARYNGITIS IN CHILDREN POPULATION OF NIS DISTRICT 1 2 3 1 1 2 Krajnovic D , Arsic J , Milijic S , Milosević Georgiev A , University of Belgrade, Belgrade, Serbia, Materna medika, Vranje, 3 Serbia, Republic Fund for Health Insurance, Nis, Serbia PIH34 H1 ASSESSING REAL CONSUMPTION OF MEDICATIONS FOR FERTILITY TREATMENTS IN UKRAINE 1 1 2 1 3 3 1 Piniazhko O , Zalis'ka O , Vons B , Pyrohova V , Malachynska M , Veresnyuk N , Danylo Halytsky Lviv National Medical University, 2 3 Lviv, Ukraine, Ternopil State Medical University, Ternopil, Ukraine, Danylo Halytsky Lviv National Medical University, Lviv Regional Reproductive Health Centre, Lviv, Ukraine PIH35 H2 USE, BELIEF, AND RISK AWERNESS TO MEDICATION AMONG PREGNANT WOMEN ATTENDING ANTENATAL CARE UNIT AT UNIVERSITY OF GONDAR TEACHING HOSPITAL, NORTHWESTETHIOPIA: CROSSSECTIONAL STUDY Tefera YG, Admasu S,University of Gondar, Gondar, Ethiopia PIH36 H3 CYPROTERONE/ETHINYLESTRADIOL USE AND INDICATIONS IN THE NETHERLANDS 1 1 1 2 1 1 Bezemer ID , Smits L , Penning-van Beest F , Asiimwe A , Herings RM , PHARMO Institute for Drug Outcomes Research, Utrecht, 2 The Netherlands, Bayer Pharma AG, Berlin, Germany PIH37 H4 CYPROTERONE/ETHINYLESTRADIOL AND CONCOMITANT USE OF OTHER HORMONAL CONTRACEPTIVES IN THE NETHERLANDS 1 1 1 2 1 1 Bezemer ID , Smits L , Penning-van Beest F , Asiimwe A , Herings RM , PHARMO Institute for Drug Outcomes Research, Utrecht, 2 The Netherlands, Bayer Pharma AG, Berlin, Germany PIH38 H5 PREVALENCE OF POTENTIALLY INAPPROPRIATE PRESCRIBING IN CENTRAL NERVOUS SYSTEM AND PSYCHOTROPIC DRUGS FOR THE KOREAN ELDERLY: A CROSS-SECTIONAL STUDY USING THE NATIONAL HEALTH INSURANCE CLAIMS DATABASE 1 1 2 1 2 Cho H , Choi J , Kang H , Yonsei University, Incheon, South Korea, College of Pharmacy, Yonsei Institute of Pharmaceutical Sciences, Yonsei University, Incheon, South Korea PIH39 H6 ASSESSMENT OF THE COSTS OF OVERALL CHILDREN VACCINATION WITH ANTIROTAVIRUS VACCINE IN UKRAINE Nemchenko A, Podgaina M, Balynska M,National University of Pharmacy, Kharkiv, Ukraine PIH40 H7 LONG TERM OUTCOME OF COUPLES UNDERTAKING THEIR FIRST IVF/ICSI ATTEMPT : A FRENCH STUDY 1 2 3 3 4 5 6 1 2 Parneix I , Arvis P , Paillet S , Longin J , Lehert P , Avril C , Lesourd F , Polyclinique Jean Villar, Bruges, France, Clinique 3 4 mutualiste de la sagesse, Rennes, France, MERCK, Lyon, France, Faculty of economics Louvain, Louvain la neuve, 5 6 Belgium, Clinique Mathilde, Rouen, France, Hôpital Paule de Viguier, Toulouse, France INFECTION - Clinical Outcomes Studies PIN1

H8

PIN2

H9

THE CHICKENPOX COMPLICATIONS AND FINANCIAL BURDEN IN HEALTHY CHILDREN AND WITH UNDERLYING A COMORBIDITY DURING THE PRE VACCINE AND POST VACCINE ERA IN A UNIVERSITY HOSPITAL 1 2 1 1 1 1 Büyükcam A , Çelik M , Cengiz AB , Ceyhan M , Kara A , Hacettepe University Faculty of Medicine, Department of Pediatric 2 Infectious Diseases, Ankara, Turkey, Keçiöğren Research Hospital, Ankara, Turkey COMORBIDITIES IN HIV-1: A LITERATURE REVIEW OF THE ASSOCIATIONS BETWEEN PATIENT- AND DISEASE-RELATED FACTORS AND NON-AIDS RELATED COMORBIDITIES (NARCS) 1 1 1 1 2 3 1 Bunting C , Eddowes LA , Buchanan-Hughes AM , Steeves S , Perard R , Hay P , Costello Medical Consulting Ltd, Cambridge, 2 3 UK, Gilead Sciences Europe Ltd, Uxbridge, UK, St George's University Hospital, London, UK

PIN3

PIN4

PIN5

PIN6

PIN7

PIN8 PIN9

H10 COMPARATIVE EFFECTIVENESS OF CARBAPENEMS VERSUS ALTERNATIVE ANTIBIOTICS FOR THE TREATMENT OF BACTERAEMIA DUE TO ENTEROBACTERIACEAE PRODUCING EXTENDED-SPECTRUM β-LACTAMASE IN DEFINITIVE THERAPY: A SYSTEMATIC REVIEW AND META-ANALYSIS Son SK, Lee NR, Park JJ, Park DA,National Evidence-based Collaborating Agency, Seoul, South Korea H11 COMPARATIVE EFFECTIVENESS OF CARBAPENEMS VERSUS ALTERNATIVE ANTIBIOTICS FOR THE TREATMENT OF BACTERAEMIA DUE TO ENTEROBACTERIACEAE PRODUCING EXTENDED-SPECTRUM β-LACTAMASE IN EMPIRICAL THERAPY: MULTICENTER COHORT STUDY Lee NR, Son SK, Park JJ, Park DA,National Evidence-based Collaborating Agency, Seoul, South Korea H12 TRANSLATION OF THE UK PAEDIATRIC INFLUENZA PRIMARY SCHOOL VACCINATION PROGRAMME TO 13 EUROPEAN COUNTRIES USING A DYNAMIC TRANSMISSION MODEL 1 2 2 3 4 1 2 Gerlier L , Hackett J , Lawson RW , Dos Santos Mendes S , Eichner M , IMS Health, Zaventem, Belgium, AstraZeneca, 3 4 Gaithersburg, MD, USA, AstraZeneca Belux, Uccle, Belgium, Epimos GmbH, Dusslingen, Germany H13 ZINFORO (CEFTAROLINE FOSAMIL) VERSUS OTHER EMPIRIC ANTIBIOTICS FOR MODERATE-TO-SEVERE COMMUNITY ACQUIRED PNEUMONIA (CAP) IN ADULTS: A NETWORK META-ANALYSIS 1 1 2 3 1 2 Rao N , Gibson E , Lawson RW , Goodall JJ , Wickenstones, Goring Heath, UK, AstraZeneca, Gaithersburg, MD, 3 USA, AstraZeneca, Luton, UK H14 ZINFORO (CEFTAROLINE FOSAMIL) VERSUS OTHER EMPIRIC INITIAL IV ANTIBIOTICS FOR COMPLICATED SKIN AND SOFT TISSUE INFECTIONS (CSSTI): A NETWORK META-ANALYSIS 1 1 2 3 1 2 Rao N , Gibson E , Lawson RW , Goodall JJ , Wickenstones, Goring Heath, UK, AstraZeneca, Gaithersburg, MD, 3 USA, AstraZeneca, Luton, UK H15 HEPATITIS C – REAL WORLD EFFECTIVENESS OF HCV TREATMENT IN POLAND Plisko R, Wladysiuk M, Miazga P, Bebrysz M,HTA Consulting, Krakow, Poland H16 THERAPEUTIC INDICATION OF LYOPHILIZED HYDROCORTISONE TO THE TREATMENT OF TRICHINOSIS WITH NEUROLOGICAL AND / OR MYOCARDIAL INVOLVEMENT 1

PIN10 H17

PIN11 H18

PIN12 H19

PIN13 H20

PIN14 H21

PIN15 H22

2

2

2

2

2

2

3

1

Viana DC , Zanghelini F , Rego MJ , Oliveira MD , Andrade CA , Pereira MC , Nunes TR , Galdino-Pitta MR , Cardoso PR , Pitta 1 2 1 2 3 Id , Pitta MG , Avenida Professor Moraes Rego, Recife, Brazil, Universidade Federal de Pernambuco, Recife, Brazil, UFPE, Recife, Brazil EVALUATION OF THE NUMBER NEEDED TO VACCINATE (NNV) WITH GARDASIL9 IN ORDER TO AVERT 1 CASE OF HUMAN PAPILLOMAVIRUS (HPV)-RELATED ANOGENITAL DISEASE IN FRANCE Uhart M, Largeron N, Drury R, Soubeyrand B,Sanofi Pasteur MSD, Lyon, France SUSCEPTIBILITY PATTERN OF PSEUDOMONAS AERUGINOSA ISOLATES TO CARBAPENEM ANTIBIOTICS 1 2 1 2 Zubair M , Hussain T , Peshawar Medical and Dental College, Peshawar, Pakistan, National University of Sciences and Technology, Islamabad, Pakistan WHY IS THE HERD PROTECTION LEVEL HIGHER IN THE UK THAN IN BELGIUM AFTER THE INTRODUCTION OF THE ROTAVIRUS VACCINE? 1 2 3 1 2 3 Standaert B , Schecroun N , Lorenc S , GSK Vaccines, Wavre, Belgium, Keyrus Biopharma C/O GSK, Wavre, Belgium, Bartech Belgium SA C/O GSK, Wavre, Belgium PREDICTION OF THE MORBIDITY WITH BACTERIAL PURULENT MENINGITIS OF VARIOUS ORIGIN WITH CONSIDERATION OF THE EXISTING VACCINE PREVENTION PROCEDURES 1 2 1 2 Ryazhenov VV , Gorokhova SG , I.M. Sechenov First Moscow State Medical University, Moscow, Russia, Research Clinical Center of JSC Russian Railways, Moscow, Russia BURDEN OF MEDICALLY ATTENDED ACUTE GASTROENTERITIS IN ENGLAND: A COHORT STUDY IN CPRD 1 2 3 4 1 1 1 1 1 Ferreira G , Lopman BA , Tam C , Harris J , Bollaerts K , Cattaert T , Riera M , Vestraeten T , P95 Pharmacovigilance and 2 Epidemiology Services, Leuven, Belgium, National Center for Immunization and Respiratory Diseases, Centers for Disease Control 3 4 and Preventiion, Atlanta, GA, USA, National University of Singapore, Singapore, Singapore, University of Liverpool, Liverpool, UK FINDINGS OF A LITERATURE REVIEW IN SUPPORT OF A PATIENT COUNT MODEL (PCM) FOR HEPATITIS C VIRUS (HCV) IN THE EU5 1 1 2 2 2 3 4 1 Gueron B , Nalpas C , Maiese BA , Cadarette SM , Campbell DJ , Arvin-berod C , Duchesne I , Janssen Pharmaceuticals, Paris, 2 3 4 France, Xcenda, Palm Harbor, FL, USA, Xcenda Switzerland GmbH, Bern, Switzerland, Janssen EMEA, Beerse, Belgium

INFECTION - Cost Studies PIN16 H23 MANAGING HEALTHCARE RESOURCES: ESTIMATED BUDGET IMPACT ON THE NATIONAL HEALTH SERVICE (ENGLAND) OF INTRODUCTION OF ANTIMICROBIAL SUTURES 1 2 3 1 2 Edmiston Jr. CE , Holy CE , Leaper DJ , Medical College of Wisconsin, Milwaukee, WI, USA, Johnson & Johnson, New 3 Brunswick, NJ, USA, Institute of Skin Integrity and Infection Prevention, Huddersfield, UK PIN17 H24 BUDGET IMPACT ANALYSIS OF CEFTOLOZANE/TAZOBACTAM (ZERBAXA) FOR THE TREATMENT OF COMPLICATED INTRA-ABDOMINAL INFECTIONS AND COMPLICATED URINARY TRACT INFECTIONS IN THE ITALIAN SETTING 1 2 2 1 2 Barbieri M , Crocchiolo D , Veneziano MA , Centre for Health Economics, University of York, York, UK, MSD Italy, Rome, Italy

PIN18 H25 BUDGET IMPACT ASSOCIATED WITH THE IMPLEMENTATION OF A DTPA-IPV-HEPB/HIB HEXA VACCINATION PROGRAM IN SLOVENIA 1 1 2 1 2 Demarteau N , Geets R , Plevnik Kapun A , GSK Vaccines, Wavre, Belgium, GSK, Ljubljana, Slovenia PIN19 H26 BUDGET IMPACT ANALYSIS OF THE INTRODUCTION OF DARUNAVIR 800 MG QD FOR THE 2ND LINE TREATMENT OF HIV-INFECTED TREATMENT-EXPERIENCED ADULTS ON THE BRAZILIAN NATIONAL HIV PROGRAM Ferreira KA, Neves JA, Asano E, Magno LA, Loureiro RG,Janssen Pharmaceuticals, São Paulo, Brazil PIN20 H27 BUDGET IMPACT ANALYSIS OF INCLUDING A PENTAVALENT (HIB-HBV-DTP) VACCINE IN THE NATIONAL CHILDHOOD IMMUNIZATION SCHEDULE OF IRAN Teimouri F, Nikfar S, Kebriaeezadeh A,Department of Pharmacoeconomics and Pharmaceutical Management, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran (Islamic Republic of) PIN21 H28 COST ANALYSIS OF RALTEGRAVIR VERSUS ATAZANAVIR/R OR DARUNAVIR/R FOR TREATMENT-NAIVE ADULTS WITH HIV-1 INFECTION IN SPAIN 1 1 2 3 3 1 2 Davis AE , Brogan AJ , Goodwin BB , Nocea G , Lozano V , RTI Health Solutions, Research Triangle Park, NC, USA, Merck & 3 Co., Inc., Kenilworth, NJ, USA, MSD, Madrid, Spain PIN22 H29 HEALTH CARE COSTS, LENGHT OF STAY AND MORTALITY OF CARBAPENEM RESISTANCE GRAM-NEGATIVE BACTEREMIA 1 1 2 3 1 Aykac K , Tanır Basaranoglu S , Ozsurekci Y , Ceyhan M , Hacettepe University Faculty of Medicine, Department of Pediatric 2 3 Infectious Diseases, Ankara, Turkey, Hacettepe University, Ankara, Turkey, Hacettepe University Pediatric Infectious Disease, Ankara, Turkey PIN23 H30 COST ANALYSIS OF COMORBITIES: EVIDENCE FROM A HIV+ PATIENTS COHORT 1 1 1 2 2 2 1 1 2 Foglia E , Ferrario L , Garagiola E , Rizzardini G , Meraviglia P , Atzori C , Croce D , LIUC University, Castellanza, Italy, ASST Fatebenefratelli Sacco, Milano, Italy PIN24 H31 COMPLICATIONS AND HEALTH CARE COSTS OF INFLUENZA IN GERMANY: A RETROSPECTIVE CLAIMS DATA ANALYSIS 1 1 2 3 2 2 2 1 1 Scholz S , Damm O , Ultsch B , Schneider U , Remschmidt C , Weidemann F , Wichmann O , Greiner W , School of Public Health, 2 3 Bielefeld University, Bielefeld, Germany, Immunisation Unit, Robert Koch Institute, Berlin, Germany, WINEG - Scientific Institute of TK for Benefit and Efficiency in Health Care, Hamburg, Germany PIN25 H32 HEALTH RESOURCES USE IN PATIENTS WITH HUMAN IMMUNODEFICIENCY VIRUS (HIV) INFECTION. REAL WORLD EVIDENCE FROM ITALIAN ADMINISTRATIVE DATABASES Perrone V, Sangiorgi D, Crovato E, Buda S, Degli Esposti L,CliCon S.r.l., Ravenna, Italy PIN26 H33 DETERMINATION OF THE VACCINE-PREVENTABLE DISEASES BURDEN IN TURKEY IN TERMS OF VARIOUS VACCINATION POLICIES 1 2 3 4 4 5 1 Ceyhan M , Bayhan C , Ozsurekci Y , Malhan S , Numanoglu Tekin R , Mcintosh D , Hacettepe University Pediatric Infectious 2 Disease, Ankara, Turkey, Hacettepe University Faculty of Medicine, Department of Pediatric Infectious Diseases, Ankara, 3 4 5 Turkey, Hacettepe University, Ankara, Turkey, Baskent University, Health Care Management, Ankara, Turkey, Imperial College,Faculty Education Office, London, UK PIN27 H34 INDIRECT COST OF HIV/AIDS: RESULTS OF A SURVEY FROM A TURKISH RESEARCH CENTER 1 2 2 2 3 3 1 1 1 1 Tatar M , Kockaya G , Ozelgun B , Zengin Elbir T , Senturk A , Tuna E , Unal S , Tumer A , Inkaya C , Hacettepe University, 2 3 Ankara, Turkey, Gilead Science, Istanbul, Turkey, Polar Health Economics and Policy Consultancy, Ankara, Turkey PIN28 H35 BURDEN OF COMORBIDITIES IN HCV AND HIV/HCV PATIENTS. REAL WORLD EVIDENCE FROM ITALIAN ADMINISTRATIVE DATABASES Perrone V, Sangiorgi D, Crovato E, Buda S, Degli Esposti L,CliCon S.r.l., Ravenna, Italy PIN29 H36 DIRECT COST OF HIV/AIDS IN TURKEY 1 2 2 2 3 3 1 1 1 1 Tatar M , Kockaya G , Ozelgun B , Zengin Elbir T , Senturk A , Tuna E , Unal S , Tumer A , Inkaya C , Hacettepe University, 2 3 Ankara, Turkey, Gilead Science, Istanbul, Turkey, Polar Health Economics and Policy Consultancy, Ankara, Turkey PIN30 H37 CLINICAL AND ECONIMIC BURDEN OF COMMUNITY-ONSET COMPLICATED SKIN AND SKIN STRUCTURE INFECTION (CSSSI) IN KOREA 1 2 1 1 2 Lee MJ , Kim Y , Cho YK , Gachon University Gil Medical Center, Incheon, South Korea, Pfizer Pharmaceuticals Korea Ltd., Seoul, South Korea PIN31 H38 EVALUATION OF THE CLINICAL CHARACTERISTICS AND ECONOMIC BURDEN OF UNITED STATES VETERAN PATIENTS DIAGNOSED WITH THE HEPATITIS C VIRUS 1 1 1 1 2 1 2 Wang L , Li L , Zhou X , Pandya S , Baser O , STATinMED Research, Plano, TX, USA, Columbia University and STATinMED Research, New York, NY, USA PIN32 I1 WHAT IS THE HOSPITAL ECONOMIC BURDEN OF HIV IN FRANCE? RESULTS FROM AN ANALYSIS OF THE NATIONAL FRENCH MEDICAL INFORMATION SYSTEM DATABASE 1 2 3 4 3 3 5 4 1 Yazdanpanah Y , Bonnet F , de Léotoing L , Finkielsztejn L , Chaize G , Vainchtock A , Nachbaur G , Aubin C , Hôpital Bichat 2 3 4 Claude Bernard, Paris, France, CHU Bordeaux, Bordeaux, France, HEVA, Lyon, France, ViiV Healthcare France, Marly-le-Roi,

5

PIN33 I2

PIN34 I3 PIN35 I4 PIN36 I5

PIN37 I6

PIN38 I7 PIN39 I8

PIN40 I9

PIN41 I10

PIN42 I11

PIN43 I12

PIN44 I13 PIN45 I14 PIN46 I15

PIN47 I16 PIN48 I17

PIN49 I18

PIN50 I19

France, GSK France, Marly le roi, France COST ASSESSMENT OF ANTIBIOTICS USE IN A HOSPITAL IN THE DOMINICAN REPUBLIC 1 2 1 1 1 1 2 Mouly M , Puello Guerrero A , Dumartin C , Silva ML , Aulois-Griot M , University of Bordeaux, Bordeaux, France, Universidad Autónoma de Santo Domingo, Public Health School, Santo Domingo, Dominican Republic PATIENT CHARACTERISTICS AND OUTCOMES OF HOSPITALIZATION FOR INFLUENZA INFECTION IN HONG KONG Chan Y, Lee N, You J,The Chinese University of Hong Kong, Shatin, Hong Kong CLINICAL AND ECONOMIC OUTCOMES OF PATIENTS HOSPITALIZED FOR HERPES ZOSTER IN HONG KONG Yu W, Chan P, You J,The Chinese University of Hong Kong, Shatin, Hong Kong DETERMINING THE CLINICAL PRACTICE AND RESOURCE USE ASSOCIATED TO THE DIAGNOSIS AND TREATMENT OF CLOSTRIDIUM DIFFICILE INFECTION IN MEXICO 1 1 2 3 1 Pérez Bolde-Villarreal C , Pastor-Martínez V , reyes-Lopez A , Jimenez-Juarez R , Merck Sharp & Dhome Mexico, Mexico, 2 3 Mexico, Hospital Infantil de México, Mexico, Mexico, Hospital Infantil de México Federico Gómez, Mexico, Mexico ASSESSING THE CONSEQUENCES OF SUSTAINED OFF-THERAPY HBSAG LOSS IN HEALTH ECONOMIC MODELS OF CHRONIC HEPATITIS B; A SYSTEMATIC LITERATURE REVIEW 1 2 2 1 1 2 Hashim M , Cerri K , Sbarigia U , Heeg B , Ingress Health, Rotterdam, The Netherlands, Janssen Pharmaceutica NV, Beerse, Belgium UNIVERSAL MASS VACCINATION WITH PHID-CV IS COST-EFFECTIVE IN CROATIA 1 2 1 2 Bencina G , Olbrecht J , GSK, Zagreb, Croatia, GSK Vaccines, Wavre, Belgium THE PUBLIC HEALTH AND ECONOMIC IMPACT OF GENDER NEUTRAL QUADRIVALENT HUMAN PAPILLOMAVIRUS VACCINATION PROGRAM IN BRAZIL 1 1 2 3 3 1 2 Coutinho MB , Serra FB , Monsanto H , Kulkarni AS , Pavelyev A , MSD Brasil, São Paulo, Brazil, Merck Sharp & Dohme IA LLC, 3 Carolina, PR, PR, Merck & Co. Inc, Rahway, NJ, USA COST-EFFECTIVENESS ANALYSIS OF HIGHLY INNOVATIVE TREATMENTS FOR HEPATITIS C: THE CASE OF LEDIPASVIR/SOFOSBUVIR IN A GREEK HEALTHCARE SETTING 1 1 1 2 2 1 1 Athanasakis K , Boubouchairopoulou N , Kyriopoulos I , Tsoulas C , Tzanakis B , Kyriopoulos J , National School of Public 2 Health, Athens, Greece, Gilead Sciences Hellas, Helliniko, Greece COST OF DENGUE AND COST-EFFECTIVENESS OF THE DENGUE VACCINE IN PANAMA 1 1 2 3 3 4 5 4 1 Garcia LN , Cerezo L , Blas A , Alvarez S , Quiroz N , Caicedo Navas AG , Lopez JG , Vandeputte C , Panama Ministry of Health, 2 3 Panama City, Panama, Instituto Conmemorativo Gorgas de Estudios de la Salud (ICGES), Panama, Panama, Cevaxin, Panamá 4 5 city, Panama, Sanofi Pasteur, Bogota, Colombia, Sanofi Pasteur, Mexico City, Mexico COST-EFFECTIVENESS EVALUATION OF PHID-CV VERSUS PCV-13 IN POLAND 1 1 2 3 1 2 3 Wepsięć K , Stryjewska I , Mrozek-Gasiorowska M , Olbrecht J , GSK, Warsaw, Poland, Pracownia HTA, Kraków, Poland, GSK Vaccines, Wavre, Belgium COST-EFFECTIVENESS OF THE 13-VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN ADULTS IN PORTUGAL 1 1 2 1 3 1 1 Alarcão J , Fiorentino F , Gouveia M , Jesus G , Costa J , Borges M , Center for Evidence Based Medicine, Faculty of Medicine, 2 3 University of Lisbon, Lisbon, Portugal, Católica Lisbon School of Business and Economics, Lisbon, Portugal, Laboratory of Clinical Pharmacology and Therapeutics, Faculty of Medicine, University of Lisbon, Lisbon, Portugal A SYSTEMATIC REVIEW OF THE COST-EFFECTIVENESS OF QUADRIVALENT INFLUENZA VACCINE van Maanen BM, Postma MJ, de Boer PT,University of Groningen, Groningen, The Netherlands COST-EFFECTIVE ANALYSIS OF THE DENGUE VACCINE IN COSTA RICA Xirinachs Y,University of Costa Rica, San Jose, Costa Rica COST EFFECTIVENESS ANALYSIS OF DIFFERENT HEALTH POLICIES BASED ON THE SECOND GENERATION DAA-IFN FREE REGIMENS IN AN ITALIAN POPULATION Ruggeri M, Romano F,ALTEMS, Università Cattolica del Sacro Cuore (UCSC), Postgraduate School of Health Economics and Management, Rome, Italy COST-EFFECTIVENESS OF GRAZOPREVIR / ELBASVIR IN PATIENTS WITH CHRONIC HEPATITIS C VIRUS Mattingly II TJ, Slejko JF, Mullins CD,University of Maryland School of Pharmacy, Baltimore, MD, USA COST-EFFECTIVENESS ANALYSIS OF DACLATASVIR WITH ASUNAPREVIR IN TREATMENT OF CHRONIC HEPATITIS C IN THE RUSSIAN FEDERATION Yagudina R, Kulikov A, Babiy VV,I.M. Sechenov First Moscow State Medical University, Moscow, Russia COST-EFFECTIVENESS ANALYSIS OF SOFOSBUVIR FOR GENOTYPE 2 HEPATITIS C IN GREECE 1 1 1 2 2 1 1 Athanasakis K , Boubouchairopoulou N , Kyriopoulos I , Tsoulas C , Tzanakis B , Kyriopoulos J , National School of Public Health, 2 Athens, Greece, Gilead Sciences Hellas, Helliniko, Greece COST-EFFECTIVENESS OF PREVENAR 13 IN CHILDREN IN PORTUGAL 1 2 1 3 1 1 Fiorentino F , Gouveia M , Jesus G , Costa J , Borges M , Center for Evidence Based Medicine, Faculty of Medicine, University of

2

PIN51 I20

PIN52 I21

PIN53 I22

PIN54 I23

PIN55 I24

PIN56 I25

PIN57 I26

PIN58 I27

PIN59 I28

PIN60 I29

PIN61 I30

PIN62 I31

PIN63 I32

PIN64 I33

3

Lisbon, Lisbon, Portugal, Católica Lisbon School of Business and Economics, Lisbon, Portugal, Laboratory of Clinical Pharmacology and Therapeutics, Faculty of Medicine, University of Lisbon, Lisbon, Portugal COST-EFFECTIVENESS ANALYSIS OF DACLATASVIR WITH ASUNAPREVIR VS PARITAPREVIR/RITONAVIR/OMBITASVIR WITH DASABUVIR IN TREATMENT OF CHRONIC HEPATITIS C IN THE RUSSIAN FEDERATION Yagudina R, Kulikov A, Babiy VV,I.M. Sechenov First Moscow State Medical University, Moscow, Russia INCLUSION OF COSTS AND EFFECTS RELATED TO TOXICITY/SAFETY IN COST -EFFECTIVENESS ANALYSIS; AN ILLUSTRATION FOR INFLUENZA VACCINES 1 1 2 1 2 Fens T , de Boer PT , Postma MJ , University of Groningen, Groningen, The Netherlands, University Medical Center Groningen, Groningen, The Netherlands ECONOMIC EVALUATION OF YELLOW FEVER ROUTINE VACCINATION IN COLOMBIA 1 2 1 3 3 1 1 2 Hoestlandt C , Broban A , Houillon G , Caicedo A , Martinez JF , Kieffer A , Sanofi Pasteur, Lyon, France, Sanofi Pasteur, 3 Istanbul, Turkey, Sanofi Pasteur, Bogota, Colombia COST OF DENGUE ILLNESS AND COST-EFFECTIVENESS OF THE CDY-TDV DENGUE VACCINE IN ECUADOR. 1 2 1 3 4 4 1 Lucio-Romero R , Henriquez-Trujillo AR , Bermudez-Gallegos K , Tello-Ponce B , Caicedo Navas AG , Vandeputte C , Sur-Este 2 3 Ltd., Quito, Ecuador, Universidad de Las Américas, Quito, Ecuador, Pontificia Universidad Catolica del Ecuador, Quito, 4 Ecuador, Sanofi Pasteur, Bogota, Colombia COST-EFFECTIVENESS OF OMBITASVIR/PARITAPREVIR/RITONAVIR WITH OR WITHOUT DASABUVIR FOR THE TREATMENT OF CHRONIC HEPATITIS C PATIENTS INFECTED WITH GENOTYPE 1 OR 4 IN FRANCE 1 1 2 1 3 4 5 1 1 Sroczynski G , Conrads-Frank A , Mühlberger N , Kühne F , Jeanblanc G , Samp JC , Durand-Zaleski I , Siebert U , UMIT 2 University for Health Sciences, Medical Informatics and Technology, Hall i.T., Austria, UMIT - University for Health Sciences, Medical Informatics and Technology, Institute of Public Health, Medical Decision Making and Health Technology Assessment, 3 Department of Public Health, Health Services Research and Health Technology Assessment, Hall i.T., Austria, AbbVie Inc., Rungis, 4 5 France, AbbVie Inc, North Chicago, IL, USA, APHP URC Eco Ile de France Hôpital de l'Hotel Dieu, Paris, France BEYOND CERVICAL CANCER: THE COST-EFFECTIVENESS OF HPV VACCINATION IN THE NETHERLANDS 1 1 2 3 1 2 Setiawan D , Cao Q , Westra TA , Postma MJ , University of Groningen, Groningen, The Netherlands, GlaxoSmithKline, Zeist, 3 The Netherlands, University Medical Center Groningen, Groningen, The Netherlands THE COST OF TREATING MUCORMYCOSIS WITH ISAVUCONAZOLE COMPARED WITH LIPOSOMAL AMPHOTERICIN B FOLLOWED BY POSACONAZOLE IN THE UNITED KINGDOM: ECONOMIC EVALUATION OF THE PHASE III VITAL STUDY AND FUNGISCOPE MATCHED CASE-CONTROL ANALYSIS 1 2 2 3 3 1 1 Kuessner D , Bagshaw E , Blackney M , Cornely OA , Heimann SM , Posthumus J , Basilea Pharmaceutica International Ltd., 2 3 Basel, Switzerland, Covance Market Access, London, UK, University Hospital of Cologne, Cologne, Germany COST MINIMIZATION ANALYSIS OF TEDIZOLID FOR THE TREATMENT OF ACUTE BACTERIAL SKIN AND SKIN SUB-STRUCTURE INFECTIONS (ABSSSI) IN GREECE 1 2 2 2 1 1 2 Insinga R , Dalakaki E , Retsa MP , Karokis A , Sarpong EM , Merck & Co., Inc., Kenilworth, NJ, USA, MSD Greece, Athens, Greece ECONOMIC EVALUATION OF ABBVIE’S REGIMEN (VIEKIRAX/EXVIERA) FOR PATIENTS WITH GENOTYPE 1A HCV IN GREECE 1 2 3 3 1 1 Mylonas C , Kourlaba G , Vernadaki A , Kakouros M , Maniadakis N , National School of Public Health, Athens, 2 Greece, Collaborative Center of Clinical Epidemiology and Outcomes Research (CLEO), Non-Profit Civil Partenrship, Athens, 3 Greece, AbbVie Pharmaceuticals S.A, Athens, Greece SYSTEMATIC REVIEW OF STUDIES ESTIMATING THE COST-EFFECTIVENESS OF HIV PRE-EXPOSURE PROPHYLAXIS (PREP) IN MEN WHO HAVE SEX WITH MEN (MSM) Damm O, Scholz S, Greiner W,School of Public Health, Bielefeld University, Bielefeld, Germany ECONOMIC EVALUATION OF ABBVIE’S REGIMEN (VIEKIRAX/EXVIERA) FOR PATIENTS WITH GENOTYPE 1B HCV IN GREECE 1 2 3 3 1 1 Mylonas C , Kourlaba G , Vernadaki A , Kakouros M , Maniadakis N , National School of Public Health, Athens, 2 Greece, Collaborative Center of Clinical Epidemiology and Outcomes Research (CLEO), Non-Profit Civil Partenrship, Athens, 3 Greece, AbbVie Pharmaceuticals S.A, Athens, Greece DETERMENING THE OPTIMAL PRICE FOR NEW NON-NUCLEOSIDE REVERSE TRANSCRITASE INHBITOR USING EARLY ECONOMIC MODELING 1 2 2 2 1 Musina N , Pogorelova E , Savilova A , Korzinov O , Sechenov First Moscow State Medical University, Moscow, Russian 2 Federation, Moscow Institute of physics and technology (State University), Dolgoprudny, Russian Federation ECONOMIC EVALUATION OF ABBVIE’S REGIMEN (VIEKIRAX) FOR PATIENTS WITH GENOTYPE 4 HCV IN GREECE 1 2 3 3 1 1 Mylonas C , Kourlaba G , Vernadaki A , Kakouros M , Maniadakis N , National School of Public Health, Athens, 2 Greece, Collaborative Center of Clinical Epidemiology and Outcomes Research (CLEO), Non-Profit Civil Partenrship, Athens, 3 Greece, AbbVie Pharmaceuticals S.A, Athens, Greece DENGUE NEGATIVELY AFFECTS GDP AND FEDERAL REVENUES IN ENDEMIC AREAS OF MEXICO Samaniego R, Aburto C,Instituto Tecnologico Autonomo de Mexico, Mexico City, Mexico

INFECTION - Patient-Reported Outcomes & Patient Preference Studies PIN65 I34

PIN66 I35

PIN67 I36

PIN68 I37

PIN69 J1

PIN70 J2

PIN71 J3

PIN72 J4

PIN73 J5

PIN74 J6 PIN75 J7

PIN76 J8 PIN77 J9

PIN78 J10

HEALTH STATE UTILITIES ASSOCIATED WITH POST-SURGICAL STAPHYLOCOCCUS AUREUS INFECTION 1 1 2 3 4 4 5 6 1 2 Matza LS , Kim K , Yu H , Belden K , Chen AF , Kurd M , Lee BY , Webb J , Evidera, Bethesda, MD, USA, Pfizer, Collegeville, 3 4 PA, USA, Sydney Kimmel Medical College, Thomas Jefferson University Hospital, Philadelphia, PA, USA, Rothman Institute, 5 Thomas Jefferson University Hospital, Philadelphia, PA, USA, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, 6 USA, Avon Orthopaedic Centre, Southmead Hospital, Bristol, UK HEALTH STATE UTILITY VALUES (HSUVS) MEASURED BY THE EUROQOL 5-DIMENSIONS (EQ-5D) QUESTIONNAIRE IN PEOPLE LIVING WITH HIV (PLHIV): A SYSTEMATIC LITERATURE REVIEW (SLR) USING RAPID REVIEW METHODOLOGY 1 1 2 3 4 1 2 Buchanan-Hughes AM , Eddowes LA , Ma Q , Perard R , Hay P , Costello Medical Consulting Ltd, Cambridge, UK, Costello 3 4 Medical Singapore Pte Ltd, Singapore, Singapore, Gilead Sciences Europe Ltd, Uxbridge, UK, St George's University Hospital, London, UK EFFECT OF SOCIODEMOGRAPHIC DETERMINANTS AND SOCIO-ECONOMIC STATUS ON POLIOMYELITIS IMMUNIZATION AMONG UNDER-FIVE CHILDREN IN PAKISTAN 1 2 2 1 Iqbal MS , Iqbal MZ , Bahari MB , Faculty of Pharmacy, Bahauddin Zakariya University, Multan, Pakistan. Department of Clinical 2 Pharmacy, Faculty of Pharmacy, MAHSA University, Selangor, Malaysia, Department of Clinical Pharmacy & Pharmacy Practice, Faculty of Pharmacy, AIMST University, Kedah, Malaysia WORK AND INCOME LOSS CONSIDERATION AMONG PATIENTS WITH HERPES ZOSTER WHEN COMPLETING A QUALITY OF LIFE QUESTIONNAIRE 1 2 1 1 2 2 1 1 Johnson KD , Brenneman S , Newransky C , Sheffler-Collins S , Becker LK , Belland A , Acosta CJ , Merck & Co., Kenilworth, NJ, 2 USA, Optum, Eden Prairie, MN, USA A SYSTEMATIC REVIEW OF UTILITIY WEIGHTS FOR INFLUENZA AND INFLUENZA-LIKE ILLNESS 1 1 2 2 2 2 11 Damm O , Scholz S , Ultsch B , Weidemann F , Remschmidt C , Wichmann O , Greiner W , School of Public Health, Bielefeld 2 University, Bielefeld, Germany, Immunisation Unit, Robert Koch Institute, Berlin, Germany HEALTH STATE UTILITY VALUES (HSUVS) MEASURED USING THE EUROQOL 5-DIMENSIONS (EQ-5D) QUESTIONNAIRE IN ADULTS WITH CHRONIC HEPATITIS C (CHC): A SYSTEMATIC LITERATURE REVIEW (SLR) Buchanan-Hughes AM, Hanman K, Langford BE, Eddowes LA,Costello Medical Consulting Ltd, Cambridge, UK WHAT MOTIVATES MOTHERS TO PAY FOR A VACCINE AGAINST CHILDREN’S DIARRHEA? PREFERENCES FOR VACCINES AGAINST CHILDREN’S DIARRHEAL ILLNESS AMONG MOTHERS IN POLAND AND HUNGARY 1 2 2 1 1 2 Poulos C , Standaert B , Sloesen B , Hauber AB , RTI Health Solutions, Research Triangle Park, NC, USA, GSK Vaccines, Wavre, Belgium GERMAN TRAVELERS’ PREFERENCENCES FOR VACCINES AGAINST TRAVEL-RELATED ILLNESSES 1 2 3 2 1 2 Poulos C , Curran D , Anastassopoulou A , De Moerlooze L , RTI Health Solutions, Research Triangle Park, NC, USA, GSK 3 Vaccines, Wavre, Belgium, GSK, Munich, Germany SOFT MODELLING OF HEALTH-RELATED QUALITY OF LIFE SPECIFIC TO HIV IN RELATION TO ANXIETY, DEPRESSION, PERSONALITY TRAITS AND PRECARIOUSNESS 1 1 2 3 1 2 1 1 1 Aboromman M , Lalanne C , Dimi S , Carrieri PM , Reeder A , Zucman D , Chassany O , Duracinsky M , University Paris Diderot, 2 3 Paris Sorbonne Cité, Paris, France, Hôpital Foch, Suresnes, France, INSERM, Marseille, France ANALYSIS OF INFLUENZA VACCINATION EFFECTIVENESS IN GENERAL PRACTITIONER Lehocka L, Masarykova L, Olearova A, Koscova D,Comenius University in Bratislava, Faculty of Pharmacy, Bratislava, Slovakia PSYCHOMETRIC VALIDATION OF FOUR PATIENT-REPORTED OUTCOME INSTRUMENTS IN A DIVERSE SAMPLE OF ADULTS WITH CHRONIC HEPATITIS C VIRUS INFECTION TREATED WITH SIMEPREVIR AND SOFOSBUVIR 1 1 2 3 4 5 1 2 Trigg A , Kitchen H , Willgoss T , Ho KF , Pierson RF , Scott J , DRG Abacus, Manchester, UK, Formerly of DRG Abacus, 3 4 5 Manchester, UK, STAT-TU Inc., Toronto, ON, Canada, Janssen Global Services, LLC, Raritan, NJ, USA, Janssen Global Services, LLC, High Wycombe, UK PSYCHOMETRIC EVALUATION OF THE REVISED HIV TREATMENT SATISFACTION QUESTIONNAIRE (HIVTSQ) 1 2 1 1 2 Romaine J , Murray M , Bradley C , Health Psychology Research Ltd, Surrey, UK, ViiV Healthcare, Brentford, UK HERPES ZOSTER AND POSTHERPETIC NEURALGIA: QUALITY OF LIFE AND HEALTHCARE UTILIZATION, A GERMAN STUDY 1 2 2 3 4 5 2 1 Anastassopoulou A , Curran D , Schmidt‐Ott R , Schutter U , Simon J , Poulsen Nautrup B , Matthews S , GSK, Munich, 2 3 4 Germany, GSK Vaccines, Wavre, Belgium, Marienhospital, Marl, Germany, Gesundheitsnetz Osthessen, Fulda, 5 Germany, EAH-Consulting, Aachen, Germany IMPAIRED QUALITY OF LIFE AFTER CHIKUNGUNYA VIRUS INFECTION: A 12-MONTHS FOLLOW-UP STUDY OF ITS CHRONIC INFLAMMATORY RHEUMATISM IN LA VIRGINIA, RISARALDA, COLOMBIA 1 1 1 1 1 Rodriguez-Morales AJ , Restrepo-Posada VM , Acevedo-Escalante N , Rodríguez-Muñoz ED , Valencia-Marín M , 1 2 2 2 1 Castrillón-Spitia JD , Londoño JJ , Bedoya-Rendón HD , Cárdenas-Pérez Jd , Cardona-Ospina JA , Lagos-Grisales 1 1 2 GJ , Universidad Tecnologica de Pereira, Pereira, Colombia, Hospital San Pedro y San Pablo, La Virginia, Colombia

INFECTION - Health Care Use & Policy Studies

PIN79 J11

PIN80 J12

PIN81 J13

PIN82 J14 PIN83 J15 PIN84 J16

PIN85 J17

PIN86 J18

PIN87 J19

PIN88 J20

PIN89 J21

PIN90 J22 PIN91 J23

PIN92 J24

PIN93 J25

PIN94 J26

IMPACT OF DOSING SCHEDULE ON THE SUCCESS OF A VACCINATION PROGRAMME IN AN ELDERLY POPULATION 1 1 2 2 3 3 1 2 Matthews IR , Dawson H , Préaud E , Lu X , Harrison J , Lee A , Sanofi Pasteur MSD, Maidenhead, UK, Sanofi Pasteur MSD, 3 Lyon, France, WG Access Ltd, High Wycombe, UK UTILISATION AND DOSAGE PATTERNS OF INTRAVENOUS ECHINOCANDINS FOR TREATMENT OF INVASIVE FUNGAL INFECTIONS WITHIN HOSPITALS IN ENGLAND 1 2 1 1 3 3 1 2 Ahir HB , McCann E , Robertson S , Patel S , Yu E , Tham R , MSD Ltd, Hoddesdon, UK, Merck & Co., Kenilworth, NJ, 3 USA, IMS Health, London, UK SEASONAL VARIATIONS OF OUTPATIENT ANTIBIOTIC USE IN AUSTRIA 1 1 2 1 Hinteregger M , Janzek-Hawlat S , Reichardt B , Main Association of Austrian Social Security Institutions (HVB), Vienna, 2 Austria, Sickness Fund Burgenland (BGKK), Eisenstadt, Austria UTILISATION OF ANTIRETROVIRALS IN THE SLOVAK REPUBLIC - A 10-YEAR RETROSPECTIVE STUDY Olearova A, Navratil M, Lehocka L, Masarykova L,Comenius University in Bratislava, Faculty of Pharmacy, Bratislava, Slovakia DISPENSING PATTERNS OF VACCINES BY PHARMACIES IN SOUTH AFRICA Truter I, Lamprecht JC,King Khalid University, Abha, Saudi Arabia GENERAL PRACTITIONERS PERCEPTIONS ABOUT FINANCIAL AND NON-FINANCIAL INCENTIVES TO IMPROVE INFLUENZA VACCINATION COVERAGE RATES IN FRANCE 1 2 3 4 5 6 6 1 1 Silva ML , Perrier L , Späth H , Paget JW , Buthion V , Mosnier A , Cohen JM , Aulois-Griot M , University of Bordeaux, Bordeaux, 2 3 4 France, Cancer Centre Leon Berard, Lyon, France, University Claude Bernard Lyon 1, Lyon, France, Netherlands Institute For 5 6 Health Services Research (NIVEL), Utrecht, The Netherlands, University Lumière Lyon 2, Lyon, France, Open Rome, Paris, France REDUCING DISPARITIES IN U.S. VACCINATION THROUGH SENIOR CENTERS: A COMPARISON OF THREE EDUCATIONAL MODELS FOR OLDER AFRICAN AMERICANS Prioli KM, Schafer JJ, Pizzi LT,Thomas Jefferson University, Philadelphia, PA, USA LENGTH OF STAY, COSTS AND MORTALITY ATTRIBUTABLE TO CLOSTRIDIUM DIFFICILE INFECTIONS IN 13 BELGIAN HOSPITALS 1 2 2 1 2 Pirson M , Poirrier J , Joubert S , Ecole de Santé Publique - Université Libre de Bruxelles, Brussels, Belgium, MSD Belgium BVBA/SPRL, Brussels, Belgium DIRECT COSTS ASSOCIATED TO MENINGOCOCCAL DISEASE AND RELATED SEQUELAE IN CHILDREN – ANALYSIS BASED ON THE BRAZILIAN PUBLIC HEALTH SYSTEM PERSPECTIVE Salgado JB, Silva DO, Lorenzato F, Cintra OA, Saturnino LT,GlaxoSmithkline, rio de janeiro, Brazil VALUE OF EXPANDING HCV TREATMENT CAPACITY IN GERMANY THROUGH NOVEL, EFFECTIVE AND SHORTER DURATION THERAPIES 1 2 3 4 5 6 6 1 Sbarigia U , Wirth D , Van Nuys K , Huber C , Brookmeyer R , Stahmeyer J , Krauth C , Janssen Pharmaceutica NV, Beerse, 2 3 4 Belgium, Janssen-Cilag, Neuss, Germany, Precision Health Ecomomics, San Francisco, CA, USA, Precision Health Economics, 5 6 New York, NY, USA, UCLA School of Public Health, Los Angeles, CA, USA, Hannover Medical School, Hannover, Germany ESTIMATING THE VALUE OF A NEW ANTIBIOTIC: A NOVEL APPROACH USING ESBL AS A CASE STUDY 1 2 2 2 3 1 2 Geale K , Geale K , Corcoran K , Virhage M , Anell B , Umeå University, Umeå, Sweden, PAREXEL International, Stockholm, 3 Sweden, Parexel International, Stockholm, Sweden THE IMPACT OF REGIONAL COST-SAVING INITIATIVES ON THE UPTAKE OF ANTIRETROVIRAL DRUGS IN LONDON Ohanjanyan A, Mukku DS, Edathodu A, Samuel JJ, Leung SK,Access Infinity Ltd, London, UK SICK LEAVE AND DISABILITY PENSION IN PATIENTS WITH CHRONIC HEPATITIS C COMPARED WITH MATCHED GENERAL POPULATION COMPARATORS: A NATIONWIDE POPULATION-BASED REGISTER STUDY 1 2 3 3 1 2 3 Büsch K , Hansson F , Kövamees J , Söderholm J , Karolinska Institutet, Solna, Sweden, Devicia, Stockholm, Sweden, AbbVie AB, Solna, Sweden FIRST RESULTS FROM A RETROSPECTIVE STUDY ON THE EPIDEMIOLOGY OF THE HUNGARIAN HIV INFECTED POPULATION 1 1 2 2 3 3 3 3 4 1 Kósa F , Takács P , Tronczynski K , Duchesne I , Kasza K , Merth G , Merész G , Rózsa P , Szlávik J , Janssen-Cilag, Budapest, 2 3 4 Hungary, Janssen EMEA, Beerse, Belgium, MediConcept, Budapest, Hungary, St. István and St. László United Hospital, Budapest, Hungary THE POTENTIAL PUBLIC HEALTH IMPACT OF VARICELLA VACCINATION IN HUNGARY 1 2 3 4 5 1 2 Meszner Z , Benedek A , Kyle J , Pillsbury M , Wolfson LJ , National Institute of Health Promotion, Budapest, Hungary, MSD 3 4 Pharma Hungary Ltd, Budapest, Hungary, Merck & Co., Inc., Kenilworth, NJ, USA, Merck & Co. Inc., North Wales, PA, 5 USA, Merck, Kenilworth, NJ, USA PUBLIC KNOWLEDGE AND ATTITUDES TOWARDS ZIKA VIRUS AND ITS PREVENTION IN MALAYSIA 1 1 1 2 2 3 1 2 Khan MU , Ahmad A , Arief M , Saleem F , Hassali MA , Bhagavathula AS , UCSI University, Kuala Lumpur, Malaysia, Universiti 3 Sains Malaysia, Penang, Malaysia, University of Gondar, Gondar, Ethiopia

PIN95 J27

PIN96 J28

PIN97 J29 PIN98 J30 PIN99 J31

PIN100 J32

PIN101 J33

EFFECTIVENESS OF PHARMACISTS-LED PROVIDER-FOCUSED INTERVENTIONS TO IMPROVE HPV VACCINATION RATES IN ADULTS IN MALAYSIA 1 2 2 1 Iqbal MS , Iqbal MZ , Bahari MB , Faculty of Pharmacy, Bahauddin Zakariya University, Multan, Pakistan. Department of Clinical 2 Pharmacy, Faculty of Pharmacy, MAHSA University, Selangor, Malaysia, Department of Clinical Pharmacy & Pharmacy Practice, Faculty of Pharmacy, AIMST University, Kedah, Malaysia INVESTIGATING INFLUENZA VACCINATIONS FOR RISK GROUPS IN UKRAINE 1 2 3 1 1 2 Leleka M , Kit S , Paparyha V , Zalis'ka O , Danylo Halytsky Lviv National Medical University, Lviv, Ukraine, Lviv Regional 3 Infectious Hospital, Lviv, Ukraine, Kyiv National Economic University, Kyiv, Ukraine THE PREVALENCE OF NOSOCOMIAL INFECTIONS IN KARAGANDA (KAZAKHSTAN) DURING 2011-2015 Kultanova E, Lavrinenko A, Turmukhambetova A,Karaganda State Medical University, Karaganda, Kazakhstan HEALTH TECHNOLOGY ASSESSMENT OF THE USE VACCINES FOR PREVENTION FLU Vorobiev P, Dugin D, Krasnova L,Russian Society for Pharmacoeconomics and Outcomes Research, Moscow, Russian Federation HCV TREATMENT WITH DAAS IN THE ‘REAL-WORLD’: HOW WELL DO ‘REAL’ PATIENTS RESPOND? THE IRISH PERSPECTIVE 1 2 1 2 O'Leary A , Ni Choitir C , Royal College of Surgeons in Ireland, Dublin, Ireland, National Centre for Pharmacoeconomics, Dublin, Ireland ECONOMIC BURDEN OF ANTI-METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS (MRSA) THERAPY IN PUBLIC HOSPITALS OF PARIS (AP-HP) AND ADEQUACY WITH THE DEFINED DAILY DOSES 1 1 1 2 1 1 2 Therasse C , Fusier I , Cordonnier A , Vittecoq D , Paubel P , AP-HP, AGEPS, Paris, France, Infectious and Tropical Diseases Department, Bicetre Hospital, AP-HP, Le Kremlin Bicêtre, France ANTIBIOTIC UTILISATION AND EXPENDITURE IN IRELAND 1 2 3 4 5 1 2 Clarke S , Bennett K , Oza A , Cunney R , Barry M , HSE Medicines Management Programme, Dublin, Ireland, Royal College of 3 4 Surgeons Ireland, Dublin, Ireland, Health Protection Surveillance Centre, Dublin, Ireland, Healthcare Associated Infection and 5 Antimicrobial Resistance Clinical Programme, Dublin, Ireland, National Centre for Pharmacoeconomics, Dublin, Ireland

NEUROLOGICAL DISORDERS - Clinical Outcomes Studies PND1 J34 PND3 J36

PND4 J37

PND5 K1

PND6 K2

PND7 K3

PND8 K4

PND9 K5

PND10 K6

META-ANALYSIS OF NEWER ANTI-EPILEPTIC DRUGS FOR TREATMENT OF PARTIAL EPILEPSY IN CHILDREN 1 2 1 2 Mohd Tahir NA , Li SC , University of Newcastle, Callaghan, NSW, Australia, The University of Newcastle, Newcastle, Australia TWO-YEAR ANTECEDENT VERSUS SUBSEQUENT DIAGNOSES OF PATIENTS NEWLY DIAGNOSED WITH PRIMARY RESTLESS LEGS SYNDROME: A LARGE-SCALE RETROSPECTIVE CLAIMS ANALYSIS Hankin C, Lee D, Wang Z,BioMedEcon, LLC, Moss Beach, CA, USA DEMOGRAPHIC AND CLINICAL CHARACTERISTICS OF MIGRAINE PATIENTS IN DENMARK 1 1 2 1 1 1 1 Ehrenstein V , Szépligeti S , Xue F , Thomsen RW , Sørensen HT , Adelborg K , Aarhus University Hospital, Aarhus N, 2 Denmark, Amgen Inc., Thousand Oaks, CA, USA PREDICTORS OF DISEASE PROGRESSION IN MILD ALZHEIMER’S DISEASE DEMENTIA PATIENTS – RESULTS FROM THE GERAS REAL WORLD COHORT AND EXPEDITION TRIALS 1 2 3 4 51 2 Reed C , Lebrec J , Andrews JS , Bruno G , Jones RW , Eli Lilly and Company Ltd, Windlesham, UK, Lilly Deutschland GmbH, 3 4 5 Bad Homburg, Germany, Eli Lilly and Company, Indianapolis, IN, USA, University of Rome, Roma, Italy, The Research Institute for the Care of Older People, Bath, UK RELAPSE RATES AND HEALTHCARE RESOURCE USE OF THERAPY PERSISTENT AND NON-PERSISTENT MULTIPLE SCLEROSIS PATIENTS IN GERMANY – A REAL WORLD ANALYSIS 1 1 2 3 1 1 2 Prosser C , Haas J , Wakeford C , Landsman-Blumberg P , Braun S , Xcenda GmbH, Hannover, Germany, Biogen Idec Inc., 3 Cambridge, MA, USA, Xcenda LLC, Palm Harbor, FL, USA DIFFERENCES IN LONG-TERM PATIENT OUTCOMES WITH DISEASE-MODIFYING VERSUS SYMPTOMATIC TREATMENTS FOR ALZHEIMER’S DISEASE (AD) Kansal A, DosSantos R, Tafazzoli A,Evidera, Bethesda, MD, USA USING CLINICAL TRIAL AND REAL WORLD DATA TO BRIDGE EFFICACY TO EFFECTIVENESS OF FINGOLIMOD IN MULTIPLE SCLEROSIS PATIENTS 1 1 2 1 1 1 3 4 3 1 Ivanov V , Torgovitsky R , Tchetgen Tchetgen E , Church B , Alas V , Khalil I , Risson V , Kahler K , Olson M , GNS Healthcare, 2 3 4 Cambridge, MA, USA, Harvard University, Boston, MA, USA, Novartis Pharma AG, Basel, Switzerland, Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA GLATIRAMER ACETATE (GA) RESULTS IN SIGNIFICANT REDUCTIONS IN ANNUALIZED RELAPSE RATE (ARR) AND PROTECTIVE EFFECT ON DISIBILTIY PROGRESSION: RESULTS FROM A NETWORK META-ANALYSIS 1 2 1 1 1 2 Ivanescu C , Wu Y , Kool-Houweling LM , van Engen A , Quintiles Advisory Services, Hoofddorp, The Netherlands, Teva Branded Pharmaceuticals Products R&D Inc, Frazer, PA, USA OBSERVATIONAL STUDY ON DAILY LIFE PRACTICE IN 15039 PATIENT WITH MULTIPLE SCLEROSIS IN FRANCE 1 2 3 4 4 5 5 5 1 Defer G , de Seze J , Clanet M , Bouee S , Courouve L , Longin J , Payet M , Jeandeleglise AS , CHU de Caen, Caen,

2

3

4

5

France, Strasbourg University, Strasbourg, France, CHU Purpan, Toulouse, France, CEMKA, Bourg La Reine, France, Merck, LYON, France PND11 K7 RELAPSE RATES AND SYMPTOM MANAGEMENT AMONG PATIENTS RECEIVING NATALIZUMAB AND OTHER DISEASE-MODIFYING THERAPIES FOR RELAPSING-REMITTING MULTIPLE SCLEROSIS 1 2 1 1 3 1 1 2 Lee L , Pike J , Kendter J , Campagnolo D , Jones E , Naoshy S , Biogen, Cambridge, MA, USA, Adelphi Real World, Bollington, 3 UK, Adelphi Real World, Manchester, UK PND12 K8 A RESTROSPECTIVE NON-INTERVENTIONAL STUDY AMONG PATIENTS WITH RELAPSING MULTIPLE SCLEROSIS SWITCHING TO FINGOLIMOD OR TO OTHER DISEASE MODIFYING THERAPIES 1 2 3 4 4 5 1 1 2 Medin J , Haddad P , Ricart J , Lara N , Pedros M , Bizouard G , Loefroth E , Novartis Pharma AG, Basel, Switzerland, Novartis 3 4 Pharmaceuticals Canada Inc., Dorval, QC, Canada, Novartis Farmaceutica SA, Barcelona, Spain, IMS Health, Barcelona, 5 Spain, IMS Health RWE, Boulogne Billancourt, France PND13 K9 STABLE MULTIPLE SCLEROSIS PATIENTS ON AN INTERFERON THERAPY HAVE BETTER OUTCOMES WHEN STAYING ON THERAPY THAN PATIENTS WHO SWITCH TO ANOTHER INTERFERON 1 1 1 2 3 3 3 4 3 1 Cohan S , Smoot K , Kresa-Reahl K , Kendter J , Garland R , Yeh D , Wu N , Serafini P , Watson C , Providence St. Vicent 2 3 4 Medical Center, Portland, OR, USA, Biogen, Weston, MA, USA, Biogen, Cambridge, MA, USA, Biogen, Sao Paulo, Brazil PND14 K10 PHARMACOTHERAPIES FOR THE TREATMENT OF BEHAVIORAL AND PSYCHOLOGICAL SYMPTOMS OF DEMENTIA - A SYSTEMATIC REVIEW ON RECENT EVIDENCE Stürzlinger H, Eisenmann A, Antony K, Laschkolnig A, Pertl D,Gesundheit Österreich GmbH, Vienna, Austria PND15 K11 DISEASE MODIFYING TREATMENT (DMT) IS ASSOCIATED WITH LOWER HAZARD FOR DEATH AMONG MULTIPLE SCLEROSIS (MS) PATIENTS: SURVIVAL ANALYSIS BASED ON 30 YEARS INCIDENT MS COHORT 1 1 2 3 4 1 1 Murtonen A , Holmberg MH , Soini EJ , Ruutiainen J , Huhtala H , Sumelahti M , School of Medicine, University of Tampere, 2 3 4 Tampere, Finland, ESIOR Oy, Kuopio, Finland, Finnish Neuro Society and University of Turku, Masku, Finland, School of Health Sciences, University of Tampere, Tampere, Finland PND16 K12 SAFETY PROFILE OF DACLIZUMAB FOR THE TREATMENT OF RELAPSING-REMITTING MULTIPLE SCLEROSIS Kanukula R, Sawant A, Sirumalla Y, Jain P, Belekar V, Bhupathi VR, Sharma S, Likhar N, Dang A,MarksMan Healthcare Solutions LLP, Health Economics and Outcomes Research (HEOR) and RWE (Real World Evidence), Navi Mumbai, India NEUROLOGICAL DISORDERS - Cost Studies PND17 K13 ALEMTUZUMAB BUDGET IMPACT FOR MULTIPLE SCLEROSIS TREATMENT IN SPAIN Casellas M, Rubio M,Sanofi, Barcelona, Spain PND18 K14 BUDGET AND PATIENT ACCESS ANALYSIS TO SECOND LINE THERAPY OF MULTIPLE SCLEROSIS IN BULGARIA Dimitrova M, Petrova G, Kamusheva M, Manova M, Savova A,Medical University-Sofia, Faculty of Pharmacy, Sofia, Bulgaria PND19 K15 BUDGET IMPACT ANALYSIS OF TERIFLUNOMIDE USED FOR MULTIPLE SCLEROSIS PATIENTS IN RUSSIA 1 1 1 1 1 1 1 1 Evdoshenko E , Solodun I , Bashlakova E , Holownia M , Poliakova K , Pokatilo A , Khachanova N , Davydovskaya M , Skoromets 2 1 A , State Budgetary Institution of Moscow City «Center of Clinical Trials Management and Performance of Moscow Department of 2 Healthcare», Moscow, Russia, Saint-Petersburg Center for Multiple Sclerosis and other Autoimmune Diseases, City Clinical Hospital № 31, Saint-Petersburg, Russian Federation PND20 K16 COST COMPARISON OF MEDICAL AND SURGICAL TREATMENTS FOR MEDICALLY INTRACTABLE EPILEPSY 1 2 3 1 1 2 1 1 Rhee J , Chung CK , Kim DW , Lee J , Kim S , Heo W , Shin HG , National Evidence-based Healthcare Collaborating Agency, 2 3 Seoul, South Korea, Seoul National University College of Medicine, Seoul, South Korea, Konkuk University School of Medicine, Seoul, South Korea PND21 K17 HEALTHCARE RESOURCE UTILISATION AND COST OF PARKINSON’S DISEASE IN THE UNITED KINGDOM 1 1 1 2 3 4 5 1 2 Weir S , Samnaliev M , Kuo T , Tierney T , Walleser Autiero S , Taylor R , Schrag A , PHMR Ltd, London, UK, University of Miami, 3 4 5 Miami, FL, USA, Medtronic International Trading Sarl, Tolochenaz, Switzerland, University of Exeter, Exeter, UK, University College London, London, UK PND22 K18 COST OF ILLNESS OF PARTIAL ONSET SEIZURES EPILEPSY IN ITALY: RESULTS FROM THE PROMETEO STUDY 1 2 2 3 4 5 1 2 Lazzaro C , Da Deppo L , Ferrò B , Iudice A , La Neve A , Zaccara G , Studio di Economia Sanitaria, Milan, Italy, UCB Pharma 3 4 5 SpA, Milan, Italy, University of Pisa, Pisa, Italy, University of Bari, Bari, Italy, Florence Health Authority, Florence, Italy PND23 K19 CENTRAL NERVOUS SYSTEM, MULTIPLE SCLEROSIS AND SOCIAL SECURITY: THE ECONOMIC BURDEN ON THE SOCIAL SECURITY SYSTEM PENSIONS IN ITALY 1 2 3 3 4 1 2 Mennini FS , Russo S , Migliorini R , Trabucco MA , Marcellusi A , University of Rome Tor Vergata, Rome, Italy, University of 3 4 Rome “Sapienza”, Rome, Italy, Italian National Social Security Institute (INPS), Rome, Italy, Faculty of Economics, Centre for Economic and International Studies (CEIS)-Economic Evaluation and HTA (EEHTA), University of Rome Tor Vergata, Rome, Italy PND24 K20 THE COST OF RELAPSE REMITTING MULTIPLE SCLEROSIS DISEASE - PATIENT REPORTED STUDY IN EGYPT 1 1 2 2 1 2 Anan I , Abdel-Monem R , Sharabi M , Sharawy M , Accsight, Cairo, Egypt, MS care, Cairo, Egypt PND25 K21 HEALTH INSURANCE COST OF MULTIPLE SCLEROSIS IN HUNGARY: A COST OF ILLNESS STUDY 1 2 3 1 2 Oberfrank F , Donka-Verebes É , Boncz I , Institute of Experimental Medicine, Budapest, Hungary, Integra Consulting Zrt.,

3

PND26 K22

PND27 K23

PND28 K24

PND29 K25

PND30 K26

PND31 K27

PND32 K28

PND34 K29

PND35 K30

PND36 K31

PND37 K32

PND38 K33

PND39 K34

PND40 K35

PND41 K36

PND42 K37

PND43 L1

Budapest, Hungary, University of Pécs, Pécs, Hungary COST AND RESOURCE UTILIZATION AMONG MULTIPLE SCLEROSIS PATIENTS WITH INCREASING DISABILITY IN LATIN AMERICA 1 2 3 1 2 3 Serafini P , Jones E , Pike J , Biogen, Sao Paulo, Brazil, Adelphi Real World, Manchester, UK, Adelphi Real World, Bollington, UK THE IMPRESS (INTERNATIONAL MULTIPLE SCLEROSIS) STUDY; RESULTS ON THE SOCIO-ECONOMIC BURDEN, HEALTH RELATED QUALITY OF LIFE AND EXPERIENCE OF MULTIPLE SCLEROSIS PATIENTS IN FRANCE 1 1 1 2 1 1 1 Kanavos P , Tinelli M , Efthymiadou O , Visintin E , Grimaccia F , Mossman J , London School of Economics and Political Science, 2 London, UK, London School of Economics and Political Sciences, London, UK INCREMENTAL DIRECT AND INDIRECT COSTS ASSOCIATED WITH MIGRAINE IN THE US 1 2 2 3 4 2 1 2 Bonafede MM , Sapra S , Shah N , Tepper SJ , Cappell KA , Desai PR , Truven Health Analytics, Cambridge, MA, USA, Amgen 3 4 Inc, Thousand Oaks, CA, USA, Dartmouth, Lebanon, NH, USA, Truven Health Analytics, Ann Arbor, MI, USA EFFICACY, COSTS AND QUALITY OF LIFE IN THE REAL WORLD SETTING FOR PATIENTS WITH MULTIPLE SCLEROSIS TREATED WITH FINGOLIMOD: INTERMEDIATE RESULTS FROM THE VIRGILE STUDY 1 1 1 1 1 1 1 2 1 Aly S , Digoin-Danzin A , Duteil E , Leiba G , Duco J , Chouette I , Allaf B , Kobelt G , Novartis Pharma, Rueil-Malmaison, 2 France, European Health Economics, Mulhouse, France PRESCRIPTION PATTERNS AND COSTS OF MIGRAINE THERAPY IN GERMANY 1 2 3 2 1 2 Voss F , Dombrowski S , Jacob L , Kostev K , Fresenius University, Idstein, Germany, IMS Health, Frankfurt am Main, 3 Germany, Ecole Normale Superieure of Lyon, Lyon, France ANALYSIS OF EXPENDITURE IN MULTIPLE SCLEROSIS DISEASE MODIFYING THERAPIES EVOLUTION BETWEEN 2004-2015 IN SPAIN 1 2 1 2 Villoro R , Hidalgo A , Instituto Max Weber, Madrid, Spain, University of Castilla-La Mancha, Toledo, Spain IMPACT OF THE INTRODUCTION OF NEW BRANDED GENERIC EQUIVALENTS ON THE PRESCRIBING PATTERNS OF ANTI-DEMENTIA MEDICATION Truter I,King Khalid University, Abha, Saudi Arabia INDIRECT COSTS OF EPILEPSY IN TURKEY: COST OF THE DISEASE IN TERMS OF WORK LOSS 1 1 1 2 3 4 4 1 Tatar M , Senturk A , Tuna E , Gurses C , Caliskan Z , Caglayan B , Firidin A , Polar Health Economics and Policy Consultancy, 2 3 4 Ankara, Turkey, Istanbul University, Istanbul, Turkey, Hacettepe University, Ankara, Turkey, UCB Pharma, Istanbul, Turkey DIRECT COSTS OF EPILEPSY IN TURKEY: A PANEL APPROACH 1 1 1 2 3 3 1 Tatar M , Senturk A , Tuna E , Gurses C , Caglayan B , Firidin A , Polar Health Economics and Policy Consultancy, Ankara, 2 3 Turkey, Istanbul University, Istanbul, Turkey, UCB Pharma, Istanbul, Turkey COST-UTILITY ANALYSIS OF ALEMTUZUMAB VERSUS NATALIZUMAB FOR THE TREATMENT OF RELAPSING-REMITTING MULTIPLE SCLEROSIS: US PAYER PERSPECTIVE Smith A, Hashemi L, Ma I,Sanofi Genzyme, Cambridge, MA, USA THE COST-EFFECTIVENESS OF DELAYED-RELEASE DIMETHYL FUMARATE VERSUS GLATIRAMER ACETATE FOR THE TREATMENT OF RELAPSING-REMITTING MULTIPLE SCLEROSIS IN THE CHILEAN NATIONAL HEALTH FUND (FONASA) 1 1 1 2 2 1 2 Noda C , de Anda JA , Anaya P , Serafini P , Machado M , IMS Health, México, D.F., Mexico, Biogen, Sao Paulo, Brazil COST-EFFECTIVENESS OF LEVOFLOXACIN INHALATION SOLUTION VS. AZTREONAM INHALATION SOLUTION AND TOBRAMYCIN DRY POWDER FOR INHALATION IN CYSTIC FIBROSIS PATIENTS IN SWEDEN Medic G, Franck-Larsson K, Wille M, Rodahl S, Hemels M,Raptor Pharmaceuticals Europe B.V., Utrecht, The Netherlands COST EFFECTIVENESS OF IVACAFTOR AND LUMACAFTOR COMBINATION FOR THE TREATMENT OF PATIENTS WITH CYSTIC FIBROSIS IN THE UNITED STATES 1 1 1 1 2 1 1 Sharma D , Xing S , Hung Y , Caskey RN , Dowell ML , Touchette DR , University of Illinois at Chicago, Chicago, IL, 2 USA, University of Chicago, Chicago, IL, USA THE COST-EFFECTIVENESS OF DELAYED RELEASE DIMETHYL FUMARATE VERSUS GLATIRAMER ACETATE FOR THE TREATMENT OF RELAPSING-REMITTING MULTIPLE SCLEROSIS IN THE MEXICAN SOCIAL SECURITY INSTITUTE (IMSS) 1 1 1 2 3 3 1 2 de Anda JA , Noda C , Anaya P , Azamar A , Machado M , Serafini P , IMS Health, Mexico City, Mexico, Stendhal, Mexico City, 3 Mexico, Biogen, Sao Paulo, Brazil COST-EFFECTIVENESS OF FINGOLIMOD VS BRACE CYCLING FOLLOWED BY A SWITCH TO FINGOLIMOD IN PATIENTS FAILING PRIOR TREATMENT 1 1 1 2 1 2 Mahon R , Callan A , Burke C , Medin J , Product Lifecycle Services - Novartis Business Services, Dublin, Ireland, Novartis Pharma AG, Basel, Switzerland COST-EFFECTIVENESS OF LEVOFLOXACIN INHALATION SOLUTION VS. AZTREONAM INHALATION SOLUTION IN CYSTIC FIBROSIS PATIENTS IN BELGIUM Medic G, Westen M, Wille M, Hemels M,Raptor Pharmaceuticals Europe B.V., Utrecht, The Netherlands COST-EFFECTIVENESS ANALYSIS FOR TREATMENT OF PARKINSON’S DISEASE: A SYSTEMATIC REVIEW 1 2 1 2 1 2 Yamabe K , Inoue S , Kuwabara H , Kobayashi M , Takeda Pharmaceutical Company Ltd., Tokyo, Japan, CRECON Medical

PND44 L2

PND45 L3

PND46 L4

Assessment Inc., Tokyo, Japan COST MINIMIZATION ANALYSIS FOR THE TREATMENT OF PRIMARY IMMUNODEFICIENCY DISEASE (PIDD) IN THE MEXICAN SOCIAL SECURITY INSTITUTE IN 2016 1 2 3 1 Maciel H , Salazar-Alvarado BE , Paladio-Hernández JÁ , Universidad Nacional Autonoma de Mexico, Mexico City, 2 3 Mexico, Instituto Nacional de Pediatría, Mexico City, Mexico, UACH, Cuautitlán Izcalli, Mexico COST MINIMIZATION OF 10% INTRAVENOUS IMMUNOGLOBULIN AGAINST OTHER INTRAVENOUS IMMUNOGLOBULIN FOR TREATING PRIMARY INMUNODEFICIENCIES 1 2 2 3 2 1 Romero Prada ME , Huerfano LM , Vasquez Melo EC , Acero G , Roa Cardenas NC , Fundación Salutia, Bogotá, 2 3 Colombia, Salutia Foundation - Research center in economy, management and health technologies., Bogota, Colombia, Salutia Foundation, Bogotá, Colombia COST MINIMIZATION OF USING ACTIVATED PROTHROMBIN COMPLEX CONCENTRATE VERSUS RECOMBINANT ACTIVATED FACTOR VII IN PATIENTS WITH A ND B HEMOPHILIA IN PRESENCE OF INHIBITORS 1

PND47 L5

PND48 L6

PND49 L7

PND50 L8

PND51 L9

PND52 L10

PND53 L11

PND54 L12

2

3

4

3

Romero Prada ME , Gomez de la rosa F , Alvis-Zakzuk NJ , Carrasquilla-Sotomayor M , Alvis-Zakzuk JS , Zakzuk-Sierra 3 1 2 J , Fundación Salutia, Bogotá, Colombia, Grupo de investigación en economía de la salud - GIES, Cartagena, 3 Colombia, Universidad de Cartagena. Centro de Investigación y Docencia. Hospital Infantil Napoleón Franco Pareja, Cartagena de 4 Indias, Colombia, ALZAK Foundation, Cartagena, Colombia COST-UTILITY ANALYSIS OF TWO TYPE-A BOTULINUM TOXINS IN THE MANAGEMENT OF BLEPHAROSPASM AND CERVICAL DYSTONIA IN SPAIN Sanz-Granda Á,Proyectos de Farmacoeconomía, Navacerrada, Spain COST-EFFECTIVENESS OF INCOBOTULINUMTOXIN-A WITH FLEXIBLE TREATMENT INTERVALS COMPARED TO FIXED TREATMENT INTERVALS IN THE MANAGEMENT OF BLEPHAROSPASM AND CERVICAL DYSTONIA Tilden D, Guarnieri C,THEMA Consulting Pty Ltd, Pyrmont, Australia COST-EFFECTIVENESS OF DACLIZUMAB VERSUS FINGOLIMOD IN THE TREATMENT OF PATIENTS WITH RELAPSING-REMITTING MULTIPLE SCLEROSIS IN NORWAY 1 1 1 2 3 4 4 1 2 Toro-Diaz H , Cele C , Hernandez L , Haines P , Liu Y , Bjørnstad BM , Haukaas FS , Evidera, Lexington, MA, USA, Biogen, Zug, 3 4 Switzerland, Biogen, Cambridge, MA, USA, Biogen Norway AS, Oslo, Norway GLATIRAMER ACETATE (GA) IS COST-EFFECTIVE COMPARED TO INTERFERONS AND BEST SUPPORTIVE CARE (BSC) FOR RELAPSING REMITTING MULTIPLE SCLEROSIS (RRMS) IN THE UK 1 2 3 2 1 2 Maervoet J , Ivanescu C , Wu Y , van Engen A , Quintiles Advisory Services, Brussels, Belgium, Quintiles Advisory Services, 3 Hoofddorp, The Netherlands, Teva Branded Pharmaceuticals Products R&D Inc, Frazer, PA, USA THE SOCIETAL IMPACT OF NATALIZUMAB TREATMENT IN THE ITALIAN RELAPSING-REMITTING MULTIPLE SCLEROSIS CLINICAL PRACTICE: THE TYSABRI® PHARMACOECONOMICS (TYPE) STUDY 1 1 2 3 4 4 5 1 Polistena B , Spandonaro F , Gasperini C , Zimatore GB , Santoni L , Fantaccini S , Capra R , University of Rome Tor Vergata, 2 3 Rome, Italy, Department of Neurosciences, S Camillo Forlanini Hospita, Rome, Italy, U.O. Neurologia, P.O. Dimiccoli, Barletta, 4 5 Italy, Biogen, Milan, Italy, Multiple Sclerosis Center, Spedali Civili of Brescia, Brescia, Italy COST-UTILITY ANALYSIS OF DIMETHYL FUMARATE VERSUS FINGOLIMOD AND TERIFLUNOMIDE IN PATIENTS WITH RELAPSING-REMITTING MULTIPLE SCLEROSIS IN COLOMBIA 1 2 2 1 2 Ordóñez J , Serafini P , Machado M , CES University, Medellin, Colombia, Biogen, Sao Paulo, Brazil RATES AND PREDICTORS OF SHORT TERM DISABILITY CLAIMS AMONG MIGRAINE PATIENTS IN THE US 1 2 3 4 5 5 5 1 Bonafede MM , Cappell KA , Juneau P , Tepper SJ , Sapra S , Shah N , Desai PR , Truven Health Analytics, Cambridge, MA, 2 3 4 USA, Truven Health Analytics, Ann Arbor, MI, USA, Truven Health Analytics, an IBM Company, Boyds, MD, USA, Dartmouth, 5 Lebanon, NH, USA, Amgen Inc, Thousand Oaks, CA, USA THE IMPACT OF INCREASING DISABILITY ON EMPLOYMENT AND CAREGIVER BURDEN AMONG MULTIPLE SCLEROSIS PATIENTS IN BRAZIL 1 2 3 1 2 3 Serafini P , Pike J , Jones E , Biogen, Sao Paulo, Brazil, Adelphi Real World, Bollington, UK, Adelphi Real World, Manchester, UK

NEUROLOGICAL DISORDERS - Patient-Reported Outcomes & Patient Preference Studies PND55 L13

PND56 L14

PND57 L15

THE ASSOCIATION OF ADHERENCE TO DISEASE-MODIFYING DRUGS AND OUT-OF-POCKET COSTS IN PATIENTS WITH MULTIPLE SCLEROSIS 1 2 3 4 1 2 Mayer L , Smrtka JM , Gupta S , Phillips AL , Central Texas Neurology Consultants, Round Rock, TX, USA, University of Miami 3 4 Multiple Sclerosis Center of Excellence, UHealth at Boca Raton, Boca Raton, FL, USA, Kantar Health, Princeton, NJ, USA, EMD Serono, Inc., Rockland, MA, USA ADHERENCE TO DRUG-RELATED MONITORING GUIDELINES FOR MULTIPLE SCLEROSIS THERAPIES: REAL-WORLD EVIDENCE FROM A US CLAIMS DATABASE 1 2 31 2 Lage MJ , Wu Y , Kolodny S , HealthMetrics Outcomes Research, LLC, Bonita Springs, FL, USA, Teva Pharmaceuticals, Malvern, 3 PA, USA, Teva Pharmaceuticals, North Ridgeville, OH, USA IMPACT OF ADHERENCE ON SUBCUTANEOUS INTERFERON BETA-1A EFFECTIVENESS ADMINISTERED BY REBISMART® IN PATIENTS WITH MULTIPLE SCLEROSIS

PND58 L16

PND59 L17 PND60 L18

PND61 L19

PND62 L20

PND63 L21

PND64 L22

PND65 L23

PND66 L24

Edo-Solsona M, Monte-Boquet E, Casanova-Estruch B, Poveda-Andrés J,HOSPITAL UNIVERSITARI I POLITÉCNIC LA FE, VALENCIA, Spain ASSESSMENT OF PATIENT PREFERENCES IN THE TREATMENT OF RELAPSING-REMITTING MULTIPLE SCLEROSIS IN PUBLIC AND PRIVATE SYSTEMS IN LATIN AMERICA 1 2 2 1 2 Serafini P , Jones E , Pike J , Biogen, Sao Paulo, Brazil, Adelphi Real World, Manchester, UK EDSS STATE AND HEALTH UTILITY MEASURED BY EQ5D IN RELAPSING-REMITTING MULTIPLE SCLEROSIS (RRMS) Daigl M, Jhuti GS, McDougall F, Bennett I,F. Hoffmann-La Roche Ltd, Basel, Switzerland THE BURDEN OF PARKINSON'S DISEASE(PD) IN JAPAN 1 1 2 3 1 2 Yamabe K , Kuwabara H , Liebert R , Umareddy I , Takeda Pharmaceutical Company Ltd., Tokyo, Japan, Kantar Health, New 3 York, NY, USA, Kantar Health, Singapore, Singapore TO DIAGNOSIS EMBRYONIC DEVELOPMENTAL ANOMALIES OF GENETIC ORIGIN WITH EXOME SEQUENCING: A DISCRETE CHOICE EXPERIMENT TO ASSESS PARENTS’ PREFERENCES FOR DISCLOSURE OF FINDINGS AND SUPPORT Pelissier A, Peyron C, Bejean S,University of Bourgogne Franche Comté, Dijon cedex, France INTERNAL CONSISTENCY AND CONSTRUCT VALIDITY OF PATIENT-REPORTED OUTCOMES IN PRIMARY PROGRESSIVE MULTIPLE SCLEROSIS 1 2 3 4 5 5 6 1 Montalban X , Wolinsky J , de Seze J , Miller D , Chin P , Lentz E , McDougall F , Vall d'Hebron University Hospital, Barcelona, 2 3 Spain, University of Texas Health Science Center at Houston, Houston, TX, USA, Strasbourg University, Strasbourg, 4 5 6 France, Cleveland Clinic, Cleveland, OH, USA, Genentech, Inc., South San Francisco, CA, USA, F. Hoffmann-La Roche Ltd, Basel, Switzerland BURDEN OF ILLNESS FOR PATIENTS WITH HEREDITARY ATTR AMYLOIDOSIS WITH POLYNEUROPATHY BEGINS WITH SYMPTOM ONSET AND INCREASES WITH DISEASE PROGRESSION 1 2 3 4 5 6 7 8 9 Denoncourt RN , Adams D , Gonzalez-Duarte A , O'Riordan W , Yang C , Yamashita T , Kristen A , Tournev I , Schmidt H , 10 11 12 1 1 13 1 2 Coelho T , Berk J , Lin K , Chen J , Gollob J , Suhr O , Alnylam Pharmaceuticals, Cambridge, MA, USA, National Reference 3 Center for FAP (NNERF)/ APHP/ INSERM U 1195/ CHU Bicêtre, Le Kremlin-Bicêtre, France, National Institute of Medical Science 4 5 and Nutrition Salvador Zubirán, Mexico City, Mexico, eStudySite, La Mesa, CA, USA, National Taiwan University Hospital, Taipei, 6 7 Taiwan, Taipei, Taiwan, Kumamoto University Hospital, Kumamoto, Japan, Heidelberg University, Heidelberg, 8 9 Germany, University Multiprofile Hospital for Active Treatment, Sofia, Bulgaria, Universitätsklinikum Münster, Münster, 10 11 Germany, Unidade Clinica de Paramiloidose, Hospital de Santo Antonio, Porto, Portugal, Boston University Medical Center, 12 13 Boston, MA, USA, Taipei Veterans General Hospital, Taipei, Taiwan, Umeå University, Umeå, Sweden QUALITY OF LIFE OF PATIENTS WITH ALZHEIMER'S DISEASE - A COMPARISON WITH GENERAL POPULATION 1 2 3 4 4 4 4 1 Wood R , Ritchie C , Jones E , Hu X , Khandker RK , Ambegaonkar BM , Black CM , Adelphi Real World, Bollington, 2 3 4 UK, University of Edinburgh, Edinburgh, UK, Adelphi Real World, Manchester, UK, Merck & Co. Inc, Rahway, NJ, USA QUALITY OF LIFE IN RELAPSING REMMITING MULTIPLE SCLEROSIS: INFLUENCE OF INTERFERON BETA-1A (AVONEX AND CINNOVEX) TREATMENT 1 2 1 2 Shahtaheri rS , Hatam N , Tehran University of Medical Science, Tehran, Iran (Islamic Republic of), Shiraz University Of Medical Science, Shiraz, Iran (Islamic Republic of) WORK PRODUCTIVITY AND USE OF DISEASE-MODIFYING THERAPIES IN MULTIPLE SCLEROSIS: RESULTS FROM A PATIENT SURVEY ACCESSED THROUGH SOCIAL MEDIA 1 2 3 4 1 1 1 2 Medin J , Ghodge B , Bonzani I , Korn JR , Olson M , Risson V , Novartis Pharma AG, Basel, Switzerland, IMS Health, Basel, 3 4 Switzerland, IMS Health, London, UK, IMS Health, Waltham, MA, USA

NEUROLOGICAL DISORDERS - Health Care Use & Policy Studies PND67 L25

PND68 L26

PND69 L27

PND70 L28

A REGIONAL ANALYSIS OF RELAPSING REMITTING MS (RRMS) PATIENTS TREATED WITH NATALIZUMAB SUGGESTS A NEED TO DIAGNOSE AND TREAT EARLY IN LATIN AMERICANS 1 2 2 3 4 5 1 2 Serafini P , Callegaro D , Apostolos S , Sato D , Jones E , Pike J , Biogen, Sao Paulo, Brazil, Hospital Das Clinicas, Sao Paulo, 3 4 5 Brazil, Hospital São Lucas da PUCRS, Porto Alegre, Brazil, Adelphi Real World, Manchester, UK, Adelphi Real World, Bollington, UK THE IMPACT OF TREATMENT ADHERENCE ON CLINICAL AND ECONOMIC OUTCOMES IN MULTIPLE SCLEROSIS: REAL-WORLD EVIDENCE FROM ALBERTA, CANADA 1 1 2 3 2 4 5 5 5 1 Gerber B , Cowling T , Chen G , Rivest D , Yeung MM , Duquette P , Kindundu C , Barbeau M , Haddad P , Medlior Health 2 3 Outcomes Research Ltd, Calgary, AB, Canada, University of Calgary, Calgary, AB, Canada, Hôtel-Dieu Lévis, Lévis, QC, 4 5 Canada, Notre Dame Hospital, Montréal, QC, Canada, Novartis Pharmaceuticals Canada Inc., Dorval, QC, Canada HAS PHARMACEUTICAL INNOVATION INCREASED PERSISTENCE AND ADHERENCE OF MULTIPLE SCLEROSIS PATIENTS IN GERMANY? 1 2 3 1 2 Fischer KE , Frey S , Lichtenberg F , University of Duisburg-Essen, Essen, Germany, University of Hamburg - Hamburg Center for 3 Health Economics, Hamburg, Germany, Columbia University, New York, NY, USA INSIGHTS INTO EARLY STAGES OF ALZHEIMER'S DISEASE USING CLAIMS DATA Ansorge S, Hapfelmeier J, Ertl J,arvato health analytics, Munich, Germany

PND71 L29

PND72 L30

PND73 L31

PND74 L32

PND75 L33

PND76 L34

PND77 L35

COMPARISON OF INFORMAL CAREGIVING TIME REQUIRED BY ALZHEIMER'S DISEASE PATIENTS AND MILD COGNITIVE IMPAIRMENT PATIENTS 1 2 3 4 4 4 4 1 Wood R , Ritchie C , Jones E , Hu X , Black CM , Khandker RK , Ambegaonkar BM , Adelphi Real World, Bollington, 2 3 4 UK, University of Edinburgh, Edinburgh, UK, Adelphi Real World, Manchester, UK, Merck & Co. Inc, Rahway, NJ, USA FUTURE INNOVATIVE THERAPIES FOR PARKINSON'S DISEASE MAY QUESTION SUSTAINABILITY OF OUR HEALTH CARE SYSTEM 1 2 3 4 4 1 1 1 Hanna E , Ma F , Cheng X , Dorey J , Aballéa S , Auquier P , Toumi M , Faculté de Médecine, Laboratoire de Santé Publique, 2 3 Aix-Marseille Université, Marseille, France, Creativ-Ceutical, Beijing, China, Creativ-Ceutical, Hong Kong, Hong 4 Kong, Creativ-Ceutical, Paris, France ECONOMIC AND HUMANISTIC BENEFITS OF MAINTAINING COGNITIVE IMPAIRMENT PATIENTS IN THE EARLY STAGE 1 2 3 3 1 1 1 1 Hu X , Ritchie C , Wood R , Jones E , Black CM , Khandker RK , Ambegaonkar BM , Merck & Co., Inc., Rahway, NJ, 2 3 USA, University of Edinburgh, Edinburgh, UK, Adelphi Real World, Bollington, UK HEALTHCARE RESOURCE USE OF PATIENTS NEWLY DIAGNOSED WITH MULTIPLE SCLEROSIS INITIATING ORAL OR SELF-INJECTABLE DISEASE-MODIFYING DRUGS: A LARGE, NATIONWIDE ANALYSIS OF US ELECTRONIC HEALTH RECORD DATA 1 2 1 2 Phillips AL , Corvino FA , EMD Serono, Inc., Rockland, MA, USA, Genesis Research, LLC, Hoboken, NJ, USA REAL WORLD DATA ON THE ADHERANCE TO THE NATIONAL POLICY OF INTEGRATIVE AND COMPLEMENTARY PRACTICES IN THE BRAZILIAN UNIFIED HEALTH SYSTEM : THE ACUPUNCTURE CASE 1 2 1 2 Silva J , Carmo E , University of Mogi das Cruzes, São Paulo - SP, Brazil, School of Oriental Therapies of Sao Paulo, São Paulo SP, Brazil HOW DO MIGRAINES IMPACT PATIENT DAY-TO-DAY LIFE? AN EXPLORATORY ANALYSIS OF PATIENT REPORTED DATA FROM THE PATIENTSLIKEME COMMUNITY 1 1 1 1 1 2 2 1 Naujoks C , Olson M , Simsek D , de Reydet de Vulpillieres F , Vo P , Kendall KR , Cerrato D , NOVARTIS PHARMA AG, Basel, 2 Switzerland, PatientsLikeMe, Cambridge, MA, USA PRESCRIPTION PATTERNS AND DRUGS COSTS IN PATIENTS WITH DEMENTIA - A RETRSOPECTIVE DATABASE ANALYSIS 1 2 3 4 3 1 2 Beck K , Jacob L , Booker A , Bohlken J , Kostev K , Fresenius University, Idstein, Germany, Ecole Normale Superieure of Lyon, 3 4 Lyon, France, IMS Health, Frankfurt am Main, Germany, Praxis Bohlken, Berlin, Germany

RESEARCH POSTER PRESENTATIONS - SESSION II HEALTH CARE USE & POLICY STUDIES HEALTH CARE USE & POLICY STUDIES - Consumer Role in Health Care PHP1

A1

PHP2

A2

PHP3

A3

PHP5

A5

PHP6

A6

PHP7

A7

PHP8

A8

PHP9

A9

RATIONING RESOURCES IN HEALTH BY INVOLVING THE PUBLIC IN PRIORITY SETTING 1 2 2 1 2 Farmakas A , Theodorou M , Kaitelidou D , Open University of Cyprus, Latsia, Cyprus, Open University of Cyprus, Latsia, Nicosia, Cyprus WHAT EU MEAN TO THE MHRA! POTENTIAL IMPACT OF ‘BREXIT’ ON PHARMACEUTICAL REGULATION IN THE UK 1 2 2 3 1 2 Macaulay R , Attri S , Pandey V , Ahuja A , Parexel Access Consulting, London, UK, Paraxel International, Chandigarh, 3 India, PAREXEL Access Consulting, Chandigarh, India MULTI-CRITERIA ASSESSMENT IN HTA PROCESS IN THE CZECH REPUBLIC: THE ROLE OF DIFFERENT STAKEHOLDERS INVOLVEMENT AND IMPACT ON APPRAISAL OF DRUGS INCLUDING ORPHANS 1 2 2 2 2 3 1 Ornstova E , Mlcoch T , Dolezalova H , Lamblova K , Mazalova M , Dolezal T , Charles University in Prague, Hradec Kralove, 2 3 Czech Republic, Institute of Health Economics and Technology Assessment, iHETA, Prague, Czech Republic, iHETA, Prague, Czech Republic USE OF INTERNET AND RELIABILITY OF INFORMATION OBTAINED ONLINE CONCERNING MEDICATION RISKS/SAFETY: PERCEPTIONS OF CONSUMERS IN THE U.S 1 2 3 4 1 2 Narayanan S , Bullman WR , Rucker NL , Rausch P , Market Access Solutions, LLC, Potomac, MD, USA, NCPIE, Rockville, MD, 3 4 USA, Enhance Value, Bethesda, MD, USA, Food and Drug Administration, Silver Spring, MD, USA PATIENT GROUP SUBMISSIONS (PGSS) IN HEALTH TECHNOLOGY ASSESSMENT (HTA) IN SCOTLAND: PREVALENCE AND IMPACT Hamilton KA, Griffiths M, Hanman K,Costello Medical Consulting Ltd, Cambridge, UK MEDICATION SAFETY WARNINGS: AWARENESS, SOURCE AND ACTIONS OF CONSUMERS IN THE U.S 1 2 3 4 1 2 Narayanan S , Bullman WR , Rucker NL , Rausch P , Market Access Solutions, LLC, Potomac, MD, USA, NCPIE, Rockville, MD, 3 4 USA, Enhance Value, Bethesda, MD, USA, Food and Drug Administration, Silver Spring, MD, USA CONSUMER PERCEPTION OF COMMUNICATION WITH HEALTHCARE PROFESSIONALS (HCPS) AND INFORMATION CLARITY CONCERNING NEWLY PRESCRIBED MEDICATION 1 2 3 4 1 2 Narayanan S , Rucker NL , Bullman WR , Rausch P , Market Access Solutions, LLC, Potomac, MD, USA, Enhance Value, 3 4 Bethesda, MD, USA, NCPIE, Rockville, MD, USA, Food and Drug Administration, Silver Spring, MD, USA RECEIPT AND DELIVERY OF MEDICATION RISK AND SAFETY INFORMATION: PERCEPTIONS OF CONSUMERS AND HEALTHCARE PROFESSIONALS (HCPS) IN THE US 1 2 3 4 1 2 Narayanan S , Bullman WR , Rucker NL , Rausch P , Market Access Solutions, LLC, Potomac, MD, USA, NCPIE, Rockville, MD, 3 4 USA, Enhance Value, Bethesda, MD, USA, Food and Drug Administration, Silver Spring, MD, USA

HEALTH CARE USE & POLICY STUDIES - Diagnosis Related Group PHP11 A11

PHP12 A12

CURRENT REIMBURSEMENT SITUATION OF ADVANCED THERAPY MEDICINAL PRODUCTS (ATMP) IN GERMANY: WHICH STRATEGY TO SECURE ADEQUATE FUNDING? Campion M, Bot D, Ecker T,Ecker + Ecker GmbH, Hamburg, Germany DEVELOPMENT OF REIMBURSEMENT OF NEW EXAMINATION AND TREATMENT METHODS (NUB) IN THE GERMAN DRG-SYSTEM – ANALYSIS OF NUB APPLICATIONS AND NUB STATUS SINCE IMPLEMENTATION 1 2 3 1 2 3 Hoffmann A , Irps S , Kersting T , IGES Institut GmbH, Berlin, Germany, IMC Clinicon, Berlin, Germany, Technical University of Berlin, Berlin, Germany

HEALTH CARE USE & POLICY STUDIES - Disease Management PHP13 A13

PHP14 A14

PHP15 A15

PHP16 A16

MANAGEMENT OF CHILDREN'S ACUTE DIARRHEA BY COMMUNITY PHARMACIES IN FIVE TOWNS OF ETHIOPIA: SIMULATED CLIENT CASE 1 1 1 1 2 3 1 Abebe TB , Abegaz TM , Belachew SA , Gebresilassie BM , Teni FS , Woldie HG , University of Gondar, Gondar, 2 3 Ethiopia, Addis Ababa University, Addis Ababa, Ethiopia, Debremarkos Teaching and Referral Hospital, Debremarkos, Ethiopia A CRITICAL REVIEW OF MEDICATION REVIEW TOOLS FOR LONG-TERM CARE FACILITIES AND DEVELOPMENT OF A NOVEL TOOL FOR QATAR Awaisu A,Qatar University, Doha, Qatar PARAMETRIC AND NON-PARAMETRIC APPROACHES FOR PREDICTING BACTERIAL RESISTANCE 1 2 2 1 2 2 3 1 Arepieva M , Kolbin A , Kurylev A , Balykina Y , Spiridonova A , Mukhina N , Sidorenko S , Saint Petersburg State University, 2 3 Saint Petersburg, Russia, First Pavlov State Medical University of St. Petersburg, Saint Petersburg, Russia, Research Institute for Paediatric Infections, Saint Petersburg, Russia BIOSIMILARS: MARKET ACCESS AND MARKET PENETRATION – A COMPARISON OF FRANCE AND GERMANY 1 1 2 1 2 Freiberg M , Schwarz R , Khoury C , Quintiles Commercial Germany GmbH, Mannheim, Germany, Quintiles Advisory Services, Saint Ouen, France

HEALTH CARE USE & POLICY STUDIES - Drug/Device/Diagnostic Use & Policy PHP17 A17 PHP18 A18

PHP19 A19 PHP20 A20

PHP21 A21

PHP22 A22

PHP23 A23

PHP24 A24

PHP25 A25

PHP26 A26

PHP27 A27 PHP28 A28

PHP29 A29

PHP30 A30

PHP31 A31 PHP32 A32

PHP33 A33

HOW REAL IS “FREE PRICING” IN THE UK? 1 2 1 2 Furniss J , Auluck J , GfK, Melton Mowbray, UK, GfK, London, UK PHARMACEUTICAL POLICIES IN EURASIAN ECONOMIC UNION COUNTRIES 1 2 3 1 2 Kostyuk A , Nurgozhin T , Akanov A , Kazakh Agency for Health Technology Assessment, Astana, Kazakhstan, Nazarbayev 3 University, National Laboratory Astana, Astana, Kazakhstan, Astana Medical University, Astana, Kazakhstan ACCESS TO ANTI-INFECTIVE MEDICINES FOR SYSTEMIC USE IN ARMENIA Sevikyan A,Yerevan State Medical University, Yerevan, Armenia THE ASSESSMENT OF ADVANCED MEDICINAL PRODUCTS (ATMP) IN GERMANY: IS THE PRACTICE TO DEFINE ATMP DRUGS AS PROCEDURES IN COMPLIANCE WITH EUROPEAN LEGISLATION? Volmer T, Bakker K,SmartStep Consulting GmbH, Hamburg, Germany ACCESS TO ORPHAN DRUGS IN POLAND - IS CHANGE IN HEALTH TECHNOLOGY ASSESSMENT APPROACH REQUIRED? 1 1 2 3 1 2 3 Caban A , Lach S , Rémuzat C , Toumi M , Creativ-Ceutical, Cracow, Poland, Creativ-Ceutical, Paris, France, Faculté de Médecine, Laboratoire de Santé Publique, Aix-Marseille Université, Marseille, France THE SHIFT FROM A COMPASSIONATE DRUG USE TO THE COMMON MARKET–ACCESS PROCESS: AN INFLATIONARY NO MAN’S LAND? Loubiere A, Degrassat-Théas A, Parent de Curzon O, Paubel P,General Agency of Equipment and Health Products (AGEPS), Assistance Publique-Hôpitaux de Paris (AP-HP), Paris, France FUNDING EXPENSIVE DRUGS IN HOSPITALS: WHERE IS FRANCE GOING? 1 1 1 2 1 Cousseau R , Degrassat-Théas A , Parent de Curzon O , Paubel P , General Agency of Equipment and Health Products 2 (AGEPS), Assistance Publique-Hôpitaux de Paris (AP-HP), Paris, France, AP-HP, AGEPS, Paris, France ASSESING THE AVERAGE PRICE LEVEL OF GENERICS IN GREECE AND OTHER COMPARABLE EUROPEAN COUNTRIES RELATIVE TO THEIR VOLUME MARKET SHARE 1 2 1 1 2 Papadopoulos C , Lolos D , Ollandezos M , Panhellenic Union of Pharmaceutical Industry, Athens, Greece, Imshealth, Athens, Greece IMPACT OF US HEALTH EXCHANGES (HIX) ON THE PHARMACEUTICAL INDUSTRY 1 2 3 4 1 2 3 Young KE , Soussi I , Kornfeld A , Toumi M , Creativ-Ceutical, Milan, Italy, Creativ-Ceutical, Tunis, Tunisia, Creativ-Ceutical, 4 Paris, France, Faculté de Médecine, Laboratoire de Santé Publique, Aix-Marseille Université, Marseille, France WHAT HAPPENS TO ORIGINATOR MEDICINES WHEN (GENERIC) FOLLOWERS ENTER THE PUBLIC MARKET 1 2 1 2 Habl CA , Leopold C , Austrian Public Health Institute GÖG, Vienna, Austria, Harvard Medical School & Harvard Pilgrim Healthcare Institute, Boston, MA, USA MARKET EXCLUSIVITY PERIODS AND PATENT CHALLENGES IN PHARMACEUTICALS IN SOUTH KOREA 1 2 1 2 Park H , Lee T , Ministry of Food and Drug Safety, Cheongju-si, South Korea, Seoul National University, Seoul, South Korea IMPLICATION OF EXTERNAL PRICE REFERENCING ON PHARMACEUTICAL LIST PRICES IN EUROPE 1 2 3 4 5 6 7 8 3 9 1 Csanadi M , Prins CP , Grélinger E , Fricke F , Fuksa L , Tesar T , Manova M , Lorenzovici L , Kiss A , Kaló Z , Syreon Research 2 3 Institute, Budapest, Hungary, Utrecht University, Department of Pharmaceutical Sciences, Utrecht, The Netherlands, National 4 5 Health Insurance Fund Administration, Budapest, Hungary, Technische Hochschule Nürnberg, Nürnberg, Germany, Department of Social and Clinical Pharmacy, Faculty of Pharmacy, Charles University in Prague, Hradec Králové, Czech 6 Republic, Department of Organisation and Management in Pharmacy, Faculty of Pharmacy, Comenius University, Bratislava, 7 8 Slovakia, National Council on Prices and Reimbursement of Medicinal Products, Sofia, Bulgaria, Syreon Research Romania, 9 Tirgu Mures, Romania, Eötvös Loránd University (ELTE), Budapest, Hungary INNOVATION : A VALUE FOR HEALTH AND GROWTH, AN INTERNATIONAL STUDY ON MARKET ACCESS STAKES FOR THERAPEUTIC INNOVATION 1 2 2 1 1 1 2 Berard I , Ginestet M , Auvray F , Sublet G , Bouchara G , NEXTEP, PARIS, France, AGIPHARM, Paris, France BIOSIMILAR INFLIXIMAB: FEEDBACK AFTER A NINE MONTHS EXPERIENCE OF THEIR USE IN THE 37 PUBLIC HOSPITALS OF PARIS Bocquet F, Degrassat-Théas A, Cordonnier A, Raybaut C, Parent de Curzon O, Fusier I, Paubel P,AP-HP, AGEPS, Paris, France PRICE AND UTILIZATION OF NEW DRUGS UNDER A SINGLE PUBLIC PAYER SYSTEM: EVIDENCE FROM TAIWAN 1 2 1 2 LIU Y , Lu CY , National Cheng Kung University, Tainan, Taiwan, Harvard Medical School, Boston, MA, USA EVALUATION OF THE VALUE OF PHARMACEUTICAL PRODUCTS IN TAIWAN 1 2 1 2 Fang CH , Chang CJ , Taiwan Society of Pharmacoeconomics and Outcome Research, Tao-Yun, Taiwan, Taiwan Society of Pharmacoeconomics and Outcome Research, TaoYuan, Taiwan AN ASSESSMENT OF BIOSIMILARS’ BEHAVIOUR IN THE EU-5 COUNTRIES 1 1 2 3 2 1 2 Planellas L , Solozabal M , Manganelli A , Rebollo P , Puig-Junoy J , IMS Health, Barcelona, Spain, CRES - Universitat Pompeu 3 Fabra, Barcelona, Spain, HEOR-RWE, IMS Health, Barcelona, Spain

PHP34 A34

PHP35 A35

PHP36 A36

PHP37 A37 PHP38 A38 PHP39 B1

PHP40 B2

PHP41 B3

PHP42 B4 PHP43 B5 PHP44 B6

PHP45 B7

PHP46 B8 PHP47 B9 PHP48 B10

PHP49 B11

SYSTEMIC SOLUTIONS, LEGISLATIVE AND ORGANIZATIONAL FRAMEWORKS AIMED TO PREVENT OR MITIGATE DRUG SHORTAGES IN EUROPEAN COUNTRIES 1 2 3 4 5 6 7 4 8 9 10 Bochenek T , Godman BB , Bucsics A , De Weerdt E , Fürst J , Gailite E , Hotvedt TA , Huys I , Inotai A , Joppi R , Malaj A , 11 12 4 13 14 15 16 17 Margus K , Marković-Peković V , Simoens S , Slaby J , Sović Brkičić L , Gürpınar EU , Vella Bonanno P , Warminska EJ , 18 1 2 Pilc A , Faculty of Health Sciences, Jagiellonian University Medical College, Krakow, Poland, Strathclyde Institute of Pharmacy 3 4 and Biomedical Sciences, University of Strathclyde, Glasgow, UK, University of Vienna, Vienna, Austria, KU Leuven, Leuven, 5 6 7 Belgium, ZZZS (Health Insurance Institute of Slovenia), Ljubljana, Slovenia, State Agency of Medicines, Riga, Latvia, Norwegian 8 9 Medicines Agency, Oslo, Norway, Syreon Research Institute, Budapest, Hungary, Local Health Unit of Verona – Veneto Region, 10 11 12 Verona, Italy, University of Medicine Tirana, Tirane, Albania, Estonian State Agency of Medicines, Tartu, Estonia, Ministry of 13 Health and Social Welfare, Banja Luka, Republic of Srpska, Bosnia and Herzegovina, State Institute for Drug Control, Prague, 14 15 Czech Republic, Croatian Health Insurance Fund, Zagreb, Croatia, Turkish Medicines and Medical Devices Agency, Ankara, 16 17 18 Turkey, , Mellieha, Malta, , Warsaw, Poland, Institute of Pharmacology, Polish Academy of Sciences, Krakow, Poland ASSESSMENT OF CORE DRUG USE INDICATORS USING WHO/INRUD METHODOLOGY AT PRIMARY HEALTH CARE CENTERS IN BAHAWALPUR, PAKISTAN Atif M, Qamar-Uz-Zaman M, Rehan Sarwar M, Azeem M,The Islamia University of Bahawalpur, Bahawalpur, Pakistan BIOSIMILAR INFLIXIMAB IN THE 37 PUBLIC HOSPITALS OF PARIS: MEETING THE CHALLENGE OF SUBSTITUTION 1 1 1 2 1 1 1 1 Bocquet F , Fusier I , Cordonnier A , Poisson N , Parent de Curzon O , Degrassat-Théas A , Paubel P , AP-HP, AGEPS, Paris, 2 France, General Agency of Equipment and Health Products (AGEPS), Assistance Publique-Hôpitaux de Paris (AP-HP), Paris, France THE IMPACT OF REGIONAL LEGISLATIVE MEASURES ON THE PRESCRIPTION OF OFF-PATENT MEDICINES Tettamanti A, Urbinati D, Tucci C,IMS Health, Milano, Italy COMPARISON OF BIOSIMILAR GUIDELINE AND REAL CONSUMPTION AMONG ITALIAN REGIONS Tettamanti A, Urbinati D, Tucci C,IMS Health, Milano, Italy OPPORTUNITIES FOR PHARMACEUTICAL COMPANIES TO SUCCESSFULLY LAUNCH PRODUCTS IN AFRICAN COUNTRIES 1 1 1 2 1 2 Mukku S , Edathodu A , Battepatti B , Dass R , Access Infinity Ltd, London, UK, University of Cambridge, Cambridge, UK HAS ACCESS TO INNOVATIVE THERAPIES IN POLAND IMPROVED FOLLOWING THE 2012 REIMBURSEMENT ACT? 1 1 2 3 1 2 3 Jaros P , Kapuśniak A , Kornfeld Å , Toumi M , Creativ-Ceutical, Kraków, Poland, Creativ-Ceutical, Paris, France, Aix-Marseille University, Marseille, France THE UK EARLY ACCESS TO MEDICINES SCHEME: A 2-YEAR STATUS UPDATE ON SUCCESSES, ISSUES AND CONTROVERSIES Macaulay R,Parexel Access Consulting, London, UK CONTRASTING THE CHARACTERISTICS OF HTA SUBMISSIONS FOR RARE VERSUS ULTRA-RARE DISEASES 1 1 2 1 1 2 Richter T , Janoudi G , Nestler-Parr S , Sehgal C , CADTH, Ottawa, ON, Canada, Roboleo & Co Ltd, London, UK DOMESTIC MANUFACTURING IN RUSSIA: MEASURING THE SUCCESS OF THE PHARMA 2020 PROGRAM Privolnev Y,Decision Resources Group, Toronto, ON, Canada ARE WE INDEED FAST ADOPTERS AS WE CLAIM TO BE? AN ANALYSIS OF THE TIME INTERVAL FROM REGULATORY APPROVAL TO COVERAGE AND REIMBURSEMENT IN THE NATIONAL LIST OF HEALTH SERVICES IN ISRAEL 1 2 1 1 2 Ribalov R , Morginstin T , Greenberg D , Ben-Gurion University of the Negev, Beer-Sheva, Israel, Ministry of Health, Jerusalem, Israel DO PHARMACEUTICAL COST CONTROL POLICIES EFFECTIVE IN REDUCING PHARMACEUTICAL EXPENDITURE AND VOLUME? A SYSTEMATIC REVIEW 1 2 2 3 1 2 Lee KS , Hendrie D , Sunderland B , Moorin RE , Ministry of Health Malaysia, Selangor, Malaysia, Curtin University, Western 3 Australia, Australia, Curtin University, Perth, Australia INTERNATIONAL REFERENCE PRICING: MEASURING COUNTRY INFLUENCE Privolnev Y,Decision Resources Group, Toronto, ON, Canada THE FUTURE OF UK DRUG PRICING: THE 2014 PPRS (AN INTERIM REVIEW) Macaulay R,Parexel Access Consulting, London, UK THE TRANSPARENCY OF PUBLISHED RECOMMENDATIONS ON REIMBURSEMENT OF HEALTH TECHNOLOGIES IN POLAND 1 1 1 2 1 3 4 1 Bochenek T , Kocot E , Rodzinka M , Godman B , Maciejewska K , Kamal S , Pilc A , Faculty of Health Sciences, Jagiellonian 2 3 University Medical College, Krakow, Poland, Division of Clinical Pharmacology, Karolinska Institutet, Stockholm, Sweden, School 4 of Pharmaceutical Sciences, University of Geneva, University of Lausanne, 1211 Geneve 4, Switzerland, Institute of Pharmacology, Polish Academy of Sciences, Krakow, Poland ITALIAN TIMINGS IN NEW DRUGS APPROVAL: AN UP-TO-DATE ANALYSIS Lanati EP, Lidonnici D, Ronco V,MA Provider Srl, Milano, Italy

PHP50 B12

PHP51 B13

PHP52 B14

PHP53 B15

PHP54 B16

PHP55 B17 PHP56 B18

PHP57 B19

PHP58 B20

PHP59 B21

PHP60 B22

PHP61 B23

PHP62 B24

PHP63 B25 PHP64 B26 PHP65 B27 PHP66 B28 PHP67 B29

DEVELOPMENT OF PREDICTIVE MODELS FOR THE ANALYSIS OF THE LIST OF VITAL ESSENTIAL AND NECESSARY DRUGS COMPILATION 1 2 3 2 4 1 1 1 1 Kolbin A , Prasolov A , Maksimkina E , Balykina Y , Golant Z , Polushin Y , Kurylev A , Vilum I , First Pavlov State Medical 2 3 University of St. Petersburg, Saint Petersburg, Russia, Saint Petersburg State University, Saint Petersburg, Russia, Ministry of 4 Healthcare of the Russian Federation, Moscow, Russian Federation, Saint Petersburg State Chemical-Pharmaceutical Academy, Saint Petersburg, Russian Federation EARLY BENEFIT ASSESSMENT OF DRUGS AND THE VALUE-BASED HEALTHCARE CONCEPT – A QUALITATIVE INQUIRY WITHIN THE PHARMACEUTICAL INDUSTRY Martschinke B, Traut A,EBS Business School, Oestrich-Winkel, Germany ACCESS TO INNOVATIVE MEDICINES IN THE CZECH REPUBLIC: LENGTH OF PRICE AND REIMBURSEMENT (P&R) PROCEDURES Klimes J, Fuksa L, Vocelka M,Department of Social and Clinical Pharmacy, Faculty of Pharmacy, Charles University in Prague, Hradec Králové, Czech Republic DRUG PRICING AND REIMBURSEMENT PROCESSES IN ALGERIA 1 2 2 3 1 2 1 2 Soualmi R , Bouabidi A , Djahdou Z , Ziouani S , Kaddar M , Mansouri K , ISPOR Chapter Algeria, Algiers, Algeria, Algiers 3 University, Algiers, Algeria, Univ Paris-Sud, Faculty of Pharmacy, GRADES, Châtenay-Malabry, France ARBITRATION BOARD SETTING REIMBURSEMENT AMOUNTS FOR PHARMACEUTICAL INNOVATIONS IN GERMANY WHEN PRICE NEGATIONS BETWEEN PAYORS AND MANUFACTURERS FAIL: AN EMPIRICAL ANALYSIS OF 5 YEARS' EXPERIENCE 1 2 1 2 Dintsios C , Ludwig S , Heinrich Heine University of Düsseldorf, Düsseldorf, Germany, HGC, Düsseldorf, Germany THE EVOLUTION AND COMPARISON OF HTA ASSESMENT ORGANISATIONS IN SELECTED EUROPEAN COUNTRIES Beletsi A, Koutrafouri V, Karampli E, Pavi E,National School of Public Health, Athens, Greece DOES REAL WORLD EVIDENCE SUPPORT CONCLUSIONS FROM EXPERIMENTAL EVIDENCE IN DECISION-MAKING PROCESSES IN POLAND? 1 2 2 1 1 1 1 2 Wilk N , Wierzbicka N , Skrzekowska-Baran I , Moćko P , Tomassy J , Kloc K , Arcana Institute, Kraków, Poland, Janssen-Cilag Polska, Warsaw, Poland REAL WORLD EVIDENCE IN DECISION-MAKING PROCESSES ON PUBLIC FUNDING OF DRUGS IN POLAND 1 2 2 1 1 1 1 1 Wilk N , Wierzbicka N , Skrzekowska-Baran I , Tomassy J , Kloc K , Stankowicz P , Włodek A , Arcana Institute, Kraków, 2 Poland, Janssen-Cilag Polska, Warsaw, Poland MARKET UPTAKE OF PHARMACEUTICAL INNOVATIONS IN GERMANY - REGULATORY APPROACHES AND ITS CONSEQUENCES Witte J, Greiner W,School of Public Health, Bielefeld University, Bielefeld, Germany HEALTH TECHNOLOGY ASSESSMENT IN BRAZIL: METRICS FROM THE REPORTS OF THE NATIONAL COMMISSION FOR INCORPORATION OF TECHNOLOGIES (CONITEC) Lemmer T, Piedade AD, de Oliveira RW, Moreira Ed, Julian G,Evidências - Kantar Health, São Paulo, Brazil PHARMACEUTICAL INDUSTRY'S EXPERIENCES WITH THE SCIENTIFIC ADVICE OFFERED BY THE FEDERAL JOINT COMMITTEE WITHIN THE EARLY BENEFIT ASSESSMENT OF DRUGS IN GERMANY 1 2 1 2 Dintsios C , Schlenkrich S , Heinrich Heine University of Düsseldorf, Düsseldorf, Germany, University of Applied Science Zittau/Görlitz, Görlitz, Germany COMPARING THE SAFETY PROFILES OF BIOSIMILARS WITH THEIR ORIGINATORS’: A CROSS SECTIONAL ANALYSIS ON THE EU-RMP 1 2 1 2 1 2 Lepelaars LR , Renda F , Mantel AK , Trotta F , Utrecht University, Utrecht, The Netherlands, Italian Medicines Agency, Rome, The Netherlands ASSESSMENT OF REGIONAL LEGISLATION RELATED TO THE USE OF SIMILAR BIOLOGICAL MEDICINAL PRODUCTS: THE ITALIAN CASE STUDY 1 2 1 2 Iorio A , Lanati EP , MA Provider Srl, Milan, Italy, MA Provider Srl, Milano, Italy COSTS, OUTCOMES AND USES OF NEW DRUGS: DRUG ASSESSMENT REPORTS VS REAL WORLD DATA Echeverría A, Irigoyen I, Burgui C, Idoate AI, Torroba B, Idoate A, Ortega A,Clínica Universidad de Navarra, Pamplona, Spain TREND OF ANTIDEPRESSANT UTILIZATION IN IRAN, 2006- 2015 1 2 1 2 Soleymani F , Taheri F , Tehran University of Medical Sciences, Tehran, Iran, Minitry of Health, tehran, Iran TRENDS IN OUTPATIENT USE OF ANTIBIOTICS IN CROATIA Bencina G,GSK, Zagreb, Croatia GENERIC DRUG UTILIZATION AMONG THE ELDERLY WITH MULTIPLE CHRONIC CONDITIONS IN THE UNITED STATES Xu Y,University of Southern California, Los Angeles, CA, USA THE BEHAVIOUR OF PHARMACISTS IN PUBLIC PHARMACIES IN RELATION TO THE COLD REGIME DRUGS 1 1 1 1 2 1 1 Milosević Georgiev A , Krajnovic D , Marinkovic V , Tasic L , Arsic J , Manojlovic J , University of Belgrade, Belgrade,

2

PHP68 B30 PHP69 B31

PHP70 B32 PHP71 B33

PHP72 B34

PHP73 B35

PHP74 B36

PHP75 B37

PHP76 B38

Serbia, Materna medika, Vranje, Serbia TIME TRENDS IN SEQUENCE OF DRUG LAUNCH ACROSS EU5 Gubbels L, Dekkers R, Nijhuis T,Quintiles Advisory Services, Hoofddorp, The Netherlands EXPLORING DETERMINANTS OF POLYPHARMACY IN THE ELDERLY POPULATION IN AUSTRIA 1 2 1 3 1 2 Mayer S , Vogler S , Simon J , Österle A , Medical University of Vienna, Vienna, Austria, Gesundheit Österreich GmbH / Austrian 3 Public Health Institute, Vienna, Austria, Vienna University of Economics and Business, Vienna, Austria REGIONAL TIME TO MARKET OF INNOVATIVE DRUGS IN ITALY Mantuano M, Daniel F, Urbinati D,IMS Health, Milano, Italy PARALLEL EXPORT AND ITS IMPACT ON AVAILABILITY OF DRUGS IN SLOVAKIA 1 1 1 1 2 1 2 Psenkova M , Mackovicova S , Holocsi L , Klapac J , Sedlakova K , Pharm-In Ltd, Bratislava, Slovakia, Faculty of Pharmacy, Comenius University, Bratislava, Slovakia UTILIZATION AND COST OF ANTIMICROBIALS USED IN MEDICINE AND SURGERY DEPARTMENTS OF A TERTIARY CARE TEACHING HOSPITAL Haligeri Veerana Goud B, Roy V,Maulana Azad Medical College, University of Delhi, New Delhi, India ECONOMIC RESOURCES OPTIMISATION IN THE HCV SETTING: THE ROLE OF THE DAAS 1 1 1 2 2 3 1 1 2 Garagiola E , Ferrario L , Croce D , Menzaghi B , Quirino T , Rizzardini G , Foglia E , LIUC University, Castellanza, Italy, ASST 3 Valle Olona, Busto Arsizio, Italy, ASST Fatebenefratelli Sacco, Milano, Italy INDUSTRIAL LANDSCAPE AND MARKET UPTAKE MODELS OF BIOSIMILARS AND OFF-PATENT BIOLOGICAL MEDICINES 1 1 1 2 1 1 1 2 Moorkens E , Meuwissen N , Huys I , Vulto A , Declerck P , Simoens S , KU Leuven, Leuven, Belgium, The Erasmus University Medical Center, Rotterdam, The Netherlands PRESCRIBING BEHAVIOUR AND DRUG USE IN PAKISTAN 1 1 1 2 1 1 2 Aziz MM , Ji W , Gillani AH , Raza MA , Fang Y , Xi'an Jiaotong University, Xi'an, Shaanxi, P. R. China, Xi'an, China, Bahauddin Zakariya University Multan, Multan, Pakistan CHANGING OF PRESCRIPTIONS FOR DIABETES, HYPERLIPIDEMIA, AND HYPERTENSION, FROM GENERIC DRUGS TO PROTECTED BRAND DRUGS : A RETROSPECTIVE COHORT STUDY USING A NATIONAL INPATIENT DATABASE IN JAPAN Shimizu S,Institute for Health Economics and Policy, minato-ku Tokyo, Japan

HEALTH CARE USE & POLICY STUDIES - Equity and Access PHP77 C1

PHP78 C2 PHP79 C3

PHP80 C4

PHP81 C5

PHP82 C6

PHP83 C7

PHP84 C8

PHP85 C9

RACIAL DISPARITIES IN ACCESS TO PHARMACY AND ITS SERVICES IN PENNSYLVANIA 1 2 1 2 Pednekar P , Peterson AM , University of the Sciences, Philadelphia, PA, USA, University of the Sciences in Philadelphia, Philadelphia, PA, USA REVIEW OF NATIONAL POLICIES FOR RARE DISEASES ACROSS EU COUNTRIES Hill CE, Garcia Sanchez JJ, Hill CA,MAP BioPharma Limited, Cambridge, UK COMPARISON OF THE RELATIONSHIP BETWEEN SOCIO-ECONOMIC STATUS AND HEALTH-RELATED QUALITY OF LIFE AMONGST ATOPIC DERMATITIS PATIENTS ACROSS DIFFERENT HEALTHCARE SYSTEMS Papsch RB, Howe T, Vrabcheva T,GfK UK, London, UK TRANS-PACIFIC PARTNERSHIP AGREEMENT AND ITS IMPACT ON ACCESSIBILITY AND AFFORDABILITY OF MEDICINES: A META-SYNTHESIS 1 1 1 2 3 1 2 Yap YY , Wong CP , Khan TM , Lee KS , Ming LC , Monash University Malaysia, Sunway, Malaysia, Ministry of Health Malaysia, 3 Selangor, Malaysia, University of Tasmania, Hobart, Australia PREDICTING ORPHAN DESIGNATION AND MARKETING AUTHORISATION BASED ON A REVIEW OF THE EUROPEAN MEDICINES AGENCY ORPHAN DISEASE REGISTER Garcia Sanchez JJ, Hill CA, Hill D,MAP BioPharma Limited, Cambridge, UK PRELIMINARY EVALUATION OF “INTRODUCING IMMIGRANTS TO THE HEALTHCARE SYSTEM IN CHILE” PILOT PROGRAMME 1 1 1 1 2 1 2 Chepo M , Cabieses B , Bernales M , MacIntyre AM , Espinoza MA , Universidad del Desarrollo, Santiago, Chile, Pontificia Universidad Catolica de Chile, Santiago, Chile MARKOV MODEL PROJECTION OF REGIONAL PHYSICIAN SUPPLY IN TURKEY SHOWS THAT PHYSICIAN DENSITY WILL NOT CHANGE SUBSTANTIALLY IN THE NEXT 15 YEARS Jansen I, Saka Ö,Deloitte, Diegem, Belgium THE COORDINATION OF CARE IN PMAQ-AB: AN ANALYSIS BASED ON THE ITEM RESPONSE THEORY Souza MF, Santos Ad, Matta Machado AT, Reis IA, Santos MA, Andrade EI, Cherchiglia ML,Federal University of Minas Gerais, Belo Horizonte, Brazil INTEGRATION OF BASIC ATTENTION TO THE SPECIALIZED ATTENTION NETWORK IN BRAZIL’S HEALTH SYSTEM

PHP86 C10 PHP87 C11

PHP89 C13

PHP90 C14 PHP91 C15

Chaves LA, Jorge Ad, Cherchiglia ML, Reis IA, Santos MA, Santos Ad, Matta Machado AT, Andrade EI,Federal University of Minas Gerais, Belo Horizonte, Brazil SELF-REPORTED CLIENT SATISFACTION IN THE PRIMARY CARE DEVELOPMENT MODEL PROGRAMME Merész G, Bálity C, Sinkó E, Dózsa KM,Semmelweis University, Budapest, Hungary MEASURING INCOME-RELATED INEQUITY IN SELF-ASSESSED HEALTH USING THE EQ-5D IN 7 COUNTRIES 1 2 2 3 1 2 Szende A , Janssen B , Ramos Goñi JM , Cabases JM , Covance, Leeds, UK, EuroQol Research Foundation, Rotterdam, The 3 Netherlands, University of Navarra, Pamplona, Spain CASE DURATION AS A SURGICAL QUALITY AND EFFICIENCY INDICATOR IN SURGICAL RESIDENCY TRAINING PROGRAMS 1 2 3 1 2 Semien GA , Gobrial W , Stahl J , Cleveland Clinic Florida, Miami Shores, FL, USA, Cleveland Clinic Florida, Weston, FL, 3 USA, University of Arizona, Tucson, AZ, USA MARKET ACCESS IN THE CONTEXT OF ECONOMIC CRISIS: INSIGHTS FROM SEVERAL EUROPEAN COUNTRIES Olariu E, Papageorgakopoulou C, Solaman DA, Fox D,PHMR Ltd, London, UK PHARMACEUTICAL PRICING STRATEGIES IN DEVELOPING COUNTRIES: A SYSTEMATIC REVIEW 1 2 3 2 1 2 Mohamed Ibrahim MI , Abdel Rida NM , Babar ZU , Owusu Y , College of Pharmacy, Qatar University, Doha, Qatar, Qatar 3 University, Doha, Qatar, The University of Auckland, Auckland, New Zealand

HEALTH CARE USE & POLICY STUDIES - Formulary Development PHP92 C16

PHP94 C17 PHP95 C18

THE 2016 US PAYOR LANDSCAPE: RESULTS FROM A SURVEY OF MEDICAL AND PHARMACY DIRECTORS ON FORMULARY MANAGEMENT 1 2 3 3 3 1 2 Brook RA , Smeeding JE , McManama SH , Carlisle JA , Sax MJ , The JeSTARx Group & NPRT, Newfoundland, NJ, USA, The 3 TPG-NPRT & JeSTARx, Glastonbury, CT, USA, The Pharmacy Group, Glastonbury, CT, USA DO SCOTTISH FORMULARY DECISIONS MATCH RECOMMENDATIONS MADE BY THE SMC? Beale RC, Kusel J,Costello Medical Consulting Ltd, Cambridge, UK GLOBAL VALUE DOSSIERS (GVDS): HOW TO ENSURE THE VALUE ISN’T LOST IN TRANSLATION Sarnes E, Shields K, Kaufman S, Meyer KL,Xcenda, LLC, Palm Harbor, FL, USA

HEALTH CARE USE & POLICY STUDIES - Health Care Costs & Management PHP96 C19 PHP97 C20

PHP98 C21

PHP99 C22

PHP100 C23

PHP101 C24

PHP102 C25

PHP103 C26

PHP104 C27

COST OF LOST PRODUCTIVITY DUE TO PREMATURE, SUICIDE-RELATED MORTALITY IN POLAND Orlewska K,Medical University of Warsaw, Warsaw, Poland SPECIALTY PHARMACY, DIAGNOSTIC, AND GENETIC TESTING COVERAGE IN THE UNITED STATES 1 2 2 3 1 2 Brook RA , McManama SH , Sax MJ , Smeeding JE , The JeSTARx Group & NPRT, Newfoundland, NJ, USA, The Pharmacy 3 Group, Glastonbury, CT, USA, The TPG-NPRT & JeSTARx, Glastonbury, CT, USA RELEVANCE AND ECONOMIC CONSEQUENCES OF MEDICINE WASTE IN VIENNA: ANALYSIS OF A HOUSEHOLD GARBAGE SAMPLE 1 1 1 2 1 2 de Rooij RH , Frederix GW , Hövels AM , Vogler S , Utrecht University, Utrecht, The Netherlands, Gesundheit Österreich GmbH / Austrian Public Health Institute, Vienna, Austria A SYSTEMATIC REVIEW: ECONOMIC BURDEN OF NEEDLESTICK INJURIES ON HEALTHCARE WORKERS 1 2 1 1 1 2 Huang HL , Lim J , Ma A , Li H , China Pharmaceutical University, Nanjing, China, China Europe International Business School, Shanghai, China THE CLINICAL AND PHARMACOECONOMIC CHALLENGES FOR SECURING REIMBURSEMENT AND ACCESS TO CDX IN THE EU 1 2 2 3 1 1 2 Senatore P , Oshinowo B , Duttagupta S , Armeni P , Chalmers M , CBPartners, London, UK, CBPartners, New York, NY, 3 USA, Bocconi University, Milano, Italy MARKET POTENTIAL OF A NEW INFLIXIMAB BIOSIMILAR IN THE EUROPEAN MARKET: A BUDGET IMPACT ANALYSIS IN FRANCE, ITALY AND THE UK 1 1 2 3 4 1 2 Psachoulia E , Martin-Rinconada MC , Bresson A , Negrini C , Keady S , Biogen International GmbH, Zug, Switzerland, Biogen 3 4 France, Nanterre, France, Biogen Italia S.r.l., Milan, Italy, Biogen Idec Ltd, Maidenhead, UK THE IMPACT OF POLICY AND DEMOGRAPHIC VARIABLES ON FUTURE PRESCRIPTION COSTS FOR A PUBLICLY FUNDED HEALTH SCHEME IN IRELAND 1 2 1 2 ConwayLenihan A , Woods N , Cork Institute of Technology, Cork, Ireland, University College Cork, Cork, Ireland FACTORS AFFECTING PHARMACEUTICAL EXPENDITURES: A SYSTEMATIC REVIEW 1 2 1 3 1 1 Maniadakis N , Kourlaba G , Zavali M , Zampoulakis D , Mylonas C , National School of Public Health, Athens, 2 Greece, Collaborative Center of Clinical Epidemiology and Outcomes Research (CLEO), Non-Profit Civil Partenrship, Athens, 3 Greece, State University of New York at Stony Brook (SUNY Stony Brook), New York, NY, USA COSTS AND OUTCOMES OF HOSPITAL INFECTIONS IN ITALY 1 1 2 3 1 Bini C , Sciattella P , Marcellusi A , Mennini FS , Faculty of Economics, Centre for Economic and International Studies

2

PHP105 C28

PHP106 C29

PHP107 C30

PHP108 C31

PHP110 C32

PHP111 C33

PHP112 C34 PHP113 C35

PHP114 C36

PHP115 C37

PHP116 C38

PHP117 D1

PHP118 D2

PHP119 D3

PHP120 D4

PHP121 D5

(CEIS)-Economic Evaluation and HTA (EEHTA), University of Rome Tor Vergata, Rome, Italy, National Research Council (CNR), 3 Rome, Italy, University of Rome Tor Vergata, Rome, Italy HEALTH EXPENDITURE BY DISEASE AGE AND GENDER IN GREECE 1 2 3 4 5 5 5 1 6 5 Siskou O , Schneider M , Craig M , Kaitelidou D , Priftis C , Kani C , Litsa P , Galanis P , Lemonidou C , Vafeiadis J , Aggouris 5 1 1 G , Liaropoulos L , Center for Health Services Management and Evaluation, National and Kapodistrian University of Athens, 2 3 4 Athens, Greece, BASYS, Augsburg, Germany, IGSS Inspection Générale de la Sécurité Sociale, Edinburgh, UK, Open 5 University of Cyprus, Latsia, Nicosia, Cyprus, EOPYY-National Organization for Health Care Provision, Marousi, 6 Greece, National and Kapodistrian University of Athens, Athens, Greece BUDGET IMPACT ANALYSIS OF SECUKINUMAB IN MODERATE TO SEVERE PLAQUE PSORIARIS, ANKYLOSING SPONDYLITIS AND PSORIATIC ARTHRITIS IN FRANCE Duteil E, Rachdi L, Cariou C, Benjamin K, Leiba G, Duco J,Novartis Pharma, Rueil-Malmaison, France COST-SHARING IN HEALTHCARE: AN APPROACH FOR PHARMACEUTICAL CARE IN GREECE Kyriopoulos I, Petropoulou A, Naoum V, Oikonomou N, Athanasakis K, Kyriopoulos J,National School of Public Health, Athens, Greece SHORT AND LONG TERM COSTS ASSOCIATED WITH DIFFERENT CARDIOVASCULAR EVENTS IN BELGIUM 1 1 1 2 3 4 1 2 Caekelbergh K , Chevalier P , Lamotte M , Kutikova L , Schutyser E , Annemans L , IMS Health, Zaventem, Belgium, Amgen 3 4 (Europe) GmbH, Zug, Switzerland, nv Amgen sa, Brussels, Belgium, Brussels, Belgium, Ghent University - Brussels University, Ghent, Belgium A REVIEW OF THE QUALITY AND ACCURACY OF BUDGET IMPACT MODELS FOR HIGH COST DRUGS IN IRELAND 1 1 1 2 1 1 2 Lucey S , Tilson L , Fogarty E , Walshe V , Barry M , National Centre for Pharmacoeconomics, Dublin, Ireland, Health Service Executive, Cork, Ireland COST OF TOTAL PARENTERAL NUTRITION SERVICES AT MINISTERY OF HEALTH IN SAUDI ARABIA 1 2 2 2 2 2 2 2 2 Alomi YA , Fallatah AO , Al-Smail EH , Al-Yahya MF , Al-Shubbar NA , Al-Enazi AD , Al-Qatany K , Al-Enazi AH , Hetete NM , 3 1 2 3 Alotibi NM , Ministry of Health, RIYADH, Saudi Arabia, King Salman Hospital, RIYADH, Saudi Arabia, Riyadh Health Affairs, MOH, RIYADH, Saudi Arabia COST-EFFECTIVENESS THRESHOLD PROPOSAL FOR BOSNIA AND HERZEGOVINA Catic T,ISPOR Bosnia and Herzegovina Chapter, Sarajevo, Bosnia INVESTIGATION ABOUT INFLUENCE OF MANAGEMENT STRATEGY IN NATIONAL HOSPITAL ORGANIZATION (NHO) HOSPITALS BY THE REVISION OF MEDICAL FEE SCHEDULE 1 2 1 1 1 Nakagawa Y , Tomita N , Irisa K , Nakagawa Y , National Hospital Organization Shikoku Medical Center for Children and Adults, 2 Zentuji city, Japan, National Institute of Public Health, Saitama, Japan A SYSTEMATIC REVIEW OF ECONOMIC EVALUATION ALONGSIDE HEMATOPOIETIC STEM CELL TRANSPLANTATION IN JAPAN Tran TT,University of Tsukuba, Tsukuba, Japan ECONOMIC CONSEQUENCES OF THE CHOICES IN INJECTABLE ANTICOAGULANTS IN FRANCE 1 2 3 4 2 1 Paubel P , Cousin M , Amar C , Gourmelen J , Detournay B , General Agency of Equipment and Health Products (AGEPS), 2 3 Assistance Publique-Hôpitaux de Paris (AP-HP), Paris, France, Cemka-Eval, Bourg-la-Reine, France, ASPEN, Marly-le-roi, 4 France, UMS 011 - Inserm - UVSQ, Villejuif, France BIOSIMILARS: WHICH VALUE FOR SOCIETY? 1 2 3 3 4 1 2 Rémuzat C , Kapuśniak A , Lach S , Dziwisz M , Toumi M , Creativ-Ceutical, Paris, France, Creativ-Ceutical, Krakow, 3 4 Poland, Creativ-Ceutical, Cracow, Poland, Faculté de Médecine, Laboratoire de Santé Publique, Aix-Marseille Université, Marseille, France DOES HOSPITAL AT HOME NEED A NEW FUNDING FOR ORAL ANTI-CANCER DRUGS ? 1 1 1 2 1 1 Gohari A , Mittaine-Marzac B , Marquestaut O , Paubel P , Farinotti R , Hospital at Home, Assistance Publique-Hôpitaux de Paris 2 (AP-HP), Paris, France, General Agency of Equipment and Health Products (AGEPS), Assistance Publique-Hôpitaux de Paris (AP-HP), Paris, France BUDGET IMPACT ANALYSIS OF THE INTRODUCTION OF BIOSIMILARS IN A BELGIAN TERTIARY CARE HOSPITAL: A SIMULATION 1 2 3 3 1 2 Claus BO , Simoens S , Vanhorebeek S , Commeyne S , Ghent University, Ghent, Belgium, KU Leuven, Leuven, 3 Belgium, Ghent University Hospital, Ghent, Belgium ASSESSMENT OF PRICES OF ESSENTIAL MEDICINES FOR CHRONIC DISEASES PREVALENT IN THE ASIA PACIFIC REGION Undela K,JSS College of Pharmacy, JSS University, Mysuru, India IMPACT OF CHANGES IN THE METHODOLOGY OF EXTERNAL PRICE REFERENCING ON PRICES Schneider P, Lepuschütz L, Zimmermann N, Vogler S,Gesundheit Österreich GmbH / Austrian Public Health Institute, Vienna, Austria ECONOMIC BURDEN OF PRIMARY IMMUNODEFICIENCY IN NATIONAL INSTITUTE OF PEDIATRICS IN MEXICO

PHP122 D6 PHP123 D7

PHP124 D8

PHP125 D9

PHP126 D10

PHP127 D11 PHP128 D12 PHP129 D13 PHP130 D14

PHP131 D15

PHP132 D16 PHP133 D17

PHP134 D18

PHP135 D19 PHP136 D20 PHP137 D21

PHP138 D22 PHP139 D23

PHP140 D24

Maciel H,Universidad Nacional Autonoma de Mexico, Mexico City, Mexico ASSESSMENT OF PRICE OF ESSENTIAL MEDICINES IN INDIA Undela K,JSS College of Pharmacy, JSS University, Mysuru, India THE IMPACT OF COST SHARING ARRANGEMENTS IN THE USE OF HEALTH CARE SERVICES DURING THE ECONOMIC CRISIS IN GREECE AND THE ATTITUDES OF CITIZENS 1 2 3 3 3 3 1 Kyriklidis K , Kaitelidou D , Angelopoulos G , Samoutis A , Konstantakopoulou O , Siskou O , Istodierevnitiki S.A., Thessaloniki, 2 3 Greece, Open University of Cyprus, Latsia, Nicosia, Cyprus, Center for Health Services Management and Evaluation, National and Kapodistrian University of Athens, Athens, Greece OVERCOMING HTA HURDLES THROUGH EARLY COLLABORATION BETWEEN PHARMACEUTICAL COMPANIES AND COMPANION DIAGNOSTIC COMPANIES 1 2 1 3 1 2 1 2 Gambari J , Senatore P , Oshinowo B , Armeni P , Duttagupta S , Chalmers M , CBPartners, New York, NY, USA, CBPartners, 3 London, UK, Bocconi University, Milano, Italy COST AVOIDANCE OF PHARMACIST RUNNING PEDIATRICS TOTAL PARENTERAL NUTRITION SERVICES AT MINISTRY OF HEALTH IN SAUDI ARABIA 1 2 1 2 Alomi YA , Fallatah AO , Ministry of Health, RIYADH, Saudi Arabia, King Salman Hospital, RIYADH, Saudi Arabia GENERIC DRUGS- DO THEY OFFER THE SAME SAFETY AND EFFICACY AS ORIGINATOR MEDICINES? -PERCEPTIONS AND ATTITUDES OF FINAL YEAR PHARMACY STUDENTS IN GREECE 1 2 2 1 1 1 Gkinou C , Kani C , Souliotis K , Karalis V , Markantonis S , National and Kapodistrian University of Athens, Athens, 2 Greece, University of Peloponnese, Corinth, Greece PRICES AND AFFORDABILITY OF REIMBURSED PHARMACEUTICALS: A EUROPEAN CROSS-COUNTRY STUDY Walter E, Lazic-Peric A,Institute for Pharmaeconomic Research, Vienna, Austria BIO-SIMILAR OR DIFFERENT? – UNDERSTANDING THE PAYER PERSPECTIVE Kalbasko A, Spoors J,RJW & partners, Royson, UK MEASURING OF THE UNCERTAINTY IN REIMBURSEMENT SYSTEM FOR MEDICINAL PRODUCTS Araja D,Riga Stradins University, Riga, Latvia CONCENTRATION ANALYSIS OF HUNGARIAN HEALTH CARE PROVIDERS BETWEEN 2006-2015 1 1 2 3 2 1 2 Csákvári T , Turcsányi K , Endrei D , Sebestyén A , Boncz I , University of Pécs, Zalaegerszeg, Hungary, University of Pécs, 3 Pécs, Hungary, National Health Insurance Fund Administration, Pécs, Hungary ANALYZING THE REVENUES AND EXPENDITURES OF THE HUNGARIAN HEALTH INSURANCE FUND BETWEEN 1993-2015 1 1 2 3 2 1 2 Csákvári T , Turcsányi K , Endrei D , Sebestyén A , Boncz I , University of Pécs, Zalaegerszeg, Hungary, University of Pécs, 3 Pécs, Hungary, National Health Insurance Fund Administration, Pécs, Hungary THE EVOLUTION OF PATIENT ACCESS SCHEMES 1 2 1 2 Spoors J , Kusel J , RJW & Partners, Royston, UK, Costello Medical Consulting Ltd, Cambridge, UK TAKING IN ACCOUNT RESEARCH AND DEVELOPMENT EXPENDITURES TO DETERMINE PRICES OF MEDICINES IN FRANCE: A REALISTIC ALTERNATIVE CHOICE? Masia C, Nedellec E, Levy P,Université Paris-Dauphine, Paris, France USE OF ELECTRONIC HEALTH INFORMATION SYSTEMS (EHIS) BY HEALTHCARE PROFESSIONALS (HCPS) AND THE PERCEPTION OF ITS VALUE IN REDUCING MEDICATION RISKS AND SAFETY FOR PATIENTS 1 2 3 4 1 2 Narayanan S , Bullman WR , Rucker NL , Rausch P , Market Access Solutions, LLC, Potomac, MD, USA, NCPIE, Rockville, MD, 3 4 USA, Enhance Value, Bethesda, MD, USA, Food and Drug Administration, Silver Spring, MD, USA DATA REQUIREMENTS TO ENABLE INNOVATIVE PRICING APPROACHES 1 2 2 1 2 Santos S , Botrugno P , Dion K , Roche, Amadora, Portugal, F. Hoffmann-La Roche Ltd, Basel, Switzerland BIG DATA IN HEALTHCARE - OPPORTUNITIES AND CHALLENGES Leppert F, Greiner W,School of Public Health, Bielefeld University, Bielefeld, Germany PREDICTING LENGTH OF STAY AFTER ROAD TRAFFIC ACCIDENT ACCOUNTING FOR COMPETING ENDPOINTS WITH TIME-DEPENDENT VARIABLES 1 1 2 2 1 2 1 1 Van Belleghem G , Devos S , Lauwaert D , Hubloue I , Buyl R , Pien K , Putman K , Vrije Universiteit Brussel, Jette, 2 Belgium, University hospital Brussel, Jette, Belgium ASSESSMENT OF GENERAL KNOWLEDGE CONCERNING HEALTH-RELATED TOPICS Zavras D, Kyriopoulos J,National School of Public Health, Athens, Greece VALUE ADDED MEDICINES: THE NEED TO ESTABLISH ONE COMMON TERMINOLOGY FOR REPURPOSED MEDICINES 1 2 1 2 Rémuzat C , Toumi M , Creativ-Ceutical, Paris, France, Faculté de Médecine, Laboratoire de Santé Publique, Aix-Marseille Université, Marseille, France VALUE ADDED MEDICINES: WHAT VALUE REPURPOSED MEDICINES MIGHT BRING TO SOCIETY?

1

PHP141 D25

PHP142 D26 PHP143 D27

PHP144 D28

PHP145 D29 PHP146 D30

PHP147 D31

PHP148 D32

PHP149 D33

PHP150 D34

PHP151 D35 PHP152 D36

PHP153 D37

PHP154 D38 PHP155 E1 PHP156 E2

PHP157 E3

PHP158 E4

2 1

2

Rémuzat C , Toumi M , Creativ-Ceutical, Paris, France, Faculté de Médecine, Laboratoire de Santé Publique, Aix-Marseille Université, Marseille, France DO FIRST-IN-CLASS DRUGS OFFER LARGER INCREMENTAL HEALTH GAINS THAN NEXT-IN-CLASS DRUGS? 1 1 1 2 1 Chambers J , Thorat T , Wilkinson C , Neumann PJ , Center for the Evaluation of Value and Risk in Health, Institute for Clinical 2 Research and Health Policy Studies,Tufts Medical Center, Boston, MA, USA, Tufts University, Boston, MA, USA TIME TO FORMAL REIMBURSABILITY FOR INNOVATIVE DRUGS IN ITALY 1 2 1 2 Eid MA , Giuliani G , University of Bologna, Bologna, Italy, Roche, Monza, Italy A STUDY EVALUATING LIVING ORGAN DONORS IN KIDNEY AND LIVER TRANSPLANTATION 1 2 1 1 1 2 Nair AG , Noone JM , Zacherle E , Blanchette CM , University of North Carolina at Charlotte, Charlotte, NC, USA, Precision Health Economics, Davidson, NC, USA COST-EFFICIENCY OF MEDICATION SAFETY PROGRAM AT PEDIATRICS, OBSTETRICS, AND GYNECOLOGY HOSPITAL, EAST PROVINCE, SAUDI ARABIA 1 2 3 3 4 4 4 1 Alomi YA , Alanazi AA , Alsallouk SA , Almaznai MM , Abu-Alnaja NI , Alduhilan M , Alhojelan B , Ministry of Health, RIYADH, 2 3 Saudi Arabia, Maternity Children Hospital Dammam, Dammam, Saudi Arabia, Health Affairs Eastern Province, MOH, RIYADH, 4 Saudi Arabia, Maternity Children Hospital Dammam, RIYADH, Saudi Arabia PHARMACISTS MANPOWER ANALYSIS IN YEARS 2006-2014 AT MINSTERY OF HEALTH IN SAUDI ARABIA Alomi YA, Alghamdi SJ, Alattyh RA,Ministry of Health, RIYADH, Saudi Arabia ASSESSMENT OF CLINICAL AND ECONOMIC OUTCOMES OF PHARMACIST INTERVENTION IN TOTAL PARENTERAL NUTRITION PROGRAM IN SAUDI ARABIA 1 2 2 1 2 Alomi YA , Fallatah AO , Al-Smail EH , Ministry of Health, RIYADH, Saudi Arabia, King Salman Hospital, RIYADH, Saudi Arabia CLINICAL AND ECONOMIC IMPACT OF PHARMACIST INTERVENTION AT CRITICAL CARE OF PRIVATE HOSPITAL IN RIYDAH, SAUDI ARABIA 1 2 2 2 2 1 2 Alomi YA , El-Bahnasawi M , Elemam AI , Elgaili SH , Kamran M , Ministry of Health, RIYADH, Saudi Arabia, Dr. Sulaiman Al-Habib Medical Group, RIYADH, Saudi Arabia WORKLOAD ANALYSIS OF PARENTERAL NUTRITION SERVICES AT MINISTRY OF HEALTH HOSPITAL IN SAUDI ARABIA 1 2 2 1 2 Alomi YA , Fallatah AO , Al-Smail EH , Ministry of Health, RIYADH, Saudi Arabia, King Salman Hospital, RIYADH, Saudi Arabia MANAGING EFFECTIVE ACCESS TO BIOSIMILARS: IN SEARCH OF AN OPTIMAL FRAMEWORK FOR CATALONIA 1 2 3 3 3 3 1 Gilabert-Perramon A , Prat A , Gil A , Gimenez E , Merino-Montero S , Badia X , Catalan Health Service, Government of 2 3 Catalonia, Barcelona, Spain, Servei Català de la Salut (CatSalut), Barcelona, Spain, Omakase Consulting, Barcelona, Spain CLINICAL AND ECONOMIC OUTCOMES OF PHARMACIST INTERVENTION DURING THERAPEUTIC DRUG MONITORING PROGRAM IN SAUDI ARABIA Alomi YA, Almudaiheem HY,Ministry of Health, RIYADH, Saudi Arabia ADHERANCE TO MEDICATION ERRORS REPOTING SYSTEM AT PUBLIC HOSPITAL, RIYADH, SAUDI ARABIA 1 2 1 2 Alomi YA , Al-Shubbar NA , Ministry of Health, RIYADH, Saudi Arabia, King Salman Hospital, RIYADH, Saudi Arabia WORKLOAD ANALYSIS AND STAFFING REQUIREMENT OF CLINICAL PHARMACY SERVICES AT MINISTRY OF HEALTH IN SAUDI ARABIA Alomi YA,Ministry of Health, RIYADH, Saudi Arabia DIMENSIONALITY OF VALUE: ARE THE US AND EUROPE MOVING TOWARDS SIMILAR OR DIFFERENT DEFINITIONS OF PHARMACEUTICAL VALUE? 1 1 1 1 2 1 2 Capuano C , Bower D , Yampolsky D , Curran K , Suponcic S , Navigant Life Sciences, Boston, MA, USA, Navigant Life Sciences, Lawrenceville, NJ, USA THE ETHICAL ISSUES OF PHARMACOGENETIC TESTS Colak M, Tunceli HD, Pak MD,baskent university, Ankara, Turkey STAKEHOLDERS VIEWS ON THE ROLE OF HTA AND RSAS IN PHARMACEUTICAL POLICY IN GREECE Tsakalogiannis C, Karampli E, Athanasakis K, Kyriopoulos J,National School of Public Health, Athens, Greece RECOMMENDATIONS IN CLINICAL GUIDELINES, ‘NO BENEFIT’ RATINGS, AND OPT-OUT DECISIONS IN GERMANY SINCE THE INTRODUCTION OF THE AMNOG LAW IN 2011: HOW DO THE PIECES FIT TOGETHER? 1 2 3 1 1 2 Staab TR , Dintsios C , Schulenburg J , Ruof J , Roche Pharma, Grenzach-Wyhlen, Germany, Bayer Vital GmbH, Leverkusen, 3 Germany, Leibniz University, Hanover, Germany GENERAL PRACTITIONERS AWARENESS ON MEDICINES COST AND FINANCING IN BOSNIA AND HERZEGOVINA 1 2 3 1 2 Catic T , Martinovic I , Avdagic L , ISPOR Bosnia and Herzegovina Chapter, Sarajevo, Bosnia, Bosnalijek JSC, Sarajevo, Bosnia 3 and Herzegovina, Faculty of Economics, Sarajevo, Bosnia and Herzegovina ACCESS TO NEW DRUGS AFTER THE INTRODUCTION OF THE 2011 REIMBURSEMENT ACT IN POLAND Zaremba A, Iwanczuk T, Tatara T, Misiak J, Krakowian P, Wysoczanski W,Agency for Health Technology Assessment and Tariff

PHP159 E5

PHP160 E6 PHP161 E7

PHP162 E8

PHP163 E9

PHP164 E10

PHP165 E11 PHP166 E12

PHP167 E13

PHP168 E14

PHP170 E16

PHP171 E17

PHP172 E18

PHP173 E19

PHP174 E20

System in Poland (AOTMiT), Warsaw, Poland IMPLEMENTATION OF THE INSURANCE PROGRAMS FOR CATASTROPHIC DISEASES IN CHINA: A QUALITATIVE STUDY MAO W, Chen W,Fudan University, Shanghai, China PHARMACEUTICAL REIMBURSEMENT OF INNOVATIVE MEDICINAL PRODUCTS IN BELGIUM Van Wilder P, Bormans V,SMART&BI, Zaventem, Belgium LINEAR, FLAT AND MIXED PRICING STRUCTURES AS NEGOTIATION QUANTITIES OF NEW MEDICINAL PRODUCTS IN CONTEXT OF AMNOG IN GERMANY: A COMPARISON AT MARKET LAUNCH AND POST PRICE NEGOTIATIONS Bot D, Campion M, Ecker T,Ecker + Ecker GmbH, Hamburg, Germany MARKET UPTAKE OF DIRECT ORAL ANTICOAGULANTS (DOACS) IN GERMANY 1 1 2 3 1 3 3 3 1 Batscheider A , Dannemann S , Gaba D , Paulus G , Antoni B , Stoecker P , Greese B , Greiner R , IMS Health Germany, 2 3 Munich, Germany, IMS Health, Gurgaon, India, IMS Health, Munich, Germany THE NORMAL REIMBURSEMENT PROCEDURE OF THE PHARMACEUTICAL SUBMISSIONS BETWEEN 2013 AND 2015 IN HUNGARY - NEEDS AND RESULTS Csordás A, Lőrincz O, Éder B,National Institute of Pharmacy and Nutrition, Budapest, Hungary BIOSIMILARS AND REFERENCE PRICE GROUPS IN GERMANY 1 2 2 2 2 1 2 Eheberg D , Pointner J , Antoni B , Gossmann JA , Batscheider A , IMS Health, Munich, Germany, IMS Health Germany, Munich, Germany EXTRA BUDGETARY REIMBURSEMENT OPTIONS FOR INNOVATIONS IN THE GERMAN HOSPITAL SECTOR Freiberg M, Schwarz R, Schalk E, Kraft T,Quintiles Commercial Germany GmbH, Mannheim, Germany REDUCING MEDICAL CLAIMS COST TO GHANA’S NATIONAL HEALTH INSURANCE SCHEME: PAPER-BASED VERSUS ELECTRONIC-BASED CLAIMS REVIEW Nsiah-Boateng E,National Health Insurance Authority, Accra, Ghana THE ROLE AND IMPACT OF EVIDENCE REVIEW GROUP ANALYSES IN THE NICE SINGLE TECHNOLOGY ASSESSMENT (STA) PROCESS 1 1 1 2 1 1 3 4 5 1 Carroll C , Kaltenthaler E , Tappenden P , Hill-McManus D , Scope A , Holmes M , Rice S , Rose M , Woolacott N , University of 2 3 4 Sheffield, Sheffield, UK, Bangor University, Bangor, UK, Newcastle University, Newcastle upon Tyne, UK, Southampton 5 University, Southampton, UK, University of York, York, UK EARLY MARKET ACCESS FOR PHARMACEUTICALS IN EU: WHAT IS THE IMPACT OF EMA’S ACCELERATED ASSESSMENT PROCEDURE? 1 1 1 2 3 4 1 2 Haijeji B , Belgaied W , Sediri Y , Parviainen L , Rémuzat C , Toumi M , Creativ-Ceutical, Tunis, Tunisia, Creativ-Ceuticals, 3 4 Rotterdam, The Netherlands, Creativ-Ceuticals, Paris, France, Aix-Marseille University, Marseille, France MARKET ACCESS PATHWAYS FOR DRUGS WITH EMA CONDITIONAL APPROVAL 1 1 1 2 1 2 Lie X , Kreeftmeijer J , Bossers N , Haigh J , Quintiles Advisory Services, Hoofddorp, The Netherlands, Quintiles Advisory Services, Reading, UK THE ROAD TO RUSSIAN PHARMACOECONOMICS: UNDERSTANDING THE DRIVERS FOR ACCESS TO HIGH-VALUE / ORPHAN DISEASE DRUGS 1 2 1 2 Subbotina E , Chowdhury CA , CBPartners, London, UK, CBPartners, New York, NY, USA RETROSPECTIVE REVIEW OF OBSERVATIONAL DATA REQUESTED BY THE FRENCH HEALTH AND TECHNOLOGY ASSESSMENT AGENCY: HOW ARE RESULTS TAKEN INTO ACCOUNT? Fernandez J, Pinet M, Taransaud J, d'Andon A,French National Authority for Health (HAS), Saint Denis La Plaine, France THE VALUE OF MCDA IN HEALTH TECHNOLOGY ASSESSMENT: A EXPLORATIVE STUDY IN THE DUTCH CONTEXT 1 2 3 4 5 2 1 van Til JA , Groothuis-Oudshoorn CG , Baltussen R , Zwaap J , Boer B , IJzerman MJ , University of Twente, Enschede, The 2 Netherlands, MIRA institute for Biomedical Technology and Technical Medicine, University of Twente, Enschede, The 3 4 Netherlands, Department for Health Evidence, Radboud University Medical Center, Nijmegen, The Netherlands, Zorginstituut 5 Nederland, Diemen, The Netherlands, Erasmus University Rotterdam, Rotterdam, The Netherlands VARIATIONS IN STAKEHOLDER PREFERENCES BETWEEN INNOVATIVE PRICING AGREEMENT TYPES ACROSS THE EU5 1 2 3 1 2 Edwards G , Staufer A , Dunlop W , IMS Consulting Group, Cambridge, UK, Mundipharma International Limited, Cambridge, 3 UK, Mundipharma International Ltd, Cambridge, UK

HEALTH CARE USE & POLICY STUDIES - Health Care Research & Education PHP175 E21

PHP176 E22

SIMULATING PATIENT-LEVEL PROFILES TO CAPTURE PATIENT HETEROGENEITY IN HEALTH-ECONOMIC APPLICATIONS 1 2 1 2 Rael M , Ishak J , Evidera, San Francisco, CA, USA, Evidera, Montreal, QC, Canada QUANTIFICATION OF PATIENT PREFERENCE ANALYSIS: WEARING THE FEDERAL JOINT COMMITTEE LENS TO ASSESS EVIDENCE

1

PHP177 E23

PHP178 E24

PHP179 E25

PHP180 E26

PHP181 E27

PHP182 E28

PHP183 E29

PHP184 E30

PHP185 E31

PHP186 E32

PHP187 E33

PHP188 E34

2

2 1

2

Gaba D , Eheberg D , Bonduelle D , IMS Health, Gurgaon, India, IMS Health, Munich, Germany PSYCHOMETRIC TESTING OF THE FINNISH VERSION OF THE PROSTHESIS EVALUATION QUESTIONNAIRE 1 2 1 3 3 4 5 1 Repo JP , Piitulainen K , Tukiainen EJ , Roine RP , Kautiainen H , Becker P , Häkkinen A , University of Helsinki and Helsinki 2 3 University Hospital, Helsinki, Finland, University of Jyvaskyla, Jyvaskyla, Finland, Helsinki and Uusimaa Hospital District, 4 5 Helsinki, Finland, University of Jyväskylä, Jyväskylä, Finland, University of Jyvaskylä, Jyvaskylä, Finland EPIDEMIOLOGICAL CHARACTERISTICS OF HOSPITALIZATIONS DUE TO ADVERSE DRUG REACTIONS (ADRS) RELAED TO ORAL ANTICOAGULANTS IN SPAIN: 2010-2013 1 1 1 1 1 1 Carrasco-Garrido P , Lopez De Andres A , Hernandez Barrera V , Esteban-Hernandez J , Jimenez-Trujillo I , Alvaro-Meca A , 2 3 1 1 2 Muñoz Robles JA , Rodriguez JM , Jimenez-Garcia R , Rey Juan Carlos University, Alcorcon (MADRID), Spain, Daiichi Sankyo 3 Iberia, MADRID, Spain, Daiichi Sankyo Europe GmbH, Munich, Germany EVOLUTIONS IN THE PEER-REVIEW PUBLICATION LANDSCAPE AND THEIR IMPLICATIONS FOR SYSTEMATIC LITERATURE REVIEWS Adkins E, Cadwell K, Pooley N, Fox D, Floyd D,PHMR Ltd, London, UK MCDA APPLICATION IN CENTRAL AND EASTERN EUROPE: SELECTION OF THE MOST IMPORTANT CRITERIA BASED ON EXAMPLES 1 2 1 2 Nemeth B , Piniazhko O , Syreon Research Institute, Budapest, Hungary, Danylo Halytsky Lviv National Medical University, Lviv, Ukraine A CROSS-NATIONAL COMPARISON OF THE EFFECT OF AGE AND GENDER ON HEALTH-RELATED QUALITY OF LIFE (HRQL) 1 1 1 2 1 1 2 Rendas-Baum R , White MK , Kosinski M , Vietri J , Bjorner JB , Optum, Lincoln, RI, USA, Kantar Health, Horsham, PA, USA EQ-5D STUDIES IN NERVOUS SYSTEM DISEASES IN EIGHT CENTRAL AND EASTERN EUROPEAN COUNTRIES 1 2 3 3 4 5 3 3 3 6 7 Prevolnik Rupel V , Turk E , Péntek M , Rencz F , Golicki D , Simon J , Brodszky V , Baji P , Zrubka Z , Zavada J , Petrova G , 8 3 1 2 3 Rotar A , Gulacsi L , Institute for Economic Research, Ljubljana, Slovenia, DNV GL, Hovik, Norway, Corvinus University of 4 Budapest, Budapest, Hungary, Department of Experimental & Clinical Pharmacology, Medical University of Warsaw, Warsaw, 5 6 7 Poland, Medical University of Vienna, Vienna, Austria, Institute of Rheumatology, Prague, Czech Republic, Medical University 8 Sofia, Faculty of Pharmacy, and President, ISPOR Bulgaria Chapter, Sofia, Bulgaria, University of Amsterdam, Amsterdam, The Netherlands HOW TO SELECT THE BEST COMPARATOR? AN INTERNATIONAL ECONOMIC EVALUATION GUIDELINES COMPARISON 1 2 1 1 2 Ziouani S , Granados D , Borget I , Univ Paris-Sud, Faculty of Pharmacy, GRADES, Châtenay-Malabry, France, Janssen, Issy-les-Moulineaux, France HEALTH-RELATED QUALITY OF LIFE (HRQOL) BASED ON PREFERENCES FROM 14 COUNTRIES IN PRIMARY HEALTH CARE SETTING (PHCS) 1 2 2 3 4 1 2 Soini EJ , Heinonen J , Miettola E , Ryynänen O , Koskela T , ESIOR Oy, Kuopio, Finland, School of Medicine, University of 3 Tampere, Finland, Faculty of Health Sciences, University of Eastern Finland, and Unit of Primary Health Care, Kuopio University 4 Hospital, Kuopio, Finland, Department of General Practice, University of Tampere, and Omapihlaja, Pihlajalinna Terveys Oy, Tampere, Finland PREFERENCES FOR THE CHARACTERISTICS OF HOME ENTERAL NUTRITION (HEN) VIA TUBE FEEDING: A DISCRETE-CHOICE EXPERIMENT 1 2 3 4 5 6 7 7 8 Olveira G , Martinez-Olmos MA , Fernandez de Bobadilla B , Ferrer M , Virgili N , Vega B , Blanco M , Layola M , Lizan L , 9 1 2 Tribaldos de Suarez M , Hospital Regional Universitario de Málaga, Malaga, Spain, Hospital Universitario de Santiago, Santiago 3 4 de Compostela, Spain, Hospital General Universitario de Ciudad Real, Ciudad Real, Spain, Hospital Clínico Universitario Virgen 5 6 de Arrixaca de Murcia, Murcia, Spain, Hospital Bellvitge, Barcelona, Spain, Hospital Universitario Ramón y Cajal, Madrid, 7 8 9 Spain, Nestle health science, Barcelona, Spain, Outcomes 10, Universitat Jaume I, Castellon, Spain, Outcomes 10, Castellon, Spain HOW TO DEFINE RELEVANT COMPARATORS IN FRANCE? AN ANALYSIS OF THE ECONOMIC EVALUATIONS SUBMITTED BY MANUFACTURERS AND REVIEWED BY THE ECONOMIC COMMITTEE (CEESP) OF THE FRENCH NATIONAL HEALTH AUTHORITY 1 2 2 1 1 Ziouani S , Granados D , Benjamin L , Borget I , Univ Paris-Sud, Faculty of Pharmacy, GRADES, Châtenay-Malabry, 2 France, Janssen, Issy-les-Moulineaux, France LIFESTYLE BELIEFS OF 672 PATIENTS WITH RHEUMATOID ARTHRITIS OR AXIAL SPONDYLOARTHRITIS 1 2 3 4 5 6 6 2 7 Gossec L , Cukierman G , Saraux A , Chauvin P , Poussière M , Saulot V , Russo-Marie F , Joubert J , Hudry C , Berenbaum 8 1 2 3 F , Paris 06 University, Paris, France; AP-HP, Hôpital Pitié Salpêtrière, Paris, France, UCB Pharma, Colombes, France, CHU La 4 Cavale Blanche and Université de Bretagne Occidentale, Brest, France, Paris 06 University, Paris, France; INSERM, Paris, 5 6 7 France, Independent Researcher, Paris, France, Arthritis Fondation Courtin, Neuilly-sur-Seine, France, AP-HP Hôpital Cochin, 8 Paris, France, Paris 06 University, Paris, France; INSERM, Paris, France; AP-HP, Hôpital Saint-Antoine, Paris, France PSYCHOMETRIC PROPERTIES OF THE FINNISH VERSION OF THE LOCOMOTOR CAPABILITIES INDEX-5 1 2 1 2 3 1 4 5 1 Becker P , Repo JP , Piitulainen K , Tukiainen EJ , Roine RP , Järvenpää S , Ylinen J , Häkkinen A , University of Jyväskylä, 2 3 Jyväskylä, Finland, University of Helsinki and Helsinki University Hospital, Helsinki, Finland, Helsinki and Uusimaa Hospital

4

PHP189 E35

PHP190 E36

PHP191 E37

PHP192 E38

PHP194 F1

PHP195 F2

PHP196 F3

PHP197 F4

PHP198 F5

PHP199 F6

PHP200 F7

PHP201 F8 PHP202 F9

PHP203 F10

5

District, Helsinki, Finland, Central Finland Central Hospital, Jyväskylä, Finland, University of Jyvaskyla, Jyvaskyla, Finland ARE ALLOCATION PREFERENCES IN HEALTH CARE CONSISTENT WITH A PARTICULAR DEFINITION OF SEVERITY? RESULTS FROM A RANDOM-SAMPLE SURVEY OF NORWEGIANS 1 2 3 1 2 Østby JT , Desser AS , Kristiansen IS , Pfizer Norway, Oslo, Norway, Norwegian Institute of Public Health, Oslo, 3 Norway, University of Oslo, Oslo, Norway PROMPT VALUE ASSESSMENT OF BREAKTHROUGH INTERVENTIONS WITH LIMITED OUTCOME DATA 1 2 3 4 1 2 3 Arbel R , Hammerman A , Triki N , Greenberg D , Sapir College, Sderot, Israel, Clalit Health Services, Tel-Aviv, Israel, Maccabi 4 Healthcare Services, Tel-Aviv, Israel, Ben-Gurion University of the Negev, Beer-Sheva, Israel DIRECTLY ELICITING PERSONAL UTILITY FUNCTIONS FROM A CONVENIENCE SAMPLE OF 30 HEALTH OUTCOMES PROFESSIONALS: A PILOT STUDY 1 2 2 3 4 1 2 Pantiri K , Shah K , Devlin N , Mulhern B , van Hout B , Pharmerit BV, Rotterdam, The Netherlands, Office of Health Economics, 3 4 London, UK, University of Technology Sydney, Sydney, Australia, University of Sheffield, Sheffield, UK INNOVATIVE MEDICAL DEVICE DESIGN SIGNIFICANTLY REDUCES SURGEON INTRA-PROCEDURAL STRESS LEVELS (IPSL) MacDonald M, Lombard J, Sutton N, Hinoul P, Ilie B,Johnson & Johnson Medical Devices, Somerville, NJ, USA HIGH LEVELS OF FEARS OF PATIENTS WITH RHEUMATOID ARTHRITIS OR AXIAL SPONDYLOARTHRITIS ARE ASSOCIATED WITH GENDER, DISEASE ACTIVITY, ANXIETY AND DEPRESSION: A CROSS-SECTIONAL STUDY OF 672 PATIENTS 1 2 3 4 5 6 6 2 7 Gossec L , Cukierman G , Chauvin P , Hudry C , Poussière M , Saulot V , Russo-Marie F , Joubert J , Saraux A , Berenbaum 8 1 2 3 F , Paris 06 University, Paris, France; AP-HP, Hôpital Pitié Salpêtrière, Paris, France, UCB Pharma, Colombes, France, Paris 06 4 5 University, Paris, France; INSERM, Paris, France, AP-HP Hôpital Cochin, Paris, France, Independent Researcher, Paris, 6 7 France, Arthritis Fondation Courtin, Neuilly-sur-Seine, France, CHU La Cavale Blanche and Université de Bretagne Occidentale, 8 Brest, France, Paris 06 University, Paris, France; INSERM, Paris, France; AP-HP, Hôpital Saint-Antoine, Paris, France PSYCHOMETRIC PROPERTIES OF THE FINNISH VERSION OF THE LOWER EXTREMITY FUNCTIONAL SCALE AMONG FOOT AND ANKLE PATIENTS 1 1 2 3 3 3 1 Repo JP , Tukiainen EJ , Roine RP , Ilves O , Jarvenpää S , Häkkinen A , University of Helsinki and Helsinki University Hospital, 2 3 Helsinki, Finland, Helsinki and Uusimaa Hospital District, Helsinki, Finland, University of Jyvaskyla, Jyvaskyla, Finland A REAL CONCERN OR JUST A HYPE? – EVIDENCE ON NEGATIVE CLINICAL CONSEQUENCES OF SWITCHING FROM ORIGINATOR TO BIOSIMILAR BASED ON A SYSTEMATIC LITERATURE REVIEW 1 2 1 3 4 5 1 2 Inotai A , Prins CP , Csanadi M , Szegner P , Vitezic D , Kaló Z , Syreon Research Institute, Budapest, Hungary, Utrecht 3 University, Department of Pharmaceutical Sciences, Utrecht, The Netherlands, Eötvös Loránd University, Budapest, 4 5 Hungary, University of Rijeka, School of Medicine and University Hospital Centre Rijeka, Rijeka, Croatia, Eötvös Loránd University (ELTE), Budapest, Hungary THE INVARIANCE ANALYSIS OF SF12V2: ¿ARE COMPARABLE THE QUALITY OF LIFE RESULTS OF MEN AND WOMEN? 1 1 2 1 2 Pedrero V , Oyarte M , Espinoza MA , Universidad del Desarrollo, Santiago, Chile, Pontificia Universidad Catolica de Chile, Santiago, Chile COMPARISON OF WEB-BASED SIGNAL DETECTION USING MEDICAL FORUMS DATA IN FRANCE FROM 2005-2015 WITH SIGNALS FROM VIGIBASE® 1 2 1 1 3 1 4 2 4 Schück S , Kürzinger M , Abdellaoui R , Texier N , Pouget J , Faviez C , Zhang L , Tcherny-Lessenot S , Juhaeri J , Welsh 4 1 2 3 S , Kappa Santé, Paris, France, Global Pharmacovigilance and Epidemiology, Sanofi, Chilly-Mazarin, France, Information 4 Technology Solutions, Sanofi, Lyon, France, Global Pharmacovigilance and Epidemiology, Sanofi, Bridgewater, NJ, USA IMPACT OF BURDENSOME CHRONIC CONDITIONS ON HEALTH-RELATED QUALITY OF LIFE AMONG EUROPEANS: ANALYSIS OF EQ-5D-5L VAS SCORES 1 2 1 2 Dreyfus J , Vietri J , Kantar Health, Paris, France, Kantar Health, Horsham, PA, USA DEVELOPMENT OF DAY SURGERY IN HUNGARY BETWEEN 2004-2014 1 2 3 2 4 2 2 1 Gresz M , Endrei D , Csákvári T , Danku N , Sebestyén A , Horváth L , Boncz I , National Healthcare Service Center, Budapest, 2 3 4 Hungary, University of Pécs, Pécs, Hungary, University of Pécs, Zalaegerszeg, Hungary, National Health Insurance Fund Administration, Pécs, Hungary THE PROBABILISTIC EFFICIENCY FRONTIER: A VALUE ASSESSMENT OF TREATMENT OPTIONS IN HEPATITIS C Mühlbacher A, Sadler A,Hochschule Neubrandenburg, Neubrandenburg, Germany ESTIMATION OF VALUE OF LIFE WITH A MODEL APPROACH DEPENDING ON NET PRESENT VALUE FOR FRANCE, GERMANY, ITALY, SPAIN AND UNITED KINGDOM 1 2 3 1 2 Tuna E , Yenilmez FB , Kockaya G , Polar Health Economics and Policy Consultancy, Ankara, Turkey, Hacettepe University, 3 Ankara, Turkey, Health Economics and Policy Association, Ankara, Turkey THE REDUCTION OF CEILING WITH THE EQ-5D-5L INCREASES WITH AGE IN THE GENERAL ADULT POPULATION 1 1 1 1 2 1 1 Scalone L , Ciampichini R , Cesana G , Cortesi PA , Janssen B , Mantovani LG , University of Milano-Bicocca, Monza, 2 Italy, EuroQol Research Foundation, Rotterdam, The Netherlands

PHP204 F11 PHP205 F12

PHP206 F13

PHP208 F14

PHP209 F15

PHP210 F16

PHP211 F17

PHP212 F18

PHP213 F19

PHP214 F20

PHP215 F21

PHP216 F22

PHP217 F23

PHP218 F24

PHP219 F25

PHP220 F26

JOB BURNOUT PREDICTORS IN COMMUNITY PHARMACISTS IN SERBIA 1 2 2 1 2 Jocic DD , Krajnovic DM , Lakic DM , BENU, Belgrade, Serbia, Faculty of Pharmacy - University of Belgrade, Belgrade, Serbia THE USE OF PHARMACOECONOMIC EVIDENCE TO ENCOURAGE GENERIC MEDICINES USE IN JORDAN: A COST MINIMIZATION ANALYSIS El-Dahiyat F,The Hashemite University, Zarqa, Jordan IS THE INSTITUTE OF CLINICAL AND ECONOMIC REVIEW (ICER) SET UP FOR SUCCESS? A COMPARISON BETWEEN ICER AND EX-U.S. HTA AGENCIES 1 1 2 3 1 2 Skolas K , Pruefert A , Yee S , van Engen A , Quintiles Advisory Services, Cambridge, MA, USA, Quintiles Advisory Services, 3 New York, NY, USA, Quintiles Advisory Services, Hoofddorp, The Netherlands RELATIONSHIP BETWEEN ORPHAN DISEASE PREVALENCE, DIFFERENTIAL HTA VALUE ASSESSMENT, AND ORPHAN DRUG PRICING IN SEVEN EUROPEAN COUNTRIES 1 1 2 2 1 2 1 2 Sladeček S , Cockerill K , Hegde S , Funderburk A , Graeve C , Gaebler JA , Health Advances GmbH, Zug, Switzerland, Health Advances LLC, Weston, MA, USA THE NUMBER OF CASES IN PHYSIOTHERAPY SERVICES WITHIN SPECIALIZED HOME CARE IN HUNGARY BETWEEN 2010 AND 2014 1 1 2 2 1 1 1 1 2 Molics B , Hanzel A , Juhász K , Sebestyén A , Gyuró M , Endrei D , Boncz I , University of Pécs, Pécs, Hungary, National Health Insurance Fund Administration, Pécs, Hungary THE UTILIZATION OF SELECTED SCREENING TESTS IN GREECE: A DESCRIPTIVE ANALYSIS 1 1 1 1 2 3 1 1 Naoum P , Mavrikou M , Charonis A , Balasopoulos T , Kyriopoulos I , Karokis A , Athanasakis K , Pavi E , Kyriopoulos 1 1 2 3 J , National School of Public Health, Athens, Greece, London School of Economics and Political Science, London, UK, MSD Greece, Athens, Greece LINGUISTIC VALIDATION OF THE FINNISH VERSION OF THE VISUAL ANALOGUE SCALE FOOT AND ANKLE INSTRUMENT 1 1 2 2 1 Repo JP , Tukiainen EJ , Ilves O , Häkkinen A , University of Helsinki and Helsinki University Hospital, Helsinki, 2 Finland, University of Jyvaskyla, Jyvaskyla, Finland EARLY PAYER SCIENTIFIC ADVICE PROCEDURES IN THE EU: WHICH ONE IS MOST SUITED FOR PHARMACEUTICAL COMPAINES? 1 1 1 2 1 2 Wolfram V , Bailey S , Foxon G , Craddy P , Remap Consulting, Cheshire, UK, Remap Consulting, Zug, Switzerland COMPARING EQ-5D-3L AND EQ-5D-5L IN A GENERAL POPULATION 1 2 3 2 1 2 Ferreira LN , Ferreira PL , Pereira LN , Antunes P , Universidade do Algarve, Faro, Portugal, CEISUC, Coimbra, 3 Portugal, Research Centre for Spatial and Organizational Dynamics (CIEO), Faro, Portugal VALIDATION OF COMORBIDITY INDICES (CHARLSON AND ELIXHAUSER) COMPUTED IN CROSS SECTIONAL HOSPITAL BILLING DATA 1 1 2 1 3 1 Wei D , Narain A , Lerner J , Yoo A , Kalsekar I , Epidemiology & Health Informatics, Medical Devices, Johnson and Johnson Co., 2 3 New Brunswick, NJ, USA, DePuy Synthes, Inc., Raynham, MA, USA, Johnson & Johnson Co., New Brunswick, NJ, USA ESTIMATION OF VALUE OF LIFE WITH A MODEL APPROACH DEPENDING ON NET PRESENT VALUE FOR TURKEY 1 2 3 1 2 Kockaya G , Yenilmez FB , Tuna E , Health Economics and Policy Association, Ankara, Turkey, Hacettepe University, Ankara, 3 Turkey, Polar Health Economics and Policy Consultancy, Ankara, Turkey PARTICIPATION OF EXTERNAL MEDICAL SOCIETIES IN THE BENEFIT ASSESSMENT OF PHARMACEUTICALS IN GERMANY Bleß H, de Millas C, Kern B,IGES Institut GmbH, Berlin, Germany PATIENTS' ACCEPTANCE AND ADHERENCE OF THEIR MEDICATION: RESULTS FROM A EUROPEAN MULTI-DISEASE STUDY WITH ONLINE PATIENT COMMUNITY 1 2 3 4 1 2 de Bock E , Chekroun M , Morisky DE , Arnould B , Mapi Group, Patient-Centered Outcomes, Lyon, France, carenity.com, Paris, 3 4 France, UCLA Fielding School of Public Health, Los Angeles, CA, USA, Mapi Group, Lyon, France ASSESSING QUALITY OF LIFE OF SELF-REPORTED RHEUMATIC PATIENTS 1 2 3 1 4 4 4 4 4 1 Ferreira LN , Ferreira PL , Pereira LN , Antunes P , Gonçalves S , Gouveia N , Rodrigues A , Canhao H , Branco JC , CEISUC, 2 3 Coimbra, Portugal, Faculty of Economics, Coimbra, Portugal, Research Centre for Spatial and Organizational Dynamics (CIEO), 4 Faro, Portugal, Sociedade Portuguesa de Reumatologia, Lisbon, Portugal ITALIAN ELECTRONIC HEALTH RECORDS MAPPING: IS CLINICAL DATA COLLECTION GETTING IN LINE WITH THE REAL WORLD EVIDENCE ERA? 1 1 1 1 1 2 1 1 2 Avitabile A , Caputo A , Gilardelli G , Golotta C , La Grasta L , Heiman F , Porrello N , Roche S.p.A., Monza, Italy, IMS Health Information Solutions Italy S.r.l., Milan, Italy DIFFERENTIATION OF HEALTH RELATED QUALITY OF LIFE OUTCOMES BETWEEN PATIENT POPULATIONS; RESULTS FROM PATIENTS WITH BREAST CANCER, RHEUMATOID ARTHRITIS, MULTIPLE SCLEROSIS, RARE CANCERS AND RARE DISEASES 1 1 2 1 2 Efthymiadou O , Kanavos P , Mossman J , London School of Economics and Political Science, London, UK, European Brain

PHP221 F27

PHP222 F28

PHP223 F29 PHP224 F30

PHP225 F31

PHP226 F32

PHP227 F33

PHP228 F34

PHP229 F35 PHP230 F36

PHP231 F37

PHP232 F38

PHP233 G1

PHP234 G2

PHP235 G3

Council, Brusells, Belgium ASSESSMENT OF PATIENT NEED DURING HOSPITALIZATION BY USING NEQ (NEED EVALUATION QUESTIONNAIRE) IN TERTIARY CARE HOSPITALS, QUETTA, PAKISTAN Nasim A, Haq N, Rehmat S, Riaz S, Aziz MF,University of Balochistan, Quetta, Pakistan ADVANCED THERAPY MEDICINAL PRODUCTS (ATMPS) IN EUROPE 8 YEARS ON: WHAT IS THE PATH TO MARKET ACCESS SO FAR? 1 2 1 1 2 1 Mycka J , Dellamano R , Lobb W , Dalal N , Dellamano L , Medical Marketing Economics LLC (MME), Montclair, NJ, 2 USA, ValueVector, Milan, Italy BUDGET IMPACT MODEL – GLOBAL NEEDS TO GO LOCAL Wang-Silvanto J, Buckland A, Hirst A, Shephard C, Vlachaki I,WG Access Ltd, London, UK ESTIMATION OF VALUE OF LIFE WITH A MODEL APPROACH DEPENDING ON NET PRESENT VALUE FOR AUSTRIA, CANADA, JAPAN AND USA 1 2 3 1 2 Yenilmez FB , Tuna E , Kockaya G , Hacettepe University, Ankara, Turkey, Polar Health Economics and Policy Consultancy, 3 Ankara, Turkey, Health Economics and Policy Association, Ankara, Turkey RAPID, COMPREHENSIVE ORAL NUTRITIONAL SUPPLEMENT QUALITY IMPROVEMENT PROGRAM REDUCES LENGTH OF STAY IN MALNOURISHED HOSPITALIZED PATIENTS 1 2 2 1 2 1 1 Summerfelt WT , Sulo S , Partridge J , VanDerBosch G , Hegazi R , Sriram K , Advocate Health Care, Downers Grove, IL, 2 USA, Abbott Nutrition, Columbus, OH, USA COMORBIDITY-BASED EQ-5D SCORES OF PRIMARY CARE PATIENTS IN FINLAND, THEIR POTENTIAL TO BENEFIT AND UNMET MEDICAL NEED 1 2 2 3 4 1 2 Soini EJ , Heinonen J , Miettola E , Ryynänen O , Koskela T , ESIOR Oy, Kuopio, Finland, School of Medicine, University of 3 Tampere, Finland, Faculty of Health Sciences, University of Eastern Finland, and Unit of Primary Health Care, Kuopio University 4 Hospital, Kuopio, Finland, Department of General Practice, University of Tampere, and Omapihlaja, Pihlajalinna Terveys Oy, Tampere, Finland INFLUENCING FACTORS ON KNOWLEDGE, ATTITUDE AND BEHAVIOUR TOWARDS ANTIBIOTIC USAGE AMONG ADULTS IN HO CHI MINH CITY, VIET NAM 1 2 3 1 2 Ngo TN , Tran MK , Nguyen TT , University of medcine and pharmacy, Ho Chi Minh City, Ho Chi Minh, Viet Nam, University of 3 medicine and pharmacy, HCMC, Ho chi minh, Viet Nam, University of medicine and pharmacy, Ho Chi Minh City, Ho Chi Minh City, Viet Nam ESTIMATING STUDY COSTS FOR USE IN VOI, A STUDY OF DUTCH PUBLICLY FUNDED DRUG RELATED RESEARCH 1 2 3 4 3 1 5 5 van Asselt AD , Ramaekers BL , Corro Ramos I , Joore MA , Al MJ , Lesman-Leegte I , Postma MJ , Vemer P , Feenstra 1 1 2 TF , University Medical Center Groningen, Groningen, The Netherlands, Maastricht University Medical Center+, Maastricht, The 3 4 Netherlands, Erasmus University, Rotterdam, The Netherlands, Maastricht University Medical Center, Maastricht University, 5 Maastricht, The Netherlands, University of Groningen, Groningen, The Netherlands SHOULD PATIENTS ESTIMATE HEALTH RELATED QUALITY OF LIFE? THE RESULTS OF EMPIRICAL STUDY Prevolnik Rupel V, Ogorevc Marko M,Institute for Economic Research, Ljubljana, Slovenia RECONSTRUCTION OF MAJOR LOWER-EXTREMITY AMPUTATION STUMP WITH A FREE LATISSIMUS DORSI FLAP 1 2 3 1 1 Repo JP , Roine RP , Sintonen H , Tukiainen EJ , University of Helsinki and Helsinki University Hospital, Helsinki, 2 3 Finland, Helsinki and Uusimaa Hospital District, Helsinki, Finland, University of Helsinki, Helsinki, Finland EXTENSION OF THE LABELS WITHIN THE EQ-5D-Y 1 2 2 3 4 5 6 7 4 Kreimeier S , Åström M , Burström K , Egmar A , Gusi N , Herdman M , Kind P , Oppe M , Pérez Sousa M , Greiner 81 2 3 W , University of Bielefeld, Bielefeld, Germany, Karolinska Institutet Stockholm, Stockholm, Sweden, The Swedish Red Cross 4 5 University College Stockholm, Stockholm, Sweden, University of Extremadura, Caceres, Spain, Insight Consulting and 6 7 Research, Barcelona, Spain, HSE University, St. Petersburg, Russia, EuroQol Research Foundation, Rotterdam, The 8 Netherlands, School of Public Health, Bielefeld University, Bielefeld, Germany INVESTIGATION OF THE WORK ABILITY OF NURSES AND ITS INFLUENCING FACTORS 1 2 2 2 1 Pocsai N , Danku N , Boncz I , Horváthné Kívés Z , Vasútegészségügyi NK Kft Szegedi Egészségügyi Központ, Szeged, 2 Hungary, University of Pécs, Pécs, Hungary EVALUATION OF THE IMPACT OF PHARMACISTS QUALIFICATION AND YEARS OF PRACTICE ON PHARMACEUTICAL CARE SERVICES IN COMMUNITY PHARMACY PRACTICE IN ENUGU NIGERIA Ogbonna B,NNAMDI AZIKIWE UNIVERSITY, AWKA, Nigeria RECENT TRENDS IN DIFFERENT DEVICES, OPERATING SYSTEMS, AND BROWSERS USED BY PATIENTS TAKING PART IN ONLINE MEDICAL SURVEYS Wade AG, Crawford GM, McLennan K,Patients Direct, Glasgow, UK CLINICAL TRIALS SCENARIO IN BRAZIL: STUDY AND SPONSOR PROFILES 1 1 1 2 2 1 2 Julian G , Moreira Ed , de Oliveira RW , Francisco Fd , Ruenis AP , Evidências - Kantar Health, São Paulo, Brazil, ABRACRO, São Paulo, Brazil

PHP236 G4

PHP237 G5

PHP238 G6

PHP239 G7

PHP240 G8

PHP241 G9

PHP242 G10

PHP243 G11

PHP244 G12

PHP245 G13

PHP246 G14 PHP247 G15

PHP248 G16

PHP249 G17

PHP250 G18

PHP252 G19

PHP253 G20

COMPARATIVE ANALYSIS OF MEDICATION POSSESSION RATIO MEASURES FOR ADHERENCE TO SINGLE-MEDICATION Ágh T,Syreon Research Institute, Budapest, Hungary GOOD ENOUGH FOR POLICY WORK? STUDY-DESIGN CHALLENGES IN IMPLEMENTING STATED-PREFERENCE METHODS FOR COMPLEX HEALTH-CARE TECHNOLOGIES 1 2 3 4 1 2 Marshall DA , Gonzalez JM , MacDonald KV , Johnson FR , Alberta Bone and Joint Health Institute, Calgary, AB, Canada, RTI 3 4 Health Solutions, Research Triangle Park, NC, USA, University of Calgary, Calgary, AB, Canada, Duke Clinical Research Institute, Durham, NC, USA HAVE BUDGET IMPACT ANALYSES INCLUDED CLINICAL OUTCOMES? 1 2 1 1 1 1 1 2 Wang-Silvanto J , Taylor M , Buckland A , Hirst A , Shephard C , Vlachaki I , WG Access Ltd, London, UK, York Health Economics Consortium, Heslington, York, UK UTILIZATION OF PHYSIOTHERAPY VISITS COMPLETED IN SPECIALIZED HOME CARE IN HUNGARY BETWEEN 2010 AND 2014 1 2 3 1 1 1 4 1 1 Molics B , Simon-Ugron Á , Mihajlovic I , Gyuró M , Ács P , Varga V , Rátgéber L , Boncz I , University of Pécs, Pécs, 2 3 4 Hungary, Babes-Bolyai University Cluj-Napoc, Cluj-Napoca, Romania, University of Novi Sad, Novi Sad, Serbia, Ratgeber Academia, Pécs, Hungary FOLLOW-UP ANALYSIS OF VALIDITY OF BIA FOR DRUGS TEMPORARILY REIMBURSED IN MODE OF COVERAGE WITH EVIDENCE DEVELOPMENT Zizalova J, Rrahmaniova D, Svorcikova J, Vrubel F,Ambruz & Dark Deloitte Legal, Prague 8, Czech Republic HEALTH INSURANCE-RELATED ASPECTS OF HOME-BASED PARENTERAL NUTRITION IN HUNGARY 1 2 3 2 4 2 2 1 Gresz M , Endrei D , Csákvári T , Danku N , Sebestyén A , Horváth L , Boncz I , National Healthcare Service Center, Budapest, 2 3 4 Hungary, University of Pécs, Pécs, Hungary, University of Pécs, Zalaegerszeg, Hungary, National Health Insurance Fund Administration, Pécs, Hungary OPTIMISING ADVERTS AND CAMPAIGNS FOR EFFICIENT AND COST-EFFECTIVE PATIENT RECRUITMENT USING SOCIAL MEDIA Wade AG, Crawford GM, McLennan K,Patients Direct, Glasgow, UK TREND OF PHARMACOECONOMICS AND HEALTH OUTCOME STUDIES IN TURKEY 1 2 3 1 2 Kockaya G , Yenilmez FB , Tuna E , Health Economics and Policy Association, Ankara, Turkey, Hacettepe University, Ankara, 3 Turkey, Polar Health Economics and Policy Consultancy, Ankara, Turkey COST MINIMISATION ANALYSIS: WHEN AND WHERE? A REVIEW OF HTA GUIDANCE ON COST MINIMISATION ANALYSIS Hirst A, Vlachaki I, Shephard C,WG Access Ltd, London, UK COST-EFFICIENCY OF CLINICAL PHARMACY SERVICES AT MINISTRY OF HEALTH IN SAUDI ARABIA APPLICATION OF AMERICAN MODEL Alomi YA,Ministry of Health, Riyadh, Saudi Arabia THE VALUE OF PATIENT REPORTED OUTCOMES IN GERMAN AMNOG DOSSIERS Borchert K, Altevers J, Braun S, Mittendorf T,Xcenda GmbH, Hannover, Germany ASSESSMENT OF WILLINGNESS TO PAY FOR CONSULTAION AND DIAGNOSTIC SERVICES IN SHEIKH KHALIFA BIN ZAYYED AL-NAYYAN MEDICAL COMPLEX, QUETTA Ahmed N, Haq N, Nasim A,University of Balochistan, Quetta, Pakistan EVALUATION OF CLINICAL AND ECONOMIC IMPACT OF DRUG RELATED PROBLEMS IN ELDERLY PATIENTS AT TERTIARY CARE HOSPITAL 1 2 1 2 Madhan R , Vineetha M , JSS College of Pharmacy, Mysore, JSS University, MYSORE, India, JSS College of Pharmacy, JSS University, MYSORE, India LINGUISTIC VALIDATION OF THE FINNISH VERSION OF THE MODIFIED MOBILITY SECTION OF THE PROSTHESIS EVALUATION QUESTIONNAIRE Repo JP, Barner-Rasmussen I,University of Helsinki and Helsinki University Hospital, Helsinki, Finland QUANTIFICATION OF QUALITY OF LIFE DIFFERENCES DUE TO COMMON DISEASES IN THE AGE GROUP 50+ IN THE UNITED KINGDOM 1 2 1 1 1 1 2 Reinders P , Zoellner YF , Wood R , Holbrook T , Piercy J , Adelphi Real World, Bollington, UK, Hamburg University of Applied Sciences, Hamburg, Germany HOW BENEFICIAL IS HRQOL ASSESSMENT IN THE COURSE OF TREATMENT DECISIONS IN PHYSICAL REHABILITATION? RESULTS OF CLINICIANS' PERSPECTIVE Meyer-Moock S, Feng Y, Kohlmann T,University Medicine Greifswald, Greifswald, Germany ICPC-2 EPISODE-BASED HEALTH-RELATED QUALITY OF LIFE AND THREE MONTHS EFFECTIVENESS IN THREE FINNISH PRIMARY HEALTH CARE SETTINGS

1

PHP254 G21

PHP255 G22

PHP256 G23

PHP257 G24

PHP258 G25

PHP259 G26

PHP260 G27

PHP261 G28

PHP262 G29

PHP263 G30 PHP264 G31 PHP265 G32

PHP266 G33

PHP267 G34 PHP269 G36

PHP270 G37

2

2

3

4 1

2

Soini EJ , Heinonen J , Miettola E , Ryynänen O , Koskela T , ESIOR Oy, Kuopio, Finland, School of Medicine, University of 3 Tampere, Finland, Faculty of Health Sciences, University of Eastern Finland, and Unit of Primary Health Care, Kuopio University 4 Hospital, Kuopio, Finland, Department of General Practice, University of Tampere, and Omapihlaja, Pihlajalinna Terveys Oy, Tampere, Finland INVESTIGATING THE PERCEPTIONS OF THE GREEK POPULATION TOWARDS THE EFFICACY AND SAFETY OF GENERIC DRUGS 1 1 1 1 2 1 1 1 1 Charonis A , Balasopoulos T , Naoum P , Mavrikou M , Karokis A , Athanasakis K , Pavi E , Kyriopoulos J , National School of 2 Public Health, Athens, Greece, MSD Greece, Athens, Greece CHANGES IN THE CAPACITY OF NEUROLOGICAL AND PSYCHIATRIC INPATIENT CARE IN HUNGARY BETWEEN 1990 AND 2014 1 1 1 1 2 1 1 1 2 Ágoston I , Endrei D , Molics B , Szarka E , Csákvári T , Gyuró M , Boncz I , University of Pécs, Pécs, Hungary, University of Pécs, Zalaegerszeg, Hungary KNOWLEDGE, ATTITUDE AND PERCEPTION OF ZIKA VIRUS AMONG HEALTHCARE STUDENTS OF MEDICINE, PHARMACY AND DENTISTRY OF AIMST UNIVERSITY 1 1 2 1 3 1 Iqbal MZ , Lokanayagi a/p SS , Rahul R , Sunil Kumar P , Tahir M , AIMST University,, Bedong, Kedah Darul Aman, Malaysia, 2 3 Malaysia, Faculty of Dentistry, AIMST University, Sungai Petani, Malaysia, University of Veterinary and Animal Sciences, Lahore, Pakistan;, Lahore, Pakistan NUMBER OF PATIENTS IN PHYSIOTHERAPY SERVICES WITHIN SPECIALIZED HOME CARE IN HUNGARY BETWEEN 2010 AND 2014 1 2 3 4 5 5 1 1 1 1 Járomi M , Simon-Ugron Á , Mihajlovic I , Rátgéber L , Juhász K , Sebestyén A , Endrei D , Boncz I , Molics B , University of 2 3 Pécs, Pécs, Hungary, Babes-Bolyai University Cluj-Napoc, Cluj-Napoca, Romania, University of Novi Sad, Novi Sad, 4 5 Serbia, Ratgeber Academia, Pécs, Hungary, National Health Insurance Fund Administration, Pécs, Hungary HEALTH RISK OF DRUGS AND ITS IMPACT ON PATIENT ADHERENCE TO MEDICAL TREATMENT Masarykova L, Lehocka L, Olearova A, Snopkova M, Buszekova B,Comenius University in Bratislava, Faculty of Pharmacy, Bratislava, Slovakia TASKS INVOLVED IN PLATELET PRODUCTION AND TRANSFUSION FROM THE U.S. HOSPITAL PERSPECTIVE: TWO PROCESS FRAMEWORKS Prioli KM, Lyons NM, Pizzi LT,Thomas Jefferson University, Philadelphia, PA, USA AUTOMATION OF HOSPITAL MEDICATION DISTRIBUTION SYSTEMS IN THE US 1 1 2 1 1 2 Badawoud EM , Seoane-Vazquez E , Alhamdan HS , Jacobson S , MCPHS University, Boston, MA, USA, King Abdulaziz Medical City, Jeddah, Saudi Arabia ASSESSMENT OF KNOWLEDGE, ATTITUDE AND PRACTICE (KAP) OF PHARMACIST REGARDING ADVERSE DRUG REACTION (ADRS) AND PHARMACOVIGILANCE IN PUBLIC HOSPITALS QUETTA Anwer M, Haq N, Nasim A,University of Balochistan, Quetta, Pakistan PRETESTING AN E-BASED VERSION OF THE OXFORD PARTICIPATION & ACTIVITIES QUESTIONNAIRE (OX-PAQ) 1 1 1 2 1 1 1 1 Kelly L , Dummett S , Dawson J , Churchman D , Fitzpatrick R , Jenkinson C , Morley D , University of Oxford, Oxford, 2 UK, Clinical Outcomes at Oxford University Innovation, Oxford, UK EXPLORING THE SOCIOECONOMIC IMPACT OF POST APPROVAL CHANGE REQUIREMENTS FOR VACCINES Angelis A, Lange A, Kanavos P,London School of Economics and Political Science, London, UK PREVALENCE, PERCEPTION AND REASONS FOR SELF MEDICATION 1 2 1 2 1 2 Jan SU , Gul R , Mustafa G , Shah A , University of Balocistan, Quetta, Pakistan, University of Balochistan, Quetta, Pakistan PRO INSTRUMENTS USED IN STUDIES PUBLISHED SINCE 2005: WHICH POPULATIONS AND DISEASES HAVE HAD THE MOST TOOLS DEVELOPED? Martin A,Crystallise Ltd., London, UK NICE COLLATERAL EFFECT: WHAT IS THE INFLUENCE OF NICE ON OTHER HTA BODIES? 1 1 1 2 1 1 Wijnands T , Kreeftmeijer J , Kooreman PJ , Wagner P , van Engen A , Quintiles Advisory Services, Hoofddorp, The 2 Netherlands, Quintiles Advisory Services, Neu-Isenburg, Germany ADHERENCE TO VANCOMYCIN THERAPEUTIC GUIDELINES AT MINISTRY OF HEALTH HOSPITAL IN SAUDI ARABIA Alomi YA, Almudaiheem HY,Ministry of Health, Riyadh, Saudi Arabia DEXHELPP - AGING POPULATION: ROUTINE DATA BASED ANALYSES OF FRACTURES DUE TO FALLS LESS THAN THREE METERS – HOSPITALIZATION, READMISSION AND MORTALITY 1 2 3 4 1 2 Zauner G , Wilbacher I , Popper N , Breitenecker F , dwh GmbH, Vienna, Austria, Main Association of Austrian Health Security 3 4 Institutions, Vienna, Austria, DEXHELPP, Vienna, Austria, TU Wien, Vienna, Austria ATTRIBUTES DEFINING PATIENT ENGAGEMENT AND CENTEREDNESS IN HEALTH CARE RESEARCH AND PRACTICE: A FRAMEWORK DEVELOPED BY THE ISPOR PATIENT-CENTERED SPECIAL INTEREST GROUP 1 2 2 3 4 5 6 7 8 9 Hanna ML , Oehrlein EM , Perfetto EM , Astratinei V , Berner T , Burke LB , Camp R , Hareendran A , Harrington R , Houÿez F ,

10

11

12

13 1

Patrick DL , Scott A , von Gizycki R , Wheeler R , School of Pharmacy, University of Maryland, Baltimore, MD, 2 3 4 USA, University of Maryland, School of Pharmacy, Baltimore, MD, USA, Melanom Romania, Bucharest, Romania, Baxalta, 5 Bannockburn, IL, USA, Study Endpoints and Labeling Development, ONDIO, CDER, U.S. Food & Drug Administration, Silver 6 7 8 Spring, MD, USA, European Patients' Academy (EUPATI), Barcelona, Spain, Evidera, London, UK, Astellas Medical Affairs 9 10 11 Americas, Northbrook, IL, USA, EURORDIS, Paris, France, University of Washington, Seattle, WA, USA, SEAS Capital 12 13 Partners, Plymouth, MI, USA, Pro Retina Europe, Berllin, Germany, Leber Hereditary Optic Neuropathy, Winchester, UK PHP271 G38 PHARMACOTHERAPY CONSULTATIONS BY CLINICAL PHARMACISTS TO IMPROVE QUALITY AND SAFE USE OF MEDICINES: AN EXPERIENCE FROM TERTIARY CARE TEACHING HOSPITAL Himanshu Patel ., Parthasarathi G ., Madhan R,JSS College of Pharmacy, Mysore, JSS University, Mysore, India PHP272 H1 ADVANCED THERAPIES: WIDENING THE GAP BETWEEN PAYERS AND REGULATORS 1 2 1 1 1 Hanna E , Rémuzat C , Auquier P , Toumi M , Faculté de Médecine, Laboratoire de Santé Publique, Aix-Marseille Université, 2 Marseille, France, Creativ-Ceutical, Paris, France PHP273 H2 MASTERS DEGREES FOR HEALTH ECONOMISTS: INVESTIGATING AND EVALUATING THEIR CONTENT Mildred M,University of Sheffield, Sheffield, UK PHP274 H3 A FRAMEWORK TO GUIDE THE USE OF REAL-WORLD EVIDENCE TO SUPPORT EVALUATION OF RELATIVE EFFECTIVENESS OF NEW MEDICINES 1 2 3 4 5 1 Stegenga H , Chambers M , Jonsson P , Thwaites R , Garner S , National Institute for Health and Care Excellence, London, 2 3 4 UK, MCHCE, London, UK, National Institute for Health and Care Excellence (NICE), Manchester, UK, Takeda, London, 5 UK, National Institute for Health and Care Excellence (NICE), London, UK PHP275 H4 JAPAN HEALTH CARE ACT REFORM: TOWARD DECENTRALIZATION AND INTEGRATED HEALTH CARE SYSTEM 1 2 2 2 1 Toumi M , Fukushima A , Murata K , Onishi Y , Faculté de Médecine, Laboratoire de Santé Publique, Aix-Marseille Université, 2 Marseille, France, Creativ-Ceutical, Tokyo, Japan HEALTH CARE USE & POLICY STUDIES - Health Technology Assessment Programs PHP276 H5

PHP277 H6

PHP278 H7 PHP279 H8

PHP280 H9

PHP281 H10

PHP282 H11 PHP283 H12

PHP284 H13

UNDERSTANDING HEALTH TECHNOLOGY ASSESSMENT (HTA) BODIES IN MAJOR EUROPEAN MARKETS: SYSTEMATIC EVALUATION IN 10 EU COUNTRIES Nanavaty M, Gala S, Nyandege A, Ramesh V, Mwamburi M,Market Access Solutions LLC, Raritan, NJ, USA CONCORDANCE OF HEALTH TECHNOLOGY ASSESSMENT RECOMMENDATIONS OF DIABETES, HEPATITIS, ONCOLOGY AND EPILEPSY PHARMACEUTICAL PRODUCTS BY FIVE AGENCIES WITHIN EUROPE: AN INTERRATER RELIABILITY AND ASSOCIATION ANALYSIS 1 1 1 2 1 Abugri I , Braun D , Manfred E , Gerbsch N , Cardiff University in collaboration with Hochschule Fresenius, Idstein, 2 Germany, Bundesverband der Pharmazeutischen Industrie e.V, Berlin, Germany CADTH’S $50,000 COST-EFFECTIVENESS THRESHOLD: FACT OR FICTION? 1 2 1 2 Griffiths EA , Vadlamudi NK , PAREXEL, London, UK, PAREXEL, Hyderabad, India NON-PARAMETRIC APPROACH TO ESTIMATING EXPECTED VALUE OF PERFECT INFORMATION: THE USEFULNESS OF THIS APPROACH TO A NATIONAL HTA AGENCY 1 2 2 3 1 2 McCullagh LM , Schmitz S , Barry M , Walsh C , Trinity College Dublin, Dublin, Ireland, National Centre for 3 Pharmacoeconomics, Dublin, Ireland, University of Limerick, Limerick, Ireland REVIEW OF THE RECOMMENDATIONS MADE BY THE NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE (NICE) AND THE SCOTTISH MEDICIAL CONSORTIUM (SMC) RELATING TO TREATMENTS FOR RARE DISEASES Garcia Sanchez JJ, Hill CA,MAP BioPharma Limited, Cambridge, UK WHAT ARE THE MOST IMPORTANT DECISION-MAKING CRITERIA FOR INNOVATIVE HEALTH TECHNOLOGY INTEGRATION? A NATIONAL SURVEY FROM FRENCH HOSPITALS DECISION-MAKERS 1 2 3 4 5 6 7 8 9 10 Piazza L , Balayssac D , Bertaux A , Deniès F , Dutheil J , Dutot C , Huot L , Martelli N , Oliveiri V , Poder T , Hayes 1 1 2 3 N , Bordeaux University Hospital, Talence, France, Clermont-Ferrand University Hospital, Clermont-Ferrand, France, Dijon 4 5 6 University Hospital, Dijon, France, Lille University Hospital, Lille, France, Caen University Hospital, Caen, France, Montpellier 7 8 University Hospital, Montpellier, France, Hospices Civils de Lyon, Lyon, France, European Georges Pompidou Hospital, Paris, 9 10 France, Nice University Hospital, Nice, France, CIUSSS de l'Estrie - CHUS, Sherbrooke, QC, Canada NICE’S CRITERIA FOR END-OF-LIFE THERAPIES: IS THERE A FOURTH HURDLE TO OVERCOME? Griffiths EA,PAREXEL, London, UK HEALTH TECHNOLOGY ASSESSMENT IN ARGENTINA: AT WHAT POINT IN THE LIFE-CYCLE OF TECHNOLOGIES ARE THEY REQUESTED Alcaraz A, Hernández-Vásquez A, Calderón M, Augustovski F, Pichon-Riviere A,Institute for Clinical Effectiveness and Health Policy (IECS), Buenos Aires, Argentina MULTI-CRITERIA DECISION ANALYSIS (MCDA): COMMON TOOLS FOR DIFFERENT NEEDS SUPPORTING HEALTHCARE DECISION MAKING IN SPAIN 1 2 3 3 4 4 4 1 Gilabert-Perramon A , Betolaza JI , March JC , Espín J , Merino-Montero S , Gil A , Badia X , Catalan Health Service, 2 3 Government of Catalonia, Barcelona, Spain, Health Department of Basque Government, Vitoria - Gasteiz, Spain, Escuela

4

PHP285 H14 PHP286 H15 PHP287 H16

PHP288 H17

PHP289 H18

PHP290 H19

PHP291 H20 PHP292 H21 PHP293 H22

PHP294 H23

PHP295 H24

PHP296 H25

PHP297 H26 PHP298 H27 PHP299 H28

PHP300 H29

PHP301 H30

PHP302 H31

Andaluza de Salud Pública, Granada, Spain, Omakase Consulting, Barcelona, Spain THE USE OF CONSENSUS TECHNIQUES TO INFORM HEALTH TECHNOLOGY APPRAISALS Gammon A, Legarreta L, Paterson G, Strachan S, Davies J,Hayward Medical Communications, Newmarket, UK PRODUCTS OUTSIDE THE GENERAL REIMBURSEMENT SYSTEMS – A SWEDISH AND NORWEGIAN COMPARISON 1 1 2 1 2 Dibbern T , Corcoran K , Medin E , PAREXEL International, Stockholm, Sweden, Karolinska Institutet, Stockholm, Sweden IS THERE A THRESHOLD IN FRANCE?: FIRST EXHAUSTIVE REVIEW OF PUBLISHED HEALTH-ECONOMIC APPRAISALS BY THE HAUTE AUTORITE DE SANTE (HAS), (FRENCH NATIONAL AUTHORITY FOR HEALTH) Cartier-Bechu C, Gherardi A, Sivignon M, Pignata M, Petitjean A, Monnier R, Roze S,HEVA HEOR Sarl, Lyon, France ISSUES RELATED TO THE FREQUENCY OF EXPLORATORY ANALYSES BY EVIDENCE REVIEW GROUPS IN THE NICE SINGLE TECHNOLOGY APPRAISAL PROCESS 1 1 2 1 1 3 4 1 5 1 Kaltenthaler E , Carroll C , Hill-McManus D , Scope A , Holmes M , Rice S , Rose M , Tappenden P , Woolacott N , University of 2 3 4 Sheffield, Sheffield, UK, Bangor University, Bangor, UK, Newcastle University, Newcastle upon Tyne, UK, Southampton 5 University, Southampton, UK, University of York, York, UK A STUDY COMPARING THE EVOLUTION OF DIFFERENT PROCEESES FOR PATIENT INPUT IN DIFFERENT EUROPEAN HTA SYSTEMS SINCE 2011 Hicks N, Djamiarova R,Commutateur, paris, France REVIEW OF HEALTH TECHNOLOGY ASSESSMENT (HTA) REQUIREMENTS FOR RARE DISEASES ACROSS EUROPEAN COUNTRIES Garcia Sanchez JJ, Sattar S, Hill CA,MAP BioPharma Limited, Cambridge, UK KEY DRIVERS OF HTA DECISIONS FOR “LIFE-CHANGING” DRUGS 1 2 2 1 2 Jaksa A , Peress E , Viana R , Context Matters, New York, NY, USA, Novartis, Basel, Switzerland OVERVIEW OF THE BUDGET IMPACT ANALYSIS OF DRUGS IN HUNGARY AND INTERNATIONALLY 1 2 1 2 Eder B , Nagy B , National Institute of Pharmacy and Nutrition, Budapest, Hungary, ELTE University, Budapest, Hungary UNDERSTANDING HEALTH TECHNOLOGY ASSESSMENT (HTA) BODIES IN MAJOR LATIN-AMERICAN (LATAM) MARKETS: SYSTEMATIC EVALUATION IN 5 LATAM COUNTRIES Nanavaty M, Gala S, Nyandege A, Ramesh V, Mwamburi M,Market Access Solutions LLC, Raritan, NJ, USA MULTI-CRITERIA DECISION ANALYSIS TO EVALUATE THE FEMTOSECOND LASER-ASSISTED CATARACT SURGERY IN CHILDREN 1 1 2 2 1 2 1 Giorgia Tedesco G , Francesco Faggiano F , Buzzonetti L , Petroni S , Di Pinto G , Chessa G , Pietro Derrico P , Matteo 1 1 2 Ritrovato M , Bambino Gesù Children's Hospital, Rome, Italy, Bambino Gesù Children's Hospital, Fiumicino (Roma), Italy RESULTS OF HTA IN BRAZIL: THE PERFORMANCE OF CONITEC IN ITS FIRST FIVE YEARS 1 1 2 1 1 Rabelo RB , Canuto Santos VC , Petramale C , DA Silveira LC , Department of Management and Incorporation of Health Technology, National Committee for Health Technology Incorporation (CONITEC), Brazilian Ministry of Health, Brasília, 2 Brazil, Department of Management and Incorporation of Health Technology, Ministry of Health of Brazil, Brasília, Brazil SWEDISH PERSPECTIVE ON HEALTH TECHNOLOGY ASSESSMENTS WITH INCREMENTALLY LOWER COSTS AND EFFECTS 1 2 2 2 2 3 1 2 Geale K , Geale K , Dibbern T , Virhage M , Medin E , Medin E , Umeå University, Umeå, Sweden, PAREXEL International, 3 Stockholm, Sweden, Karolinska Institutet, Stockholm, Sweden CURRENT AND PREFERRED STATUS ON HTA IMPLEMENTATION: A UKRAINIAN PERSPECTIVE Zalis'ka O, Piniazhko O, Tolubaiev V,Danylo Halytsky Lviv National Medical University, Lviv, Ukraine TOWARDS MORE TRANSPARENT HTA PROCESS IN POLAND – NEW POLISH HTA METHODOLOGICAL GUIDELINES 1 1 2 2 1 2 Lach K , Dziwisz M , Rémuzat C , Toumi M , Creativ-Ceutical, Krakow, Poland, Aix-Marseille University, Marseille, France MARKET ACCESS ROUTES FOR ORPHAN ONCOLOGY DRUGS: HOW DO HEALTH SYSTEMS HELP PATIENTS RECEIVE TREATMENTS THAT ARE NOT COST-EFFECTIVE? 1 2 2 2 1 Chevrou-Severac H , Adkins E , Solaman DA , Ratcliffe M , Takeda Pharmaceuticals International AG, Glattpark-Opfikon, 2 Switzerland, PHMR Ltd, London, UK IS THERE EVIDENCE OF A DIFFERENCE BETWEEN WILLINGNESS TO PAY AND WILLINGNESS TO ACCEPT THRESHOLDS? A REVIEW OF NICE TECHNOLOGY APPRAISALS 1 2 1 2 Minacori R , Geale K , PAREXEL International, London, UK, Umeå University, Umeå, Sweden UNDERSTANDING HEALTH TECHNOLOGY ASSESSMENT (HTA) BODIES IN MAJOR ASIA-PACIFIC (APAC) MARKETS: SYSTEMATIC EVALUATION IN 10 APAC COUNTRIES Nanavaty M, Nyandege A, Gala S, Ramesh V, Mwamburi M,Market Access Solutions LLC, Raritan, NJ, USA SYSTEMATIC REVIEW AND NETWORK META-ANALYSIS (NMA) IN REIMBURSEMENT SUBMISSION; WHAT NICE SAYS VERSUS WHAT NICE WANTS 1 2 1 1 2 Sarri G , Rizzo M , Iheanacho I , Evidea, London, UK, Evidera, London, UK

PHP303 H32 PHP304 H33

FIXED-DOSE COMBINATION DRUGS UNDERGOING AMNOG - LEARNINGS FROM 5 YEARS Froehlich H, Drechsler M,AbbVie Deutschland GmbH & Co. KG, Wiesbaden, Germany PERCEPTION SURVEY ON HEALTH TECHNOLOGY ASSESSMENT IN TURKEY: DOES PRACTICE MEET WITH REGULATIONS 1

PHP305 H34

PHP306 H35 PHP307 H36

PHP309 H38

PHP310 I1

2

3

1

4

5

6

7

8

7

Koselerli R , Caliskan Z , Kuzucu G , Gursoy K , Ergun H , Kaya Y , Turkoglu S , Dereli U , Koksal T , Deger C , Dokuyucu 9 10 1 2 3 O , Saylan M , Turkish Social Security Institution, Ankara, Turkey, Hacettepe University, Ankara, Turkey, Lundbeck Turkey, 4 5 6 Istanbul, Turkey, Ankara University, Ankara, Turkey, Bristol-Myers Squibb, Istanbul, Turkey, Nobel Pharma, Ankara, 7 8 Turkey, Association of Research-Based Pharmaceutical Companies, Istanbul, Turkey, Pharmaceutical manufacturers 9 10 association of Turkey, Ankara, Turkey, AMGEN, Istanbul, Turkey, Bayer AG Turkey, Istanbul, Turkey G-BA EARLY ADVICE VS. EMA/HTA PARALLEL ADVICE FROM A GERMAN PERSPECTIVE 1 2 2 3 1 2 Wiebe K , Schmitter S , Leverkus F , Heathfield A , Pfizer Germany, Berlin, Germany, Pfizer Deutschland GmbH, Berlin, 3 Germany, Pfizer, Surrey, UK GLOBAL EVALUATION OF EUROPEAN SUBMISSION TEMPLATE TO INFORM HTA AND PAYER SUBMISSIONS Tatt ID, Gyldmark M, Correia HC,F.Hoffman-La Roche Ltd, Basel, Switzerland IMPLEMANTATION OF PROCESSES TO ESTABILISHING A HTA UNIT IN CZECH HOSPITAL ENVIROMENT 1 2 2 2 1 2 Zavadil M , Matlonova V , Kubatova I , Rogalewicz V , Motol University Hospital, Prague, Czech Republic, Czech Technical University in Prague, Kladno, Czech Republic “BEST SUPPORTIVE CARE” OR “THERAPY ACCORDING TO PHYSICIAN'S CHOICE” AS APPROPRIATE COMPARATOR FOR GERMAN HTA DOSSIERS – AN UNDERESTIMATED CHANCE OR RISK FOR THE BENEFIT ASSESSMENT? 1 2 2 1 1 2 Eheberg D , Dannemann S , Jakovac M , Bonduelle D , IMS Health, Munich, Germany, IMS Health Germany, Munich, Germany DIFFERENT METHODS, DIFFERENT RESULTS? COMPARING HEALTH TECHNOLOGY ASSESSMENTS IN THE UNITED KINGDOM AND GERMANY Schaefer R, Schlander M,Institute for Innovation & Valuation in Health Care (InnoVal-HC), Wiesbaden, Germany

HEALTH CARE USE & POLICY STUDIES - Patient Registries & Post-Marketing Studies PHP311 I2 PHP312 I3

IMPACT OF POST-INSCRIPTION STUDIES ON REASSESSMENT IN FRANCE: A CASE STUDY ON ORPHAN DRUGS Jubert H, Ouali I, Kolahi C,IMS Health, La Défense, France PATIENT INFORMATION AND CONSENT FORM IN EUROPE: REQUIREMENTS FROM REGULATORY AUTHORITIES FOR PHARMACO-EPIDEMIOLOGICAL STUDIES Baconnier C, Bourhis Y, Logette E, Bugnard F,Mapi, Lyon, France

HEALTH CARE USE & POLICY STUDIES - Population Health PHP313 I4 PHP314 I5

PHP315 I6

THE EFFECT OF PHYSICAL ACTIVITY ON THE MENTAL AND EMOTIONAL STATE OF UNIVERSITY STUDENTS Fónai A, Makai A, Boncz I, Ács P, Molics B, Gyuró M, Járomi M,University of Pécs, Pécs, Hungary SOCIO-ECONOMIC STATUS AND SELF-RATED HEALTH: ARE THEY GOOD PREDICTORS OF INCOME? AN ANALYSIS OF SURVEY PANEL DATA FROM TURKEY 1 2 1 2 Cinaroglu S , Baser O , Hacettepe University, Ankara, Turkey, Columbia University/MEF University/STATinMED Research, New York, NY, USA UNDERSTANDING THE RELATIONSHIP BETWEEN EFFECTIVENESS AND OUTCOME INDICATORS IN HEALTH CARE 1 2 1 2 Cinaroglu S , Baser O , Hacettepe University, Ankara, Turkey, Columbia University/MEF University/STATinMED Research, New York, NY, USA

HEALTH CARE USE & POLICY STUDIES - Prescribing Behavior & Treatment Guidelines PHP316 I7 PHP317 I8

PHP318 I9

INFLUENCE OF MEDICAL REPRESENTATIVES ON PRESCRIBING PRACTICES IN MEKELLE, NORTHERN ETHIOPIA Belay yB,Mekelle University, Mekelle, Ethiopia HOW CAN HEALTHCARE PATHWAYS EXPLAIN POLYPHARMACY IN FRANCE? A LONGITUDINAL ANALYSIS BETWEEN 2011 AND 2014 Louchez A, Perronnin M, Pichetti S, Sermet C,IRDES, Paris, France NATIONAL SURVEY OF DRUG INFORMATION CENTERS PRACTICE IN SAUDI ARABIA: EVIDENCE BASED MEDICINE-THERAPEUTICS GUIDELINES SYSTEM (EBM-TG) AT MOH Alomi YA, Almudaiheem HY, Alsharari A,Ministry of Health, Riyadh, Saudi Arabia

HEALTH CARE USE & POLICY STUDIES - Quality of Care PHP319 I10

IMPLEMENTATION OF MEDICATION ERRORS REPORTING SYSTEM BY CLINICAL PHARMACISTS AT TERTIARY CARE TEACHING HOSPITAL: A PILOT STUDY 1 2 2 1 2 Ramesh M , Parthasarathi G . , Himanshu Patel . , JSS College of Pharmacy, JSS University, Mysore, India, Mysore, India, JSS College of Pharmacy, Mysore, JSS University, Mysore, India

HEALTH CARE USE & POLICY STUDIES - Regulation of Health Care Sector

PHP320 I11

PHP321 I12

PHP322 I13

PHP323 I14

PHP324 I15 PHP325 I16

PHP326 I17

PHP327 I18

PHP328 I19 PHP329 I20

PHP330 I21 PHP331 I22

PHP332 I23

THE EVALUATION OF RELATIONSHIP BETWEEN REGULAR INSPECTION AND COMMITTING MAJOR MALPRACTICE IN PAKDASHT PHARMACIES 1 2 3 1 Sabbagh-Bani-Azad M , Varastehmoradi B , Nikfar S , Tehran University Of Medical Sciences, Faculty of Pharmacy, Tehran, Iran 2 3 (Islamic Republic of), Shahid Beheshti University Of Medical Sciences, Tehran, Iran (Islamic Republic of), Tehran University of Medical Sciences, Faculty of Pharmacy, Tehran, Iran (Islamic Republic of) SUPPLY-SIDE AND DEMAND-SIDE POLICIES FOR BIOSIMILARS: AN OVERVIEW IN 10 EUROPEAN MEMBER STATES 1 2 3 4 4 4 5 1 Rémuzat C , Kapuśniak A , Caban A , Ionescu D , Radière G , Mendoza C , Toumi M , Creativ-Ceutical, Paris, 2 3 4 France, Creativ-Ceutical, Krakow, Poland, Creativ-Ceutical, Cracow, Poland, Sandoz International GmbH, Holzkirchen, 5 Germany, Faculté de Médecine, Laboratoire de Santé Publique, Aix-Marseille Université, Marseille, France FRENCH HEALTH POLICIES: FRONT RUNNER FOR EARLY ACCESS TO INNOVATION 1 1 1 2 1 2 Rémuzat C , Thivolet M , Kornfeld A , Toumi M , Creativ-Ceutical, Paris, France, Faculté de Médecine, Laboratoire de Santé Publique, Aix-Marseille Université, Marseille, France HEALTH CARE SYSTEM INEFFICIENCIES RELATED TO MEDICINES: ANY POTENTIAL ROOM FOR IMPROVEMENT? 1 2 1 2 Rémuzat C , Toumi M , Creativ-Ceutical, Paris, France, Faculté de Médecine, Laboratoire de Santé Publique, Aix-Marseille Université, Marseille, France THE DYNAMIC EVOLUTION OF EXTERNAL PRICE REFERENCING IMPLEMENTATION IN VARIOUS COUNTRIES Fontrier A, Efthymiadou A, Boekstein N, Kanavos P, Gill J,London School of Economics and Political Science, London, UK KEY DRIVERS FOR MARKET PENETRATION OF BIOSIMILARS IN EUROPE 1 1 1 2 2 2 3 1 2 Rémuzat C , Dorey J , Cristeau O , Ionescu D , Radière G , Mendoza C , Toumi M , Creativ-Ceutical, Paris, France, Sandoz 3 International GmbH, Holzkirchen, Germany, Faculté de Médecine, Laboratoire de Santé Publique, Aix-Marseille Université, Marseille, France SETTING RECOMMENDATIONS FOR GOOD PRACTICE OF HEALTH TECHNOLOGY ASSESSMENT IN THE EGYPTIAN MINISTRY OF HEALTH 1 2 3 4 4 4 3 3 5 1 Griffin A , Elsisi G , Ragab S , Ziada R , Aboushady R , Abdelgawad S , Atef M , Khataby N , Ashraf RM , Johnson & Johnson, 2 3 4 High Wycombe, UK, Central Administration for Pharmaceutical Affairs, Cairo, Egypt, Ministry of Health, Cairo, Egypt, Central 5 Administration for Pharmaceutical Affairs, cairo, Egypt, Janssen, Cairo, Egypt A PROSPECTIVE ASSESSMENT OF ATTITUDES AND EXPERIENCES AMONG UROLOGISTS REGARDING OFF LABEL USE OF BCG VACCINE IN SERBIA 1 2 3 1 1 1 Marinkovic V , Bekcic S , Djordjevic J , Tasic L , Stojkovic T , University of Belgrade-Faculty of Pharmacy, Belgrade, 2 3 Serbia, Research and Technology Center, Novi Sad, Serbia, Alvogen d o o, Belgrade, Serbia THE IMPACT OF EXTERNAL PRICE REFERENCING WITHIN AND ACROSS A COUNTRY'S BORDERS Fontrier A, Efthymiadou A, Boekstein N, Kanavos P, Gill J,London School of Economics and Political Science, London, UK OBSTACLES FOR ADOPTION OF VALUE ADDED MEDICINES: CALL FOR POLICY CHANGES FOR VALUE RECOGNITION OF REPURPOSED MEDICINES 1 2 1 2 Rémuzat C , Toumi M , Creativ-Ceutical, Paris, France, Faculté de Médecine, Laboratoire de Santé Publique, Aix-Marseille Université, Marseille, France HOW DO COST-CONTAINMENT MEASURES IMPACT PHARMACEUTICAL INDUSTRY? Zimmermann N, Gombocz M, Vogler S,Gesundheit Österreich GmbH / Austrian Public Health Institute, Vienna, Austria ARE DRUG PROCUREMENT PROCEDURE AND AWARD CRITERIA IN EU HOSPITAL SETTING STANDARDIZED AND DO THEY TAKE INTO ACCOUNTS EFFECTIVE SUPPLY QUALITY? Triulzi I, Trieste L, Turchetti G,Scuola Superiore Sant'Anna, Pisa, Italy REAL WORLD EVIDENCE IN EUROPE: A SNAPSHOT OF ITS CURRENT STATUS Olariu E, Papageorgakopoulou C, Bovens SM, Solaman DA, Fox D,PHMR Ltd, London, UK

HEALTH CARE USE & POLICY STUDIES - Risk Sharing/Performance-Based Agreements PHP333 I24

PHP334 I25 PHP335 I26

PHP336 I27

THE EVOLUTION OF RISK-SHARING AGREEMENTS IN THE PROCESS OF UPDATING THE NATIONAL LIST OF HEALTH SERVICES IN ISRAEL 1 1 1 2 3 2 1 2 Triki N , Ash N , Porath A , Birnbaum Y , Greenberg D , Hammerman A , Maccabi Healthcare Services, Tel-Aviv, Israel, Clalit 3 Health Services, Tel-Aviv, Israel, Ben-Gurion University of the Negev, Beer Sheva, Israel INNOVATIVE CONTRACTING IN SPAIN (2010-2016). GETTING MORE "IN" 1 1 1 2 1 2 Gimenez E , Badia X , Gil A , Espinosa C , Omakase Consulting, Barcelona, Spain, Ferrer, Barcelona, Spain INSIGHTS FROM 6 YEARS' MANAGED ENTRY AGREEMENT EXPERIENCE IN BELGIUM Quanten A, Van de Vijver I, Knappenberg V, Arickx F, De Ridder R,National Institute for Health and Disability Insurance (NIHDI), Brussels, Belgium SUCCESS AND FAILURE OF STRAIGHTFORWARD VERSUS SOPHISTICATED MANAGED ENTRY AGREEMENTS Van de Vijver I, Quanten A, Knappenberg V, Arickx F, De Ridder R,National Institute for Health and Disability Insurance (NIHDI), Brussels, Belgium

PHP337 I28

PHP338 I29

PHP339 I30

PHP340 I31

PHP341 I32 PHP342 I33

PHP343 I34 PHP344 I35

PHP345 I36

PHP346 I37

PHP347 J1

PHP349 J3 PHP350 J4

PHP351 J5

THE QUEV SCORE: A QUANTITATIVE EVALUATION OF THE QUALITY OF CLINICAL EVIDENCE IN HTA 1 2 3 4 1 2 Schmitz S , McCullagh L , Walsh C , Dolan E , Luxembourg Institute of Health, Strassen, Luxembourg, Trinity College, Dublin, 3 4 Ireland, University of Limerick, Limerick, Ireland, Royal College of Surgeons in Ireland, Dublin, Ireland SIMILARITIES AND DIFFERENCES OF RISK SHARING ARRANGEMENTS IN AUSTRALIA, UNITED KINGDOM, ITALY, AND KOREA Kim S, Kim A, Bae S,Ewha Womans University, Seoul, South Korea RISK SHARING AGREEMENTS (RSA): EXPLORATORY ANALYSIS OF THE CURRENT SITUATION IN DEVELOPED AND EMERGING MARKETS Saggia MG,Asigma, Sao Paulo, Brazil MARKET ACCESS AGREEMENTS: WHAT IMPACTS DRUGS PURCHASING IN FRENCH HOSPITALS 1 1 2 1 1 Ceyrac T , Poisson N , Tilleul P , Paubel P , General Agency of Equipment and Health Products (AGEPS), Assistance 2 Publique-Hôpitaux de Paris (AP-HP), Paris, France, Hospital Pitie-Salpetriere, Paris, France MANAGED ENTRY AGREEMENTS: PORTUGUESE EXPERIENCE Gonçalves L, Teixeira M, Caldeira S, Ramos R,INFARMED, I.P., Lisbon, Portugal A RISK-BENEFIT ANALYSIS OF KEY PERFORMANCE-BASED RISK SHARING AGREEMENTS (PBRSAS) IN THE EU AND US (2002-2016) Carroll E, Truglio A,GfK, New York, NY, USA TYPES OF RISK-SHARING SCHEMES PROPOSED IN REIMBURSEMENT APPLICATION RECEIVED BY AOTMIT IN 2015 Pomorski MK, Matusewicz W, Lipińska A,Agency for Health Technology Assessment and Tariff System, Warsaw, Poland CREATING USEFUL AND COMPREHENSIVE DECISION SUPPORT TOOLS FOR SELECTING AND DESIGNING MANAGED ENTRY AGREEMENTS Lucas F,Pope Woodhead & Associates Ltd, St. Ives, UK DEFINING EPISODES OF CARE FOR CHRONIC DISEASES: A TARGETED LITERATURE REVIEW 1 2 3 1 1 Ng DB , Sherman S , Desroziers K , Gooch K , Astellas Pharma Global Development, Inc., Northbrook, IL, 2 3 USA, Creativ-Ceutical, Chicago, IL, USA, Creativ-Ceutical, Paris, France A NEW COVERAGE WITH EVIDENCE DEVELOPMENT DEDICATED TO INNOVATIVE MEDICAL BIOLOGY AND PATHOLOGICAL ANATOMY AND CYTOLOGY PROCEDURES IN FRANCE: OVERVIEW OF THE SITUATION AFTER ONE YEAR OF IMPLEMENTATION AND FOCUS ON INNOVATIVE GENETICS PROCEDURES Sam E, Carbonneil C,French Ministry of Health, General Directorate for Healthcare Provision (DGOS/PF4), Paris, France COUNTRY TRENDS THAT MAY IMPACT THE COMMERCIAL OPPORTUNITY OF NEW HIGH COST TREATMENTS IN THE USA, EU5, JAPAN AND BRAZIL 1 2 1 3 1 2 3 Klebba S , Pacheco L , Czira A , Panciera D , GfK, London, UK, GfK Market Access, London, UK, GfK UK Ltd, London, UK IMPACT OF TRIAL DESIGN ON PRICE DISCOUNTS AFTER EARLY BENEFIT ASSESSMENT (AMNOG) IN GERMANY Theidel U, Löpmeier J, Mittendorf T,Xcenda GmbH, Hannover, Germany POLICIES FOR USE OF REAL-WORLD DATA IN HEALTH TECHNOLOGY ASSESSMENT: A COMPARATIVE STUDY OF 6 HTA AGENCIES 1 2 3 4 2 1 1 Makady A , ten Ham R , de Boer A , Hillege JL , Klungel O , Goettsch W , The National Healthcare Institute (ZIN), Diemen, The 2 3 4 Netherlands, Utrecht University, UTRECHT, The Netherlands, Utrecht University, Utrecht, The Netherlands, University Medical Center Groningen, Groningen, The Netherlands WHAT IS REAL-WORLD DATA?: A REVIEW OF DEFINITIONS BASED ON LITERATURE & STAKEHOLDER INTERVIEWS 1 2 3 4 1 1 Makady A , de Boer A , Hillege JL , Klungel O , Goettsch W , The National Healthcare Institute (ZIN), Diemen, The 2 3 Netherlands, Utrecht University, Utrecht, The Netherlands, University Medical Center Groningen, Groningen, The 4 Netherlands, Utrecht University, UTRECHT, The Netherlands

HEALTH CARE USE & POLICY STUDIES - Conceptual Papers PHP352 J6

PHP353 J7

PHP354 J8

PHP355 J9

THE NICE ACCELERATED ACCESS REVIEW, HOW DOES IT COMPARE TO THE DUTCH CONDITIONAL REIMBURSEMENT PATHWAY? Bovens SM, Solaman DA, Crutwell JR, Adkins E, Ratcliffe M,PHMR Ltd, London, UK COULD AMNOG BECOME IRRELEVANT IN THE 21ST CENTURY? POTENTIAL REDUNDANCIES IN THE AMNOG PROCESS IN THE ERA OF CURATIVE THERAPIES Macaulay R,Parexel Access Consulting, London, UK ROMANIAN CLAW-BACK TAXATION: FROM A FINANCIAL SOLUTION TO A CHALLENGE FOR PATIENTS ACCESS TO DRUGS Radu PC, Chiriac ND, Pravat MA,Roche Romania Srl, Bucharest, Romania GENERATING CONSISTENT AND RELIABLE EVIDENCE ON SURVIVAL ESTIMATES FOR HEALTH TECHNOLOGY ASSESSMENT IN ONCOLOGY AND HAEMATOLOGY

1

PHP356 J10 PHP357 J11

PHP358 J12 PHP359 J13 PHP360 J14 PHP361 J15

PHP362 J16 PHP363 J17 PHP364 J18 PHP365 J19

PHP366 J20 PHP367 J21

PHP368 J22 PHP370 J23

PHP371 J24

PHP372 J25

PHP373 J26

2

3

3

3 1

Grouin J , Rose M , Magrez D , Tehard B , Bardet A , University of Rouen - INSERM 1219 « Population Health », 2 3 Mont-Saint-Aignan, France, Celgene, Paris La Défense Cedex, France, Roche, Boulogne-Billancourt, France ADOPTION OF ONCOLOGY BIOSIMILARS IN EUROPE Grosvenor AS, Saraf S, Vidal Pinheiro A, Vithlani M,Precision for Value, London, UK ACCESS TO NEW HEALTH TECHNOLOGIES IN THE BRAZILIAN HEALTH SYSTEM: DISSEMINATING INFORMATION TO LAW OPERATORS FOR QUALIFYING THE HEALTH DECISIONS 1 2 3 2 1 2 Silva SN , Rabelo RB , Simabuku EM , Canuto Santos VC , Ministry of Health, Brasilia, Brazil, Department of Management and Incorporation of Health Technology, National Committee for Health Technology Incorporation (CONITEC), Brazilian Ministry of 3 Health, Brasília, Brazil, Brazilian Ministry of Health, Brasilia, Brazil THE IMPACT ON ACCESS TO INNOVATIVE DRUGS OF THE FIRST MANAGED ENTRY AGREEMENTS IN ROMANIA Chiriac ND, Radu PC, Pravat MA,Roche Romania Srl, Bucharest, Romania LAUNCHING NOVEL ANTIBIOTICS: ACCESS OPPORTUNITIES AND RESISTANCE IN EUROPEAN MARKETS 1 2 2 1 2 Hakim P , Gilbane A , Schlegel R , Navigant Consulting Inc, London, UK, Navigant Consulting Inc., London, UK MACRO-ECONOMIC CONSIDERATIONS IN HEALTHCARE DECISION MAKING 1 2 1 2 Eggleston A , Caputo J , E.K.K.A. Health Care Consulting, Sydney, Australia, ESSEC Asia-Pacific, Singapore, Singapore THE USE OF THE APPRAISAL OF GUIDELINES FOR RESEARCH AND EVALUATION II (AGREE II) TOOL FOR APPRAISAL OF MULTIPLE MYELOMA TREATMENT GUIDELINES Orzel K, Strzelec E, Pelczarska A, Zawada A, Matusewicz W,The Agency for Health Technology Assessment and Tariff System, Warsaw, Poland STANDARDISATION AND COMPATIBILITY BETWEEN HTA NETWORKS: WHAT IMPACTS ON QUALITY? Pacheco L,GfK Market Access, London, UK CHALLENGES FOR HTA SUBMISSIONS CONCERNING CONDITIONS LACKING ESTABLISHED TREATMENT PATHWAYS Adkins E, Fountain DL, Bovens SM,PHMR Ltd, London, UK THE EVALUATION OF INNOVATIVE DRUGS APPLYING BUSINESS VALUATION CONCEPTS 1 2 1 2 Nuijten MJ , Vis J , A2M, Amsterdam, The Netherlands, Talanton, Amsterdam, The Netherlands UNLOCKING ESTABLISHED PRODUCTS PATIENT AND SOCIETAL VALUE IN ADDITIONAL INDICATIONS 1 1 2 3 3 4 5 6 7 8 Nayroles G , Gabriel S , Toumi M , Kornfeld A , Frybourg S , Antonanzas F , Espin J , Jommi C , de Pouvourville G , Tolley K , 9 1 2 3 Wasem J , IPSEN Pharma, Boulogne-Billancourt, France, Aix-Marseille University, Marseille, France, Creativ-Ceutical, Paris, 4 5 6 France, University of La Rioja, Logroño, Spain, Andalusian School of Public Health, Granada, Spain, Cergas, Bocconi 7 8 9 University, Milano, Italy, ESSEC Business School, Cergy-Pontoise, France, Tolley Health Economics, Buxton, UK, University Duisburg-Essen, Essen, Germany PHARMACEUTICAL TRACKING SYSTEM: AN IMPROVEMENT IN DATA ACCURACY AND USES Afify Y,Ministry of Health, Cairo, Egypt MAPPING OF THE BIOSIMILAR DRUG POLICY IN 10 CENTRAL EASTERN EUROPEAN COUNTRIES 1 1 2 3 4 5 6 7 8 9 10 Inotai A , Csanadi M , Petrova G , Bochenek T , Tesar T , York K , Fuksa L , Kostyuk A , Araja D , Lorenzovici L , Egyed K , Kaló 11 1 2 3 Z , Syreon Research Institute, Budapest, Hungary, Medical University-Sofia, Faculty of Pharmacy, Sofia, Bulgaria, Faculty of 4 Health Sciences, Jagiellonian University Medical College, Krakow, Poland, Department of Organisation and Management in 5 6 Pharmacy, Faculty of Pharmacy, Comenius University, Bratislava, Slovakia, Independent, Innsbruck, Austria, Department of 7 Social and Clinical Pharmacy, Faculty of Pharmacy, Charles University in Prague, Hradec Králové, Czech Republic, Kazakh 8 9 Agency for Health Technology Assessment, Astana, Kazakhstan, Riga Stradins University, Riga, Latvia, Syreon Research 10 11 Romania, Tirgu Mures, Romania, Egis Pharmaceuticals, Budapest, Hungary, Eötvös Loránd University (ELTE), Budapest, Hungary BEYOND RISK-BASED VACCINATION POLICIES - A LIFE-COURSE APPROACH TO VACCINATION 1 2 1 2 1 2 Lach K , Jaroslawski S , Pisarczyk K , Toumi M , Creativ-Ceutical, Krakow, Poland, Aix-Marseille University, Marseille, France BALANCING COMMERCIAL CONFIDENTIALITY WITH ACCOUNTABILITY: A PROPOSAL FOR ENHANCED DISCLOSURE OF COST-EFFECTIVENESS DECISIONS O'Mahony JF,Trinity College Dublin, Dublin, Ireland LEGISLATIVE FRAMEWORK FOR REIMBURSEMENT CONDITIONS FOR GENE THERAPIES 1 2 2 1 2 Ligri D , Kani C , Souliotis K , Aristotle University of Thessaloniki, Thessaloniki, Greece, University of Peloponnese, Corinth, Greece MANAGED ACCESS AGREEMENTS: A NEW MODEL PATHWAY FOR THE REIMBURSEMENT OF NON-ONCOLOGY DRUGS IN ENGLAND APPROVED UNDER EUROPEAN ADAPTIVE PATHWAYS? Macaulay R,Parexel Access Consulting, London, UK USING SOCIAL FINANCE TO FUND GENERIC DRUG REPURPOSING FOR RARE DISEASES: A SOCIAL IMPACT BOND PROOF OF CONCEPT 1 2 3 3 1 1 1 2 Thompson RS , Potter J , Griffiths A , Eljamel S , Raffai F , Sireau NT , Findacure, Cambridge, UK, Numbers for Good, London,

3

PHP374 J27

PHP375 J28

PHP376 J29

PHP377 J30 PHP378 J31

PHP380 J32 PHP381 J33

PHP382 J34

PHP383 J35

PHP384 J36 PHP385 J37

PHP386 K1 PHP387 K2

PHP388 K3

PHP389 K4

UK, Costello Medical Consulting Ltd, Cambridge, UK STRATEGIC CONSIDERATIONS TO ENGAGE IN EARLY ADVICE WITH EUROPEAN HEALTH TECHNOLOGY ASSESSMENT BODIES 1 1 1 2 1 2 Rémuzat C , Kornfeld A , Thivolet M , Toumi M , Creativ-Ceutical, Paris, France, Faculté de Médecine, Laboratoire de Santé Publique, Aix-Marseille Université, Université de la Méditerranée, Marseille, France EUROPEAN REGULATORS AND PAYERS INITIATIVES FOR DRUG ACCESS: COLLABORATIONS OR DIVERGENCES? 1 1 2 3 1 2 Rémuzat C , Kornfeld A , Falissard B , Toumi M , Creativ-Ceutical, Paris, France, INSERM Unit U669 (Public Health and Mental 3 Health), University Paris-Sud, Maison de Solenn, Paris, France, Faculté de Médecine, Laboratoire de Santé Publique, Aix-Marseille Université, Marseille, France COULD EUROPEAN REGULATORS CONTRIBUTE TO DRUG BUDGET CONTAINMENT? 1 1 2 3 1 2 Rémuzat C , Thivolet M , Falissard B , Toumi M , Creativ-Ceutical, Paris, France, INSERM Unit U669 (Public Health and Mental 3 Health), University Paris-Sud, Maison de Solenn, Paris, France, Faculté de Médecine, Laboratoire de Santé Publique, Aix-Marseille Université, Marseille, France COMPARATIVE ANALYSIS OF THE GUIDELINES FOR CONDUCTING HTA IN POLAND AND BULGARIA Benisheva T, Trendafilova PD, Sidjimova DA, Vodenitcharov TV,Medical University-Sofia, Sofia, Bulgaria GETTING MEDICAL INNOVATION TO PATIENTS IN DEVELOPING COUNTRIES - A SYSTEMIC APPROACH TO SETTING PRICE AND ACCESS Shankar R,IMS Consulting Group, Cambridge, UK STRUCTURE OF HTA NETWORKS FROM THE PERSPECTIVE OF NETWORK ECONOMICS Pacheco L,GfK Market Access, London, UK TOWARD A NEW BUSINESS MODEL FOR BIOSIMILARS 1 1 2 3 1 2 3 Rémuzat C , Kornfeld M , Caban A , Toumi M , Creativ-Ceutical, Paris, France, Creativ-Ceutical, Cracow, Poland, Faculté de Médecine Laboratoire de Santé Publique, Aix-Marseille Université, Université de la Méditerranée, Marseille Cedex, France, Marseille, France CHANGE MANAGEMENT OF POLYPHARMACY AND ADHERENCE: THE EXPERIENCE OF EU SIMPATHY PROGRAM 1 1 1 1 1 1 1 2 3 Geitona M , Balasopoulou A , Latsou D , Kousoulakou H , Vontetsianos T , Kampolis C , Gennimata D , Michael N , McKenzie D , 2 1 2 3 Mair A , University of Peloponnese, Corinth, Greece, SCOTTISH GOVERNMENT, Edinburgh, UK, Kite Innovation, Edinburgh, UK ADAPTIVE REIMBURSEMENT MODEL: HOW TO CORRELATE THE PRICE TO THE LEVEL OF EVIDENCES DURING THE ENTIRE DRUG LIFE CYCLE 1 1 2 3 1 2 3 Deroo V , Giuliani G , Era S , Dotti MC , Roche Spa, Monza, Italy, Roche Spa, Monza (MB), Italy, Roche, Monza, Italy THE CHALLENGE OF CRITICAL MASS TO BE OVERCOME BY INTERNATIONAL HTA NETWORKS Pacheco L,GfK Market Access, London, UK ETHICAL AND TECHNOLOGICAL EVALUATION OF SECURITY OF CONNECTED OBJECTS AND HEALTH APPLICATIONS: HOW TO MOVE TOWARDS CERTIFICATION Allaert F,Medical evaluation Chair ESC Dijon, Dijon, France WIDENING ENGAGEMENT WITH HTA THOUGH OPEN ONLINE LEARNING Beecroft CA, Hock E,University of Sheffield, Sheffield, UK PUBLIC CONSULTATION AS A TOOL FOR PATIENT AND PUBLIC INVOLVEMENT IN THE BRAZILIAN HTA PROCESS 1 2 3 4 1 2 Silva AS , Rabelo RB , Canuto Santos VC , Petramale C , Brazilian Ministry of Health, Brasilia, Brazil, Ministry of Health, Brasilia, 3 Brazil, Department of Management and Incorporation of Health Technology, National Committee for Health Technology 4 Incorporation (CONITEC), Brazilian Ministry of Health, Brasília, Brazil, Department of Management and Incorporation of Health Technology, Ministry of Health of Brazil, Brasília, Brazil THE IMPORTANCE OF CONITEC RECOMMENDATION ABOUT ANALOGUES INSULINS OF THE TREATMENT OF DIABETES TYPE 1 1 1 2 3 1 2 Simabuku EM , Silva SN , Santos VC , Petramale C , Brazilian Ministry of Health, Brasilia, Brazil, Department of Management and Incorporation of Health Technology, National Committee for Health Technology Incorporation (CONITEC), Brazilian Ministry of 3 Health, Brasília, Brazil, Department of Management and Incorporation of Health Technology, Ministry of Health of Brazil, Brasília, Brazil THE EUROPEAN SOCIAL PREFERENCE MEASUREMENT (ESPM) STUDY: CONCEPTUAL CONSIDERATIONS AND IMPLEMENTATION 1 2 3 4 5 6 7 8 9 Schlander M , Telser H , Holm S , Marshall DA , Nord E , Richardson J , Garattini S , Kolominsky-Rabas P , Persson U , Postma 10 11 12 13 14 1 MJ , Simoens S , de Sola-Morales O , Tolley K , Toumi M , Institute for Innovation & Valuation in Health Care (InnoVal-HC), 2 3 4 Wiesbaden, Germany, Polynomics AG, Olten, Switzerland, University of Manchester, Manchester, UK, Alberta Bone and Joint 5 6 Health Institute, Calgary, AB, Canada, Norwegian Institute of Public Health, Oslo, Norway, Monash University, Clayton, Victoria, 7 8 Australia, Mario Negri Institute for Pharmacological Research, Milano, Italy, Interdisciplinary Centre for Health Technology Assessment and Public Health (IZPH), Friedrich-Alexander-University of Erlangen-Nürnberg; National Leading-Edge Cluster

9

PHP390 K5

Medical Technologies ‘Medical Valley EMN’, Erlangen, Germany, The Swedish Institute for Health Economics (IHE), Lund, 10 11 12 Sweden, University of Groningen, Groningen, The Netherlands, KU Leuven, Leuven, Belgium, Health Innovation Technology 13 14 Transfer, Barcelona, Spain, Tolley Health Economics Ltd., Buxton, UK, University Claude Bernard Lyon 1, Lyon, France INCREASING EFFICIENCY OF PRICING AND MARKET ACCESS DECISIONS BY CROSS FUNCTIONAL INTERACTIONS Mukku S, Edathodu A,Access Infinity Ltd, London, UK

DISEASE- SPECIFIC STUDIES GASTROINTESTINAL DISORDERS - Clinical Outcomes Studies PGI1 K6

PGI2 K7

PGI3 K8

PGI4 K9

PGI5 K10

PGI6 K11

PGI7 K12

PGI8 K13

PGI9 K14

UNSPECIFIED INTESTINAL MALABSORPTION ASSOCIATED WITH ANGIOTENSIN RECEPTOR BLOCKER THERAPY: RESULTS FROM A NATIONWIDE, POPULATION-BASED STUDY IN ITALY AND GERMANY 1 1 2 1 2 Ripellino C , Cataldo N , Scarpignato C , IMS Health, Milan, Italy, University of Parma, Parma, Italy DOSE ESCALATION OF BIOLOGICS IN CROHN’S DISEASE: SUMMARY OF OBSERVATIONAL STUDIES IN THE UK 1 2 3 4 4 1 2 Worbes-Cerezo M , Lee XY , Lelli F , Bereza BG , Einarson TR , Janssen-Cilag UK, High Wycombe, UK, Janssen-Cilag A/S, 3 4 Birkerød, Denmark, Janssen-Cilag SpA, Cologno Monzese (MI), Italy, University of Toronto, Toronto, ON, Canada EFFECTIVENESS OF ANTIVIRAL THERAPY FOR GENOTYPE 1 CHRONIC HEPATITIS C IN REAL-WORLD PATIENTS FROM THE VALENCIAN COMMUNITY (SPAIN) 1 2 2 2 1 1 Buigues-Pastor L , Ventura-Cerdá JM , Lacruz-Gimeno P , Saurí-Ferrer MI , Vivas-Consuelo D , Universitat Politècnica de 2 València (UPV), Valencia, Spain, General Directorate for Pharmacy and Healthcare Products, Valencia, Spain HBSAG SEROCLEARANCE AFTER TREATMENT-INDUCED HBEAG SEROCLEARANCE IN CHRONIC HEPATITIS B PATIENTS IN BEIJING, CHINA 1 1 2 2 1 2 1 1 Wang L , Cheng K , Duan Z , Chen Y , Zhao X , Xu M , Wang Y , Chinese Academy of Medical Sciences, Peking Union Medical 2 College, Beijing, China, Beijing You’ an Hospital of Capital Medical University, Beijing, China REAL-WORLD TREATMENT PATTERNS WITH ANTI-TUMOR NECROSIS FACTOR THERAPY IN INFLAMMATORY BOWEL DISEASE IN ISRAEL 1 2 3 4 2 1 2 Weil C , Chodick G , Yarden A , Khalid JM , Shalev V , Maccabi Healthcare Services, Tel Aviv, Israel, Maccabi Healthcare Services 3 4 and Tel Aviv University, Tel Aviv, Israel, Takeda Israel Ltd., Petach Tikva, Israel, Takeda Development Centre Europe Ltd, London, UK A COHORT STUDY TO ACCESS THE IMPACT OF PAEDIATRIC USE OF PROTON POMP INHIBITOR ON THE RISK OF COMMUNITY ACQUIRED INFECTIONS – UTOPIE 1 2 1 1 2 Luu M , LE Ray I , Bardou M , Centre Hospitalier Universitaire Le Bocage, Dijon, France, CHU Strasbourg, Strasbourg, France HCV: ESTIMATION OF THE NUMBER OF DIAGNOSED PATIENTS ELIGIBLE TO NEW ANTI-HCV THERAPIES IN ITALY 1 1 1 2 3 4 1 2 Gardini I , Bartoli M , Conforti M , Mennini FS , Marcellusi A , Lanati EP , EpaC Onlus, Vimercate (MB), Italy, University of Rome 3 Tor Vergata, Rome, Italy, Faculty of Economics, Centre for Economic and International Studies (CEIS)-Economic Evaluation and 4 HTA (EEHTA), University of Rome Tor Vergata, Rome, Italy, MA Provider Srl, Milano, Italy RATE AND HEALTHCARE UTILIZATION (LOS AND COSTS) OF ADHESION RELATED COMPLICATIONS AFTER COLON RESECTION PROCEDURES 1 2 3 1 1 2 Etter K , Sutton N , Wei D , Yoo A , Johnson & Johnson Co., New Brunswick, NJ, USA, Johnson & Johnson Medical Devices, 3 Somerville, NJ, USA, Johnson & Johnson Co., Raleigh, NC, USA RATE AND HEALTHCARE UTILIZATION (LOS AND COSTS) OF ADHESION RELATED COMPLICATIONS AFTER LIVER RESECTION SURGERY 1 2 3 1 1 2 Etter K , Sutton N , Wei D , Yoo A , Johnson & Johnson Co., New Brunswick, NJ, USA, Johnson & Johnson Medical Devices, 3 Somerville, NJ, USA, Johnson & Johnson Co., Raleigh, NC, USA

GASTROINTESTINAL DISORDERS - Cost Studies PGI10 K15 THE IMPACT OF RIFAXIMIN-A ON NON-ELECTIVE HOSPITAL ADMISSION AND ATTENDANCE COSTS IN UK PATIENTS WITH HEPATIC ENCEPHALOPATHY 1 2 2 1 2 Hudson M , Whitehouse JT , Di Maggio P , Freeman Hospital, Newcastle upon Tyne, UK, Norgine, Uxbridge, UK PGI11 K16 ECONOMIC BURDEN OF HOSPITALIZATION FOR HEPATIC ENCEPHALOPATHY IN FRANCE: AN ANALYSIS OF COST DISCRIMINATING FACTORS BY PATIENT PROFILE 1 1 2 3 4 5 6 7 1 2 Amaz C , Blein C , Benamouzig R , Bureau C , Hagege H , Leurs I , Ribot-mariotte E , Abergel A , HEVA, Lyon, France, AP-HP, 3 4 Bobigny, France, CHU de Toulouse, Toulouse cedex 9, France, Centre Hospitalier Intercommunal de Créteil, CRETEIL, 5 6 7 France, Norgine, RUEIL MALMAISON, France, ALFA WASSERMANN, Levallois-Perret, France, CHU de Clermont Ferrand, Clermont-Ferrand, France PGI12 K17 HEPATITIS C TREATMENT WITH FIRST-GENERATION PROTEASE INHIBITORS IN A REAL-WORLD COHORT: RISK-BENEFIT PROFILE AND COSTS OF THE THERAPY 1 1 1 1 2 2 2 3 1 1 1 Cacciola I , Giardina C , Sirna V , Macrì R , D'Ausilio A , Aiello A , Latorre E , Toumi M , Filomia R , Raimondo G , Arcoraci V , 4 1 2 3 Caputi AP , University Hospital "G. Martino", University of Messina, Messina, Italy, Creativ Ceutical, Milan, Italy, Faculté de 4 Médecine, Laboratoire de Santé Publique, Aix-Marseille Université, Université de la Méditerranée, Marseille, France, University of Messina, Messina, Italy

PGI13 K18 HOSPITALIZATION COSTS ASSOCIATED WITH CROHN'S DISEASE AND ULCERATIVE COLITIS IN BELGIUM Chevalier P, Lamotte M,IMS Health, Zaventem, Belgium PGI14 K19 THE IMPACT OF INFLAMMATORY BOWEL DISEASE ON WORK PRODUCTIVITY: COMPARISON OF A REAL-WORLD SAMPLE OF PATIENTS WITH CROHN'S DISEASE AND ULCERATIVE COLITIS 1 2 1 1 1 1 1 1 1 Katz Avitan A , Schwartz D , Greenberg D , Friger M , Vardy H , Sarid O , Slonim-Nevo V , Odes S , Ben-Gurion University of the 2 Negev, Beer-Sheva, Israel, Soroka Medical Center, Beer-Sheva, Israel PGI15 K20 ORAL VERSUS INTRAVENOUS IRON TREATMENT IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE AND IRON DEFICIENCY AND/OR ANEMIA IN GERMANY 1 2 3 2 4 3 4 3 2 5 1 Stein J , Haas J , Ong SH , Borchert K , Hardt T , Lechat E , Nip KT , Foerster D , Braun S , Baumgart DC , Interdisciplinary Crohn Colitis Centre Rhein-Main and Gastroenterology & Clinical Nutrition, Krankenhaus Sachsenhausen, Teaching Hospital of the J.W. 2 3 4 Goethe University, Frankfurt, Germany, Xcenda GmbH, Hannover, Germany, Vifor Pharma Ltd., Glattbrugg, Switzerland, Vifor 5 Pharma Deutschland GmbH, München, Germany, Inflammatory Bowel Disease Center, Department of Gastroenterology and Hepatology, Charité Medical School, Humboldt-University of Berlin, Berlin, Germany PGI16 K21 5 YEAR AND LONG-TERM BUDGET IMPACT ANALYSIS OF NEW HEPATITIS C THERAPIES FROM A PAYER PERSPECTIVE IN SWITZERLAND Schnyder A,Zürcher Hochschule für Angewandte Wissenschaften, Winterthur, Switzerland PGI17 K22 COST PER RESPONSE/REMISSION ACROSS BIOLOGICS FOR THE TREATMENT OF BIOLOGIC NAÏVE PATIENTS WITH MODERATE-TO-SEVERE ULCERATIVE COLITIS FROM THE ITALIAN HEALTHCARE PROVIDER PERSPECTIVE 1 2 2 1 2 Azzabi Zouraq I , Fioravanti L , Vernia M , Takeda Pharmaceuticals International AG, Zurich, Switzerland, Takeda Italia S.p.A., Roma, Italy PGI18 K23 HEALTH-ECONOMIC EVALUATION OF OMBITASVIR/PARITAPREVIR/RITONAVIR AND DASABUVIR FOR TREATMENT OF CHRONIC GENOTYPE 1 HCV INFECTION IN GERMANY 1 1 2 1 3 4 5 6 7 1 Sroczynski G , Conrads-Frank A , Kühne F , Mühlberger N , Fröhlich H , Dietz B , Samp JC , Zeuzem S , Siebert U , UMIT University for Health Sciences, Medical Informatics and Technology, Institute of Public Health, Medical Decision Making and Health 2 3 Technology Assessment, Hall i.T., Austria, UMIT, Hall i.T., Austria, AbbVie Deutschland GmbH & Co. KG, Wiesbaden, 4 5 6 Germany, AbbVie Deutschland GmbH & Co. KG, Ludwigshafen, Germany, AbbVie Inc, North Chicago, IL, USA, University 7 Hospital Frankfurt, Frankfurt, Germany, UMIT - University for Health Sciences, Medical Informatics and Technology, Hall i.T., Austria PGI19 K24 COST-EFFECTIVENESS OF PARITAPREVIR/ROTANAVIR/OMBITASVIR WITH OR WITHOUT DASABUVIR IN IRELAND 1 1 2 1 1 2 Baj R , Kavanagh J , Egan KM , McKinley C , AbbVie Ltd., Dublin 24, Ireland, AbbVie Ltd., Dublin, Ireland PGI20 K25 COST-EFFECTIVENESS OF ENDOSCOPIC TREATMENT WITH RADIOFREQUENCY ABLATION FOR PATIENTS WITH BARRETT'S ESOPHAGUS AND HIGH OR LOW GRADE DYSPLASIA IN SPAIN 1 2 3 4 4 5 5 1 Esteban JM , González Carro P , Gornals J , Collados C , Álvarez M , Pérez-Mitru A , Serip S , Hospital Clínico San Carlos, 2 3 Madrid, Spain, La Mancha-Centro Hospital Complex, Alcázar de San Juan, Spain, Hospital Universitari de Bellvitge, Barcelona, 4 5 Spain, Medtronic Ibérica, S.A., Madrid, Spain, Oblikue Consulting, Barcelona, Spain PGI21 K26 COST EFFECTIVENESS ANALYSIS OF SOFOSBUVIR AND LEDIPASVIR/SOFOSBUVIR IN HEPATITIS C VIRUS (HCV) PATIENTS 1 1 2 1 Ruggeri M , Romano F , Cicchetti A , ALTEMS, Università Cattolica del Sacro Cuore (UCSC), Postgraduate School of Health 2 Economics and Management, Rome, Italy, Catholic University of Sacred Heart, Rome, Italy PGI22 K27 COST-EFFECTIVENESS ANALYSIS OF FIDAXOMICIN VERSUS ORAL VANCOMYCIN FOR THE TREATMENT OF CLOSTRIDIUM DIFFICILE INFECTION IN EGYPT Hossam M, Elsisi G,Central Administration for Pharmaceutical Affairs (CAPA), Ministry of Health and Population, Cairo, Egypt PGI24 K29 COST-EFFECTIVENESS ANALYSIS OF RIFAXIMIN-Α ADMINISTRATION FOR THE REDUCTION OF THE OVERT HEPATIC ENCEPHALOPATHY EPISODES IN RECURRENCE IN FRANCE Kabeshova A, Launois R,REES France, Paris, France GASTROINTESTINAL DISORDERS - Patient-Reported Outcomes & Patient Preference Studies PGI25 K30 UTILITIES ASSOCIATED WITH THE NUMBER OF DAYS ON PARENTERAL SUPPORT IN THE TREATMENT OF SHORT BOWEL SYNDROME 1 1 2 3 1 2 Ballinger RS , Macey J , Lloyd AJ , Brazier JE , ICON Clinical Research UK Ltd, Abingdon, UK, Bladon Associates, Oxford, 3 UK, University of Sheffield, Sheffield, UK PGI26 K31 MAPPING OF THE GASTROINTESTINAL SHORT FORM QUESTIONNAIRE (GSFQ) INTO SF-6D AND EQ-5D IN SPANISH POPULATION 1 1 2 3 1 2 3 Monroy M , Ruiz MA , Rejas J , Soto J , Universidad Autónoma de Madrid, Madrid, Spain, Pfizer, Alcobendas, Spain, Pfizer Spain SLU, Madrid, Spain PGI27 K32 THE BURDEN OF INFLAMMATORY BOWEL DISEASE(IBD) IN JAPAN 1 1 2 3 1 2 Yamabe K , Kuwabara H , Umareddy I , Flores NM , Takeda Pharmaceutical Company Ltd., Tokyo, Japan, Kantar Health, 3 Singapore, Singapore, Kantar Health, Foster City, CA, USA PGI28 K33 JOINTLY MODELING SURVIVAL AND EQ-5D DATA TO ESTIMATE HEALTH UTILITIES FOR HER2+ METASTATIC GASTRIC

CANCER 1 2 3 1 2 3 Paracha N , Thuresson P , Ray J , F. Hoffman-La Roche, Basel, Switzerland, F. Hoffmann-La Roche Ltd., Basel, Switzerland, F. Hoffmann-La Roche, Basel, Switzerland PGI29 K34 THE IMPACT OF DIFFERENT GASTROINTESTINAL SYMPTOMS ON THE WELL-BEING OF AFFECTED PATIENTS - UTILITY WEIGHTS FOR THE GASTROINTESTINAL SYMPTOM SCORE (GIS) Mühlbacher AC, Kaczynski A,Hochschule Neubrandenburg, Neubrandenburg, Germany PGI30 K35 A SYSTEMATIC REVIEW OF THE SF-36® HEALTH SURVEY FOR MEASURING HEALTH-RELATED QUALITY OF LIFE IN PATIENTS WITH ULCERATIVE COLITIS 1 1 2 1 2 3 4 2 1 Yarlas A , Bayliss M , Cappelleri JC , Maher SM , Bushmakin AG , Chen LA , Manuchehri A , Healey P , Optum, Lincoln, RI, 2 3 4 USA, Pfizer Inc, Groton, CT, USA, New York University, New York, NY, USA, Pfizer Ltd, Tadworth, UK PGI31 K36 THE HUMANISTIC AND ECONOMIC BURDEN OF IRRITABLE BOWEL SYNDROME WITH DIARRHOEA (IBS-D) BY DISEASE SEVERITY AMONG PATIENTS IN THE EU5 REGION 1 2 3 3 4 1 2 Flores NM , Tucker C , Carson RT , Abel JL , Liebert R , Kantar Health, Foster City, CA, USA, Allergan plc, Marlow, 3 4 Buckinghamshire, UK, Allergan plc, Jersey City, NJ, USA, Kantar Health, New York, NY, USA GASTROINTESTINAL DISORDERS - Health Care Use & Policy Studies PGI32 K37 BIOLOGICS USE IN CROHN’S DISEASE IN FRANCE 1 2 3 4 5 1 2 Gaudry J , Morand F , Willemin L , Lee XY , Lelli F , IMS Health, Boulogne-Billancourt, France, IMS Health, Paris La Défense, 3 4 5 France, Janssen-Cilag, Issy-les-Moulineaux, France, Janssen-Cilag A/S, Birkerød, Denmark, Janssen-Cilag SpA, Cologno Monzese (MI), Italy PGI33 L1 HCV: TREAT RATIO AND GOVERNANCE FOOTPRINTS. ANALYSIS OF REGIONAL DIFFERENCES IN ITALY Lanati EP, Pizzi A, Marcelli A,MA Provider Srl, Milano, Italy PGI34 L2 MARKET ACCESS CHALLENGES OF DRUGS FOR CHRONIC HEPATITIS C: A THEMATIC ANALYSIS OF HEALTH TECHNOLOGY ASSESSMENTS Akesson C, Quinn C,PRMA Consulting, Fleet, UK PGI35 L3 ASSESSMENT OF PROTON PUMP INHIBITORS CONSUMPTION IN UKRAINE IN COMPARISON WITH OTHER COUNTRIES OF THE WORLD Iakovlieva L, Gerasymova O, Mishchenko O, Bezditko N, Tkachova O, Kyrychenko O, Matyashova N,National University of Pharmacy, Kharkiv, Ukraine PGI36 L4 REAL WORLD USE OF BIOLOGICS THERPIES FOR PATIENTS WITH ULCERATIVE COLITIS IN JAPAN Kuwabara H, Yamabe K,Takeda Pharmaceutical Company Ltd., Tokyo, Japan PGI37 L5 THE BENEFITS OF EARLIER TREATMENT WITH PARITAPREVIR/ROTANAVIR/OMBITASVIR WITH OR WITHOUT DASABUVIR IN IRELAND Baj R, Kavanagh J, O'Meara M, McKinley C,AbbVie Ltd., Dublin 24, Ireland PGI38 L6 HEALTHCARE COSTS OF INFLAMMATORY BOWEL DISEASE IN THE BIOLOGIC ERA: A STUDY OF 2,451 PATIENTS WITH TWELVE YEARS FOLLOW-UP EVALUATION 1 2 2 3 2 2 2 2 1 Odes S , Vardi H , Greenberg D , Schwartz D , Friger M , Chernin E , Sarid O , Slonim-Nevo V , Ben-Gurion University of the 2 3 Negev, Beer Sheva, Israel, Ben-Gurion University of the Negev, Beer-Sheva, Israel, Soroka Medical Center, Beer-Sheva, Israel PGI39 L7 A QUALITATIVE COMPARISON OF GERMAN AND UK HEALTH TECHNOLOGY ASSESSMENTS: VEDOLIZUMAB CASE STUDY Krieger T,RTI Health Solutions, Manchester, UK URINARY/KIDNEY DISORDERS - Clinical Outcomes Studies PUK1 L8

COST-OUTCOME ANALYSIS OF DIFFERENT INTRAVENOUS IRON SUCROSE PREPARATIONS IN HEMODIALYSIS PATIENTS Bourdoncle M, Sémély D, Porteils C, Oses S, Pagès A, Labadens I, Parmier M, Juillart-Condat B, Del Bello A,Toulouse University Hospital Center, TOULOUSE, France PUK2 L9 USE OF ANTIHYPERTENSIVE MEDICATIONS IN DIABETIC AND NON-DIABETIC CHRONIC KIDNEY DISEASE AND HEMODIALYSIS PATIENTS: A DUE STUDY Kumar P, Begum A, Attur RP,Manipal University, Manipal, India PUK3 L10 EPIDEMIOLOGY OF CHRONIC KIDNEY DISEASE AND PREDICTORS OF HYPERKALEMIA: ANALYSIS OF NHANES 2007– 2014 Stuntz M, Livoti C,Deerfield Institute, New York, NY, USA PUK4 L11 THE RISK OF FALLS AND FRACTURES AMONG THOSE WITH OVERACTIVE BLADDER: A SYSTEMATIC REVIEW 1 2 2 1 3 1 2 Szabo SM , Gooch K , Walker D , Johnston KM , Wagg A , Broad Street HEOR, Vancouver, BC, Canada, Astellas Pharma Global 3 Development, Inc., Northbrook, IL, USA, University of Alberta, Edmonton, AB, Canada URINARY/KIDNEY DISORDERS - Cost Studies

PUK5 L12 BUDGET IMPACT OF SWITCHING FROM AN EXTENDED-RELEASE TO AN IMMEDIATE-RELEASE FORMULATION OF TACROLIMUS IN RENAL TRANSPLANT RECIPIENTS IN SPAIN 1 2 3 3 1 Sanz-Granda Á , Ramos-Verde A , Aguinaga-Barrilero A , Rebollo-Laserna FJ , Proyectos de Farmacoeconomía, Navacerrada, 2 3 Spain, Fundación Jiménez Díaz, Madrid, Spain, SANDOZ, Aravaca, Madrid, Spain PUK6 L13 BUDGET IMPACT ANALYSIS OF SUCROFERRIC OXYHYDROXIDE IN TREATMENT OF HYPERPHOSPHATEMIA IN PATIENTS WITH CHRONIC KIDNEY DISEASE Ugrekhelidze D, Yagudina R, Kulikov A,I.M. Sechenov First Moscow State Medical University, Moscow, Russia PUK7 L14 WEB-BASED BUDGET IMPACT MODEL ESTIMATING COST SAVINGS OF DIALYSIS PROGRAM IN THE UK 1 2 2 1 2 Topachevskyi O , Siabro V , Volovyk A , Digital Health Outcomes, Brussels, Belgium, Digital Health Outcomes, Kiev, Ukraine PUK8 L15 HEALTHCARE RESOURCE CONSUMPTION AND COST OF CARE IN PATIENTS WITH AUTOSOMAL DOMINANT POLYCYSTIC DISEASE (ADPKD) IN ITALY – FINAL STUDY RESULTS 1 1 1 1 1 2 1 2 Degli Esposti L , Veronesi C , Perrone V , Buda S , Crovato E , Santoro A , CliCon S.r.l., Ravenna, Italy, Policlinico S Orsola-Malpighi, Bologna, Italy PUK9 L16 OAB IN POLAND - THIS IS TIME FOR A CHANGE 1 1 1 1 1 1 1 Borowiack E , Borowiack M , Garbacka M , Jarosz J , Kowalska Kędziora M , Nowotarska A , Raczyńska G , Jankowska 2 1 2 E , NUEVO HTA CLP, Cracow, Poland, USP Zdrowie, Warszawa, Poland PUK10 L17 COST-EFFECTIVENESS ANALYSIS OF SUCROFERRIC OXYHYDROXIDE IN TREATMENT OF HYPERPHOSPHATEMIA IN PATIENTS WITH CHRONIC KIDNEY DISEASE Ugrekhelidze D, Yagudina R, Kulikov A,I.M. Sechenov First Moscow State Medical University, Moscow, Russia PUK11 L18 ESTIMATING THE ECONOMIC AND CLINICAL BENEFITS OF MIRABEGRON VERSUS ANTIMUSCARINICS FOR THE TREATMENT OF OVERACTIVE BLADDER (OAB) IN THE UNITED KINGDOM (UK) 1 2 3 4 5 6 1 2 Nazir J , Berling M , McCrea C , Fatoye F , Hakimi Z , Wagg A , Astellas Pharma Europe Ltd, Surrey, UK, Parexel International, 3 4 5 Stockholm, Sweden, Parexel International, London, UK, Manchester Metropolitan University, Manchester, UK, Astellas Pharma 6 Europe B.V., Leiden, The Netherlands, University of Alberta, Edmonton, AB, Canada PUK12 L19 COST PER RESPONDER ANALYSIS OF SUCROFFERRIC OXHYDROXIDE VERSUS SEVELAMER CARBONATE IN PATIENTS ON HEMODIALYSIS IN EUROPE 1 2 3 3 3 1 2 Connolly M , Kotsopoulos N , Vrouchou P , Dubois E , Walpen S , University of Groningen, Groningen, The Netherlands, Global 3 Market Access Solutions, Saint-Prex, Switzerland, Vifor Fresenius Medical Care Renal Pharma, Glattbrugg, Switzerland PUK13 L20 COST-EFFECTIVENESS OF COMBINATION THERAPY WITH DUTASTERIDE/TAMSULOSIN: AN ANALYSIS BASED ON CONDUCT TRIAL 1 2 3 4 5 1 6 1 Vallejo-Aparicio LA , Miñana López B , Brenes FJ , Molero JM , Fernández-Pro A , Huerta A , Cozar JM , GlaxoSmithKline, Tres 2 3 Cantos (Madrid), Spain, Hospital General Universitario J.M. Morales Meseguer, Murcia, Spain, CAP Badalona-6 Llefià Badalona, 4 5 6 Barcelona, Spain, Centro de Salud San Andrés, Madrid, Spain, Centro de Salud de Menasalbas, Toledo, Spain, Hospital Universitario Virgen de las Nieves, Granada, Spain PUK14 L21 ANTIBIOTIC TREATMENT OF UNCOMPLICATED URINARY TRACT INFECTION IN WOMEN: A COMPARATIVE COST-EFFECTIVENESS STUDY 1 2 3 4 4 2 1 2 Sadler S , Holmes M , Holden S , Sadler S , Jha S , Thokala P , Sheffield University, Sheffield, UK, University of Sheffield, 3 4 Sheffield, UK, Nottingham University Hospital, Nottingham,, UK, Sheffield Teaching Hospitals, Sheffield, UK PUK15 L22 COST-EFFECTIVENESS OF SOLIFENACIN FOR THE TREATMENT OF OVERACTIVE BLADDER FROM A US PRIVATE PAYER AND MEDICARE ADVANTAGE PERSPECTIVE 1 2 2 2 1 1 2 Ng DB , Wielage R , Klein TM , Klein RW , Gooch K , Astellas Pharma Global Development, Inc., Northbrook, IL, USA, Medical Decision Modeling Inc., Indianapolis, IN, USA PUK16 L23 COST-MINIMISATION ANALYSIS OF SUCROFERRIC OXHYDROXIDE AND SEVELAMER CARBONATE IN PATIENTS ON DIALYSIS WITH SECONDARY HYPERPARATHYROIDISM IN SIX EUROPEAN COUNTRIES 1 2 2 1 1 1 1 van Stiphout J , Vrouchou P , Braunhofer PG , Schwenkglenks M , Szucs TD , Blank P , European Center of Pharmaceutical 2 Medicine - University of Basel, Basel, Switzerland, Vifor Fresenius Medical Care Renal Pharma, Glattbrugg, Switzerland PUK17 L24 EXPLORING THE POTENTIAL VALUE OF IMPROVED CARE FOR SECONDARY HYPERPARATHYROIDISM (SHPT) WITH A NOVEL INVESTIGATIONAL CALCIMIMETIC THERAPY 1 2 3 4 1 2 Stollenwerk B , Iannazzo S , Cooper K , Belozeroff V , Amgen (Europe) GmbH, Zug, Switzerland, SIHS SRL, Torino, 3 4 Italy, Amgen, Inc., Thousand Oaks, CA, USA, Amgen Inc, Thousand Oaks, CA, USA PUK18 L25 ASSESSING THE COST-UTILITY OF ETELCALCETIDE: A MARKOV MODEL 1 2 3 4 5 6 7 6 1 Stollenwerk B , Iannazzo S , Akehurst R , Adena M , Briggs A , Dehmel B , Parfrey P , Belozeroff V , Amgen (Europe) GmbH, Zug, 2 3 4 Switzerland, SIHS SRL, Torino, Italy, BresMed Health Solutions, Sheffield, UK, Datalytics Pty Ltd, Bruce ACT, 5 6 7 Australia, University of Glasgow, Glasgow, UK, Amgen Inc, Thousand Oaks, CA, USA, Memorial University, St. John's, NF, Canada URINARY/KIDNEY DISORDERS - Patient-Reported Outcomes & Patient Preference Studies PUK19 L26 THE EFFECT OF THERAPEUTIC DRUG MONITORING IN PATIENTS COMPLIANCE: AN IMPROVEMENT IN DRUG EFFICACY

AND CORRESPONDING REDUCTION IN TOXICITY USING AMINOGLYCOSIDES Okoro KI,UNIVERSITY OF NIGERIA, NSUKKA, ENUGU STATE, Nigeria URINARY/KIDNEY DISORDERS - Health Care Use & Policy Studies PUK20 L27 ALBUMINURIA AND SERUM CREATININE IN PREDICTING RENAL FUNCTION DECLINE IN PATIENTS WITH DIABETIC KIDNEY DISEASE: A SYSTEMATIC LITERATURE REVIEW 1 2 3 4 5 1 2 Grubb E , Van der Vaart J , Norris K , Smoyer KE , Rolland C , AbbVie, North Chicago, IL, USA, AbbVie BH, Wegalaan 9, The 3 4 5 Netherlands, UCLA, Marina Del Ray, CA, USA, Envision Pharma Group, Philadelphia, PA, USA, Envision Pharma Group, London, UK PUK21 L28 ISOLATION AND ANTIBIOTIC SUSCEPTIBILITY OF PATHOGENIC MICROORGANISMS AMONG UTI PATIENTS IN TERTIARY CARE HOSPITAL, ABBOTTABAD, PAKISTAN 1 2 1 3 1 2 Akhtar F , Iqbal A , Shujaat N , Murtaza G , Hazara University, Mansehra, Pakistan, COMSATS Institute of Information and 3 Technology Abbottabad 22060, Pakistan, Abbottabad, Pakistan, Department of Pharmacy, COMSATS Institute of Information Technology, Abbottabad, Pakistan PUK22 L29 RENAL ANEMIA TREATMENT IN THE US- HOW PAYER POLICIES AND PHYSICIAN PREFERENCES DRIVE PRESCRIBING AND HOW WILL THE EMERGING ORAL HIF-PH INHIBITORS INFLUENCE PAYERS AND PHYSICIANS? 1 2 3 3 2 1 2 Khan J , O'Connor E , Moore R , Lewis C , Fletcher-Louis M , Decision Resources Group, Burlington, MA, USA, Decision 3 Resources Group, London, UK, Decision Resources Group, Nashville, TN, USA PUK23 L30 REAL WORLD DATA IN HEALTH TECHNOLOGY ASSESSMENTS –USE OF ROUTINELY COLLECTED DATA TO ADDRESS EPIDEMIOLOGIC QUESTIONS IN KIDNEY TRANSPLANTATION IN THE AMNOG PROCESS IN GERMANY 1 2 1 3 1 2 Herrmann KH , Neubauer AS , Dombrowsky W , Koenig T , Bristol-Myers Squibb, Munich, Germany, Institut für 3 Gesundheitsökonomik München GbR, Munich, Germany, AQUA-Institut für angewandte Qualitätsförderung und Forschung, Goettingen, Germany PUK24 L31 IMPACT OF MEDICATION THERAPY MANAGEMENT SERVICE PROVIDED BY CLINICAL PHARMACISTS ON DRUG THERAPY OF PATIENTS UNDERGOING HEMODIALYSIS 1 2 3 1 1 Srikanth MS , Mahendra Kumar B , Himanshu Patel . , Ramesh A , Department of Pharmacy Practice, JSS College of 2 3 Pharmacy,JSS University, Mysuru, India, Department of Pharmacy Practice, SAC College of Pharmacy, Mandya, India, JSS College of Pharmacy, Mysore, JSS University, Mysore, India, Mysore, India